Biomimetic screening of class B G protein-coupled receptors by Devigny, Christian
 Dissertation zur Erlangung des Doktorgrades 
der Fakultät für Chemie und Pharmazie 
der Ludwig-Maximilians-Universität München 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Biomimetic Screening of Class B G protein-Coupled Receptors: 
Design of Tailored Ligands for the  
Corticotropin-Releasing-Hormone Receptor 
 
 
 
 
 
 
 
 
 
 
 
 
Christian Serge Marie Devigny 
 
 
aus  
 
Chevreuse, Frankreich 
 
 
 
2012 
 
  
Erklärung  
 
Diese Dissertation wurde im Sinne von § 7 der Promotionsordnung vom 28. November 2011 von 
Herr Prof. C. Turck betreut von der Fakultät für Chemie und Pharmazie vertreten.  
 
 
Eidesstattliche Versicherung  
 
Diese Dissertation wurde eigenständig und ohne unerlaubte Hilfe erarbeitet.  
 
 
 
 
 
 
 
 
 
 
München, den 20.02.2012 
.............................................................................  
        Christian Devigny 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dissertation eingereicht am 20.02.2012 
 
1. Gutachter: Prof. Dr. C. W. Turck 
2. Gutachter: Prof. Dr. R. Beckmann 
 
 
Mündliche Prüfung am 12.07.2012 
 
CONTENTS 
3 
Table of Contents 
Abbreviations ................................................................................................................... 7 
Abstract ......................................................................................................................... 11 
Zusammenfassung .......................................................................................................... 13 
1 Introduction ............................................................................................................ 15 
1.1 Stress and the hypothalamic-pituitary-adrenal axis ............................................................ 15 
1.2 Implication of the HPA axis in psychiatric disorders ............................................................ 17 
1.3 The CRH receptor and its ligands ......................................................................................... 19 
1.3.1 The CRHR: structure, localization and function ............................................................... 19 
1.3.2 CRH and CRH-like peptides .............................................................................................. 20 
1.3.3 Peptide ligands binding mechanism ................................................................................ 22 
1.3.4 G protein-coupled receptor-dependent signaling cascades ............................................ 24 
1.4 CRHR1 antagonists ................................................................................................................ 26 
1.4.1 Peptide antagonists ......................................................................................................... 26 
1.4.2 CRHR1 non-peptide ligands .............................................................................................. 27 
2 Objective of the study .............................................................................................. 31 
3 Results and discussion ............................................................................................. 33 
3.1 Peptide-peptide conjugates as CRH mimics ........................................................................ 33 
3.1.1 Choice of a ligation technique for the synthesis of biomimetic probes .......................... 33 
3.1.2 Synthesis and characterization of CRHR1-ECD1 high affinity probes ............................... 35 
3.1.3 Synthesis of a “clicked” biomimetic probe: proof of concept ......................................... 39 
3.1.4 Urocortin11-15 C- and N-terminal truncation: characterization of a minimal CRHR1 
stimulation sequence ....................................................................................................... 42 
3.1.5 Alternative ligation method: the hydrazone bioconjugation of a UCN4-15 biomimetic 
probe ................................................................................................................................ 45 
3.1.6 Role of the ethylene glycol connector between the two ligands binding domains ........ 49 
3.2 Urocortin14-15 biomimetic screening ................................................................................... 54 
3.2.1 Synthesis and potency evaluation of a Urocotin14-15 peptide conjugate library ............. 54 
3.2.2 Purification of exemplary conjugates: validation of the crude biomimetic screening .... 60 
3.2.3 Synthesis and evaluation of optimized UCN4-15 peptide probes ...................................... 63 
3.2.4 Pharmacological characterization of a CRHR1-TMD specific probe ................................. 72 
CONTENTS 
4 
3.2.5 Synthesis and evaluation of a peptide amide library....................................................... 81 
3.2.6 Structure-Activity-Relationship at [Phe11]UCN4-15 ............................................................ 84 
3.2.7 Summary of the UCN biomimetic screening .................................................................... 86 
3.3 Biomimetic screening of a synthetic CRHR1 modulator: astressin ...................................... 88 
3.3.1 Evaluation of astressin conjugates: rationale and proof of concept ............................... 89 
3.3.2 Astressin1-14 truncations: characterization of a minimal inhibition sequence ................. 91 
3.3.3 Role of the Astressin1-11 conjugate middle domain .......................................................... 93 
3.3.4 Astressin1-11 stimulation biomimetic screening ............................................................... 96 
3.3.5 Astressin1-11 inhibition biomimetic screening ................................................................ 100 
3.3.6 Evaluation of multisubstituted Astressin1-11 biomimetic probes ................................... 104 
3.3.7 Summary of the astressin biomimetic screening ........................................................... 111 
3.4 Synthesis and characterization of nonpeptide CRHR1 antagonists ................................... 113 
4 Conclusion ............................................................................................................. 117 
5 Material and methods ........................................................................................... 119 
5.1 Chemical methods ............................................................................................................. 119 
5.1.1 Nuclear Magnetic Resonance ........................................................................................ 119 
5.1.2 Mass Spectrometry ........................................................................................................ 119 
5.1.3 Liquid chromatography-mass spectrometry .................................................................. 119 
5.1.4 High-performance liquid chromatography .................................................................... 119 
5.1.5 Flash chromatography ................................................................................................... 120 
5.1.6 Thin layer chromatography ............................................................................................ 120 
5.1.7 Chemicals ....................................................................................................................... 121 
5.1.8 Solvents .......................................................................................................................... 126 
5.1.9 Others materials ............................................................................................................ 127 
5.2 Synthetic methods ............................................................................................................. 128 
5.2.1 Synthesis of azide-functionalized spacers ..................................................................... 128 
5.2.2 Synthesis of HNA and SFB modification reagents .......................................................... 135 
5.2.3 Solid phase synthesis of peptides .................................................................................. 137 
5.2.4 The bioconjugation of peptide fragments ..................................................................... 154 
5.2.5 Synthesis of nonpeptide CRHR1 antagonists .................................................................. 166 
5.3 cAMP cell-based assays ..................................................................................................... 172 
5.3.1 Stimulation assay typical protocol ................................................................................. 173 
5.3.2 Inhibition assay standard protocol ................................................................................ 173 
5.4 Data analysis ...................................................................................................................... 176 
CONTENTS 
5 
References ................................................................................................................... 177 
Acknowledgments ........................................................................................................ 187 
Curriculum Vitae .......................................................................................................... 189 
 
ABBREVIATIONS 
7 
Abbreviations 
3D    three dimensional 
AA    amino acid 
AC    adenylyl cyclase 
AcOEt    ethyl acetate 
ACTH     adrenocorticotropin 
AST    astressin 
AVP    arginine vasopressin 
BAL    backbone amide linker 
Boc    tert-butyloxycarbonyl 
cAMP    cyclic adenosine monophosphate 
CNS    central nervous system 
CPM    counts per minute 
CRE    cAMP response element 
CREB    cAMP response element-binding 
CRH    corticotropin-releasing hormone 
CRH-BP    CRH binding protein 
CRHR    CRH receptor 
CSF    cerebrospinal fluid 
CuCAAC   copper-catalyzed azide-alkyne cycloaddition 
DAG    diacylglycerol 
DCM    dichloromethane 
DEG    diethylene glycol 
DIEA    diisopropylethylamine 
DMF    dimethylformamide 
DMSO    dimethyl sulfoxide 
DST    dexamethasone suppression test 
EC50    half maximal effective concentration 
ECD    extracellular domain 
eq.    equivalent 
Emax    maximal potency 
Emin    minimal potency 
ERK    extracellular signal-regulated kinase 
ESI    electrospray ionisation 
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Fmoc    Fluorenylmethyloxycarbonyl 
FRET    fluorescence resonance energy transfer 
GDP    guanosine diphosphate 
GLP1    glucagon-like peptide-1 
GLP1R    glucagon-like peptide receptor 
GPCR    G protein-coupled receptor 
GR    glucocorticoid receptor 
GRK    G protein-coupled receptor kinase 
GTP    guanosine triphosphate 
HATU O-(7-azabenzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium 
hexafluorophosphate 
HBA    hydrogen bond-accepting atom 
HBTU O-(benzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium 
hexafluorophosphate 
HEK293    human embryonic kidney 293 cells 
HNA    hydrazinonicotinic acid 
HOBt    1-hydroxybenzotriazole 
HPA     hypothalamic-pituitary-adrenocortical 
HTRF    homogenous time-resolved fluorescence 
ICD    intracellular domain 
IP3    inositol 1,4,5-trisphosphate 
MAPK    mitogen-activated protein kinase 
MEG    monoethylene glycol 
MS    mass spectrometry 
MTS    medium-throughput screening 
NBD    4-(7-nitro)benzofurazanyl 
NMM    N-methylmorpholine 
NMP    N-methyl-2-pyrrolidone 
NMR    nuclear magnetic resonance 
PEG    polyethylene glycol 
PEG4    tetraethylene glycol 
PEG5    pentaethylene glycol 
PKA    protein kinase A 
PKC    protein kinase C 
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PLC    phospholipase C 
POMC    propiomelanocortin 
PTH    parathyroid hormone 
PTHR    parathyroid hormone receptor 
PVN    hypothalamic paraventricular nucleus 
PyBop benzotriazol-1-yl-oxytripyrrolidinophosphonium 
hexafluorophosphate 
SAR structure-activity-relationship 
s.e.m. standard error of the mean 
SFB 4-formylbenzoate 
SPPS    solid phase peptide synthesis 
SVG    sauvagine 
TBTA    tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine 
TEG    triethylene glycol 
TFA    trifluoroacetic acid 
TIS    triisopropylsilane 
TLC    thin layer chromatography 
TMD    transmembrane domain 
UCN    urocortin 
UV    ultraviolet 
WHO    World Health Organization 
WT    wild type 
 
Please note that all units are indicated as defined by the International System of units (SI) or are SI 
derived units with the respective prefixes and are therefore not considered in the list of 
abbreviations. 
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Abstract 
Dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis is a hallmark of complex and 
multifactorial psychiatric diseases such as anxiety and mood disorders. The 41-amino acid 
neuropeptide Corticotropin Releasing Hormone (CRH) is a major regulator of the mammalian stress 
response. Upon stressful stimuli, it binds to the Corticotropin Releasing Hormone Receptor 1 
(CRHR1), a typical member of the class B GPCRs and a potential novel target for the therapeutic 
intervention in major depressive disorder. A precise understanding of the peptide-receptor 
interactions is an essential prerequisite towards the development of efficient CRHR1 specific 
antagonists. To chemically probe the molecular interaction of CRH with its cognate receptor, a high-
throughput conjugation approach which mimics the natural activation mechanism for class B GPCRs 
was developed. Acetylene-tagged peptide libraries were synthesized and conjugated to high-affinity 
azide-modified carrier peptides using copper-catalyzed dipolar cycloaddition. The resulting 
conjugates reconstitute potent ligands and were tested in situ for modulation of the CRHR1 activity 
in a cell-based assay. This approach allows to (i) define the sequence motifs which are required for 
receptor activation or inhibition, (ii) identify the critical functional groups and investigate structure-
activity-relationships, and (iii) develop novel optimized, highly potent peptide probes which are 
specific for the transmembrane domain of the receptor. The membrane recruitment by a high-
affinity carrier peptide enhances the potency of tethered peptides and allows the initial testing of 
weak fragments that otherwise would be inactive. The biomimetic screening led to the discovery of 
transtressin, a highly modified and potent CRHR1 transmembrane domain-specific optimized agonist 
(EC50 = 4 nM). Beyond its intrinsic agonistic activity, transtressin is an essential tool for the 
pharmacological characterization of CRHR1 antagonists in competition assays (Devigny et al. 2011; 
Sakmar 2011). 
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Zusammenfassung 
Die Fehlregulation der Hypothalamus-Hypophysen-Nebennierenrinde-Achse ist ein Kennzeichen 
psychiatrischer Erkrankungen wie Angststörungen und Depressionen. Das 41-Aminosäuren-lange 
Neuropeptid Corticotropin-freisetzende Hormon (CRH) ist ein wichtiger Regulator der Stress-
Antwort in Säugetieren. Nach einem Stressstimulus bindet das Hormon an den Corticotropin-
freisetzendes Hormon Rezeptor Typ 1 (CRHR1), einem typischen Vertreter der Klasse B G-Protein-
gekoppelten Rezeptoren (GPCR) und einem potenziellen neuen pharmakologischen Zielprotein für 
die Therapie depressiver Störungen. Ein genaues Verständnis der Peptid-Rezeptor-Interaktion ist 
eine essenzielle Vorausetzung für die Entwicklung spezifischer und effizienter CRHR1-Antagonisten.  
Um die molekulare Interaktion zwischen CRH und seinem zugehörigen Rezeptor chemisch zu 
charakterisieren, wurde eine Hochdurchsatz-Konjugationsstrategie entwickelt, welche den 
natürlichen Aktivierungsmechanismus für Klasse B GPCRs nachahmt. Peptidbibliotheken wurden mit 
Acetylen-Markierungen synthetiziert und mit hochaffinen Azid-modifizierten Trägerpeptiden durch 
Kupfer-katalysierte, 1,3-dipolare Cycloaddition konjugiert. Die enstandenen Konjugate stellen 
potente Liganden dar und wurden in situ in Zell-basierten Assays für die Modulation der CRHR1 
Aktivität getestet. Dieses Verfahren ermöglicht (i) das minimal Sequenzmotiv, welche für die 
Rezeptoraktivierung oder -inhibition notwendig ist, zu definieren, (ii) die wesentlichen funktionellen 
Gruppen zu identifizieren und systematisch die Struktur-Aktivität-Beziehung zu untersuchen und (iii) 
neue, optimierte, hoch-potente Peptide zu entwickeln, welche spezifisch für die 
Transmembrandomäne des Rezeptors sind. Die Rekrutierung über hochaffine Trägerpeptide 
verstärken die Potenz von gebundenen Peptiden und erlaubt dadurch ein initiales Testen von 
schwach bindenden Fragmenten, die sonst inaktiv wären. Unsere biomimetische Untersuchung 
führte zur Entdeckung von „Transtressin“, einem modifizierten und hoch-potenten, 
Transmembrandomän-spezifischen CRHR1-Agonisten (EC50 = 4 nM). 
Neben seiner intrinsischen Aktivität als Agonist fand Transtressin als pharmakologisches 
Hilfsmittel in Kompetitionverfahren für die Charakterisierung von peptidischen und nicht-
peptidischen CRHR1-Antagonisten Verwendung. Dabei führte die biomimetische Untersuchung des 
peptidischen Antagonisten Astressin zu neuen und überaschend potenten, verkürzten 
Peptidagonisten. Zudem wurde ein neuer Syntheseweg für nicht-peptidische CRHR1-Antagonisten 
etabliert. Dabei wurden Pyrazolotriazin-Derivate wie DMP696 im Grammaβstab synthetisiert, und in 
Tierexperimente zur Characterisierung von Stressverhalten eingestetzt.  
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1 Introduction 
1.1 Stress and the hypothalamic-pituitary-adrenal axis 
Stress is defined as “conditions where an environmental demand exceeds the natural regulatory 
capacity of an organism” (Koolhaas et al. 2011). First described by the pioneering endocrinologist 
Hans Selye, the so-called “general adaptation syndrome” constitutes an essential mechanism for the 
survival of all organisms (SELYE 1951). Different stressors, internal or external stimuli, activate the 
stress system and lead to major biochemical, functional and behavioral changes. The behavioral and 
physical responses include enhanced vigilance and cognition, analgesia, activation of the 
cardiovascular system and suppression of vegetative functions such as appetite, sex drive and sleep 
(Chrousos 1998; Tsigos and Chrousos 2002). 
The neuroendocrine response to stress is mediated by the hypothalamic-pituitary-adrenal (HPA) 
axis (Figure 1). The key regulator of the HPA axis is the corticotropin-releasing-hormone (CRH), a 41 
amino-acid neuropeptide discovered in 1981. CRH coordinates the neuroendocrine, autonomic, 
immune and behavioral responses to stress constituting an “acute defense of homeostasis” (Vale et 
al. 1981; Vale et al. 1983). Upon stressful stimuli, increased CRH secretions are released from the 
hypothalamic paraventricular nucleus (PVN) into the median eminence. CRH subsequently enters 
the hypothalamic-pituitary portal system and binds the corticotropin-releasing-hormone receptor 
type 1 (CRHR1). The activation of the CRHR1-dependent signaling cascades causes the processing of 
propiomelanocortin (POMC) into adrenocorticotropic hormone (ACTH) and its release in the 
bloodstream. ACTH in turn stimulates the secretion of glucocorticoids by the cortex of adrenal 
glands. Glucocorticoids, such as cortisol, regulate a variety of important metabolic, immunologic and 
homeostatic functions. Glucocorticoids levels in the blood are regulated by a negative feedback 
mechanism that in turn, downregulates the HPA axis activity (Dallman et al. 1987). In addition, the 
arginine vasopressin neuropeptide (AVP) plays an important role in modulating ACTH responsiveness 
in stressful conditions. Major evidences show that AVP and CRH acts synergistically to potentiate the 
release of ACTH (DeBold et al. 1984; Young et al. 2007). 
CRH is also a neuromodulator that regulates the neuronal activity. Expression of the CRH system 
in extrahypothalamic regions mediate the behavioral response to stress (DeSouza 1985; Koob 1999). 
The expression of the CRH system in forebrain glutamatergic and γ-aminobutyric acid containing 
neurons as well as in midbrain dopaminergic neurons was recently shown to control the emotional 
response to stress (Refojo et al. 2011). CRH has been shown to modulate various behavioral 
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attributes including learning and memory, food intake, anxiety, arousal, startle and fear responses, 
general motor activity and sexual behavior (Bale et al. 2000; Hauger et al. 2006; Radulovic et al. 
1999).  
CRH
ACTH
glucocorticoids
gluconeogenesis ↑
lipolysis/proteolysis ↑
inflammation ↓
reproductive function ↓
negative-feedback
inhibition
central effects
on autonomic, hormonal, 
immune and behavioral
responses to stress
stress
pituitary
adrenal cortex
PVN
hippocampus
 
Scheme illustrating the activation, the effects and the negative-feedback inhibition of the HPA axis 
(courtesy of H. Kronsbein). Upon stress, CRH release from the hypothalamic PVN to the pituitary is 
increased. In turn, the pituitary releases more ACTH. ACTH stimulates the production and the release 
of glucocorticoids. Within this cascade, CRH has profound effects on autonomic, hormonal, immune 
and behavioural responses to stress. Amongst others, glucocorticoids activate gluconeogenesis, 
lipolysis and proteolysis and diminish inflammation and reproductive function. Additionally, 
glucocorticoids exert a negative feedback mechanism on the pituitary and on structures of the CNS 
like the PVN in the hypothalamus and the hippocampus. 
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1.2 Implication of the HPA axis in psychiatric disorders 
Several clinical and preclinical findings demonstrate the central role of CRH in a variety of 
psychiatric disorders such as depression and anxiety. Persistent enhancement of stress reactivity 
leads to dysregulation of the HPA axis and increased CRH levels (Raadsheer et al. 1994). 
Environmental factors but also genetic factors contribute to the development of these HPA system 
abnormalities (Hauger et al. 2006). Exposure to stress early in life was shown to produce long-term 
sensitization of CRH-mediated stress responses and increases the risk of developing anxiety and 
depressive disorders (Carpenter et al. 2004; Essex et al. 2002). Increased CRH concentrations lead to 
elevated ACTH and glucocorticoid levels, thus causing hypercortisolemia (Gold et al. 1988; Nemeroff 
1996). In contrast, reduced CRH secretions lead to hypoactivation of the stress system and an 
enhanced negative feedback mechanism (Juruena et al. 2004). CRH plays an important role in the 
mediation of emotional processes such as fear, anxiety and panic. Hence, a dysregulation of the HPA 
axis is involved in the pathology of several neuropsychiatric disorders (Table 1) (Tsigos and Chrousos 
2002). In predisposed humans, chronic stress or continuous exposure to stress may trigger the 
symptoms of depression and anxiety. 
 
Table 1. Disorders associated with disturbed HPA axis function (Tsigos and Chrousos 2002). 
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Mood and anxiety disorders have a high prevalence in the general population of industrialized 
countries. Recently, the World Health Organization (WHO) estimated the 12-month prevalence of 
mood disorders to 3.6 % in Germany and 9.6 % in the United States. The evaluated 12-month 
prevalence of anxiety disorders ranges to 6.2 % in Germany and to 18.2 % in the United States 
(Demyttenaere et al. 2004). According to the WHO, depression will become the second cause of 
disability in 2020. Neuropsychiatric disorders lead to a tremendous loss of life quality and have a 
considerable impact on the economy. 
Common and characteristic symptoms of depression and anxiety disorders are insomnia, reduced 
sex drive, loss of appetite, weight loss, constipation and psychomotor changes among others. The 
important neuroendocrine findings among depressive patients are elevated levels of CRH in the 
cerebrospinal fluid (CSF) as well as hypercortisolemia (Holsboer 2000; Nemeroff et al. 1984). 
Additionally, an unrestrained CRH release in the context of impaired glucocorticoid receptor (GR) 
function has been proposed to have an impact on the development and course of major depression 
(Holsboer 1999). In the standard dexamethasone suppression test (DST), patients with various 
affective disorders display elevated cortisol levels suggesting an impaired feedback mechanism 
through the GRs. Although pronounced HPA axis alterations are commonly found in patients 
suffering from depressive disorders, HPA abnormal functions are also found in other 
neuropsychiatric disorders such as e.g. acute mania, anxiety and schizophrenia. Altogether, a 
number of clinical and preclinical studies have characterized the crucial role of the CRH system and 
HPA dysregulation in the etiology of stress-related disorders such as depression and anxiety. In view 
of these data, the CRH system has been suggested as a novel and promising target for the treatment 
of stress-related disorders. 
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1.3 The CRH receptor and its ligands 
1.3.1 The CRHR: structure, localization and function 
The corticotropin-releasing-hormone receptors (CRHRs) are G protein-coupled receptors (GPCRs), 
which are widely distributed throughout the body (Civelli 2005). GPCRs constitute a superfamily of 
proteins whose function is to transduce a chemical signal across the cell membrane. All GPCRs 
possess seven highly conserved transmembrane helices and interact with a heterotrimeric G protein 
that subsequently triggers signal transduction pathways. Because of their integral role in cell 
signaling, GPCRs are important in understanding and treating a variety of diseases. GPCRs are prime 
drug targets and it is estimated that greater than 40 % of all modern marketed drugs target GPCRs 
(Moro et al. 2005). 
 
Figure 2. Diagram of the human CRHR1: extracellular domain (ECD), transmembrane domain (TMD), 
and intracellular domain (ICD). The peptide binding site (ECD1) is highlighted in dark blue. The 
G protein binding site is highlighted in pink (ICD3). 
The CRH receptor (CRHR) is a GPCR belonging to the class B or secretin family (Figure 2) (Bale and 
Vale 2004; Dautzenberg and Hauger 2002; Hoare et al. 2003; Hoare 2005). Three subtypes of CRHRs 
have been identified. The human CRHR1 and CRHR2 consist of 415 and 411 amino acids respectively, 
sharing 70 % of amino acid sequence homology and are coded by separate genes (Grammatopoulos 
and Chrousos 2002; Liaw et al. 1997). The structure of the CRH receptors consists of a large N-
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terminus (ECD1) and three loops in the extracellular domain (ECDs), seven hydrophobic 
transmembrane α-helices constituting the transmembrane domain (TMD), and the C-terminus as 
well as three loops in the intracellular domain (ICDs). The ECD loops region is the initial region for 
ligand binding and possesses the greatest variation between the receptor subtypes 
(Grammatopoulos and Chrousos 2002). The N-terminus regions (ECD1) share only 40 % sequence 
identity between CRHR1 and CRHR2. However, the TMD and ICD regions are highly conserved and 
share more than 80 % homology. The third IC loop (IC3) is found to be strictly identical between all 
CRH receptors and interacts with the G protein (Bale and Vale 2004; Dautzenberg and Hauger 2002). 
Interestingly, the receptors subtypes differ in their tissue distribution and pharmacology, suggesting 
different physiological functions. CRHR1 is mainly expressed in the central nervous system (e.g., 
pituitary gland, cerebral cortex, sensory relay nuclei and cerebellum), whereas CRHR2 expression is 
limited to peripheral organs and to specific brain regions (Chalmers et al. 1995; Van et al. 2000). 
CRHR1 is the primary receptor involved in the response to stress, thus the CRH/CRHR1 system 
constitute the key regulator of the HPA axis. In addition to CRHRs, class B GPCRs include important 
drug targets such as the calcitonin, the glucagon-like peptide (GLP1R) and parathyroid hormone 
receptors (PTHR). 
1.3.2 CRH and CRH-like peptides 
The Corticotrophin-Releasing-Hormone (CRH) is a 41 amino acid polypeptide that was isolated 
and characterized in 1981 (Table 2) (Vale et al. 1981). The CRH peptides from different species show 
a remarkable degree of sequence homology. Among mammalian CRH peptides, human, rat, mouse 
and pig CRH homologues are strictly identical (Hauger et al. 2006). Besides CRH as regulator of the 
HPA axis, closely related peptides (CRH-like peptides) have been identified. In mammals, the CRH 
family comprises three distinct CRH-like peptides: urocortin 1 (UCN), urocortin 2 (UCN2) and 
urocortin 3 (UCN3) (Hsu and Hsueh 2001; Vaughan et al. 1995). In addition to endogenous CRH and 
CRH-like peptides, a variety of synthetic peptides have been reported (e.g., stressin1-A, astressin 2B 
and cortagine). CRH and CRH-like peptides expressing neurons are widely distributed throughout the 
body. In the mammalian CNS, a very high density of CRH-expressing neurons is present in the PVN of 
the hypothalamus. These neurons are primary responsible for mediating and regulating the stress 
response. CRH-containing neurons are also found in the central nucleus of the amygdala and 
hindbrain regions as well as in the periphery (Bale and Vale 2004; Swanson et al. 1983). Beyond the 
multiple brain functions, the presence of CRH-expressing neurons in the pancreas, stomach, 
intestine and lymphocytes suggests a possible role of CRH in digestion and immune functions. 
Similarly, UCN, UCN2, and UCN3 peptides are widely expressed within the brain and the periphery. 
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Both CRH and UCN have high affinities for the CRH-binding protein (CRH-BP) whereas neither UCN2 
nor UCN3 bind to this protein (Dautzenberg and Hauger 2002). 
 
Table 2. Sequence and homology of peptide agonists and antagonists with affinities at the CRH1 
and CRH2 receptors (Grigoriadis 2005; Yamada et al. 2004). X = cyclohexyl alanine; f = D-
phenylalanine; EAEK = lactam bridge. 
The CRHR1 and CRHR2 have been shown to bind the CRH and CRH-like peptides with different 
affinities. CRH is selective for CRHR1 and possess a tenfold higher affinity for CRHR1 than for CRHR2. 
UCN has equal binding affinities for both receptors subtypes (Perrin et al. 1995). In contrast, UCN2 
and UCN3 are the CRHR2-selective natural peptides. Synthetic CRH analogues such as 
α-helical CRH9-41 and astressin have been shown to bind both CRHR1 and CRHR2 (Figure 4 and 
Table 2). 
 
 
 
Figure 3. Mammalian family members of 
CRH-related neuropeptides and their 
receptors. Arrows represent ligand-receptor 
interactions. The thickness of arrows reflects 
the relative binding affinities of the peptide 
ligands for the receptor subtypes (Deussing 
and Wurst 2005) 
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1.3.3 Peptide ligands binding mechanism 
Peptide ligands bind and activate class B GPCRs in a two step general mechanism, called the 
“two-domain” model (Figure 4). In this low-resolution model, the C-terminal segment of the peptide 
ligand binds the ECD1 of the CRHR with high-affinity, mainly via hydrophobic interactions. Formation 
of this complex orients the ligand and the receptor, enabling receptor activation and intracellular 
signalling through interaction between the serpentine segment of the receptor and the N-terminal 
segment of the ligand. Although complex and multiple receptor-ligand contact are present, this 
simplified two-step activation model provides a useful conceptual and analytical framework to 
evaluate the properties of peptide ligands (Hoare 2005).  
 
Figure 4. The “two-domain” mechanism of peptide ligands binding to class B GPCRs. The peptide 
hormone carboxyl-terminal portion first binds the CRHR1-ECD1 with high-affinity. A second 
interaction then occurs between the CRHR1 juxtamembrane domain and peptide hormone amino-
terminal portion that induces a structural rearrangement leading to G protein activation.  
Although the exact spatial arrangement between the ECD1- and J-domains is presently unclear, 
many studies support the two-domain model for CRHR1 stimulation. In particular, the ECD1- and 
J-domain peptide interactions have been shown to be functionally independent. The CRH and CRH-
related peptides (e.g., UCN, UCN2, UCN3) can be segmented into three functional parts. The N-
terminal segment (residues 1-16) is believed to be important for agonist binding and receptor 
activation. The middle segment (residues 17-31) contains the CRH-BP binding site and is assumed to 
control the structural conformation of the peptide hormone, while the C-terminal segment (residues 
32-41) is crucial for ECD1 receptor binding (Mazur et al. 2004). The 3D structure of these peptides is 
not fully established but it is believed that the central region is α-helical, and that both terminal ends 
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are relatively unstructured. However there are strong evidences that the C-terminus of the peptide 
form another α-helix when bound to the receptor (Hoare 2005). 
Recently, a considerable insight into the ligand binding mechanisms of class B GPCRs has been 
gained from several reports of ECD-peptide complex structures determined by NMR and X-ray 
methods (Grace et al. 2007; Grace et al. 2010; Pioszak et al. 2008). The NMR solution structure of 
astressin (a peptide antagonist analogue based on human CRH, table 2) bound to the mouse CRHR2-
ECD1 showed that the ECD1 consists of two antiparallel β-sheets, each with two β-strands that are 
held together by three conserved disulfide bonds. The astressin 27-41 amino acid fragment forms an 
α-helix that interacts with a hydrophobic surface of the ECD1 at the interface of three loops regions. 
Similar 3D NMR and cocrystal structures of the CRHR1-ECD1 in complex with the peptide antagonist 
α-helical CRH9-41 or CRH were recently disclosed (Grace et al. 2010; Pioszak et al. 2008). Interestingly, 
these studies show that complex formation between a peptide ligand and the CRHR1-ECD1 promotes 
the ligands helical conformation, thereby enhancing the ligands affinity. 
 
Figure 5. NMR structure of the peptide antagonist astressin bound to the CRHR2-ECD1 (Grace et al. 
2007). Shown are hydrophobic interactions (red), hydrogen bonds (blue) and salt bridges (yellow). 
INTRODUCTION 
24 
1.3.4 G protein-coupled receptor-dependent signaling cascades  
The CRH receptors are members of the class B subfamily of GPCRs and activate different 
G protein and signaling cascades upon ligand binding. In most tissues, stimulation of both CRHR1 and 
CRHR2 by CRH or CRH-like peptides leads to guanine nucleotide stimulatory protein (Gs) signaling and 
activates the adenylyl cyclase protein kinase (AC-PKA) pathway (Aguilera et al. 1983; Olianas et al. 
1995). Upon ligand binding, an allosteric change occurs within the CRH receptor that increases its 
affinity for Gs, triggering activation and dissociation of the G protein heterotrimers in its Gα and Gβ  
subunits. Similarly, the coupling of Gs to the intracellular loop of the CRHR1 (CRHR1-IC3) produces a 
~1300-fold increase in the receptor affinity for CRH . 
 
Figure 6. Major intracellular pathways for signal transduction by CRH receptors. Upon CRH binding 
to CRHR1, signaling pathways both in the cytoplasm and in the nucleus are initiated. ACTH synthesis 
and release are induced by the activation of PKA and PKC as well as the MAP kinase cascade. 
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The dissociated Gα and Gβ  subunits then interact with a variety of effector molecules. In 
particular, the released Gαs subunit triggers the activation of adenylyl cyclase (AC) inducing an 
increase of cyclic adenosine monophosphate (cAMP) levels. In turn, cAMP binds and regulates the 
activity of the protein kinase A (PKA). Among others, the PKA activates the cAMP responsive element 
binding protein (CREB), which in turn binds the cAMP response element (CRE). This cascade of 
biochemical events ultimately stimulates gene transcription and leads to the synthesis of ACTH from 
the POMC precursor molecule (Figure 6). The AC-PKA pathway, which regulates stress and anxiety 
responses, is the dominant signaling pathway in endogenous and recombinant cell lines. 
Both CRHR1 and CRHR2 have been shown to couple to Gq and signal via the phospholipase C-
protein kinase C pathway (PLC-PKC). Activation of PLC promotes the formation of inositol (1,4,5)-
triphosphate (IP3) and diacylglycerol (DAG), leading to increased intracellular Ca2+ levels and 
activation of protein kinase C (PKC) isoforms. CRHRs can also signal via the ERK-mitogen-activated 
protein kinase (MAPK) pathway. In addition, β-arrestin recruitment terminates G protein activation, 
inhibits further downstream signaling and induces desensitization and internalization. A potential 
mechanism of stress adaptation has been associated with G protein-coupled receptor kinases (GRKs) 
and β-arrestin-recruitment when exposed to increased levels of CRH (Dautzenberg et al. 2001). 
Upon excessive agonist binding, GRKs are recruited to the intracellular domain of the CRH receptor 
and phosphorylates specific residues, enhancing the receptors affinity for β-arrestin. β-arrestin-
bound receptor is G protein uncoupled and therefore downstream signaling is inhibited. CRHRs have 
also been shown to signal via a variety of other pathways such as the Akt/protein kinase B-PI-3 
kinase pathway, the NOS-guanylyl cyclase pathway and the caspase pro-apoptotic pathway (Hauger 
et al. 2006). 
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1.4 CRHR1 antagonists 
Tricyclic antidepressants, selective reuptake inhibitors and monoamine oxidase inhibitors are the 
common drugs used for the treatment of psychiatric disorders such as depression and anxiety. All 
three drug classes act by modulating the concentration of neurotransmitter (e.g., serotonin, 
noradrenalin and dopamine, respectively) in the synaptic cleft (Nestler et al. 2002). Although the 
effectiveness of antidepressants is significant for patients with severe forms of depression, it is 
minimal for those with mild or moderate forms of the disease (Kirsch 2009; Kirsch 2010). It is 
estimated that greater than 40 % of the patients treated with an antidepressant do not show any 
response (Baghai et al. 2006; Ruhe et al. 2006). Moreover, the mechanisms of action of 
antidepressants are not fully understood. Lack of efficacy and severe side effects have pointed out 
the need of drugs based on alternative biochemical mechanisms. The CRH/CRHR1 system is a target 
of choice for the therapeutic intervention in stress-related disorders. 
1.4.1 Peptide antagonists 
Structure-activity-relationship (SAR), mutant, chimeric and substitution studies of the 
endogenous peptide ligands have led to the development of highly potent CRHR1 peptide 
antagonists. In particular, N-terminal truncation of the first twelve amino acids of CRH abolishes 
agonistic activity and led to the development of astressin (cyclo(30-33)-[D-Phe12, Nle21,38, Glu30, 
Lys33]r/h CRH12-41) (Gulyas et al. 1995). Recently, Yamada et al. described a twelve amino acid long 
peptide antagonist based on the C-terminus of CRH, indicating that this short C-terminal sequence is 
enough for binding the extracellular domain of the CRHR1 (CRHR1-ECD1) (Yamada et al. 2004). 
Peptide antagonists such as astressin are highly alpha-helical and often use an intramolecular lactam 
bridge to constrain the peptide conformation (Table 2).  
Peptide antagonists bind with high-affinity to the extracellular domain of the receptor and blocks 
binding of an agonist and subsequent signal transduction (Rivier et al. 2002). This mechanism of 
inhibition supports the two domain model hypothesis for the activation of class B GPCRs. In general, 
the C-terminal segment of a CRHR1 peptidic ligand determines the binding affinity, while the N-
terminal segment governs the potency of the agonist. Lacking the N-terminus responsible for CRHR1 
activation, peptide antagonists effectively block the endogenous ligand from binding the CRHR1-
ECD1 by competition (Figure 7). 
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Figure 7. Mechanism of the CRHR1 peptidic antagonism. Peptide antagonists such as astressin bind 
the CRHR1-ECD1 with high-affinity, an interaction which blocks the endogenous peptide agonist from 
binding by competition. 
1.4.2 CRHR1 non-peptide ligands 
Small molecule, orally active, brain-penetrating CRHR1 antagonists represent a promising and 
novel class of drugs for therapeutic use in the treatment of anxiety, depression and other stress-
related disorders (Holsboer and Ising 2008; Ising and Holsboer 2007; Kehne and De 2002; Stahl and 
Wise 2008). First reports of small molecule CRHR1 antagonists date to 1996 (Chen et al. 1997b; 
Schulz et al. 1996b). Since then, hundreds of small molecules with high and selective CRHR1 affinity 
have been identified; however none have made it onto the pharmaceutical market. The 
pharmacology and properties of the most well-studied CRHR1 nonpeptide antagonists were recently 
reviewed (Chen 2006; Tellew and Luo 2008; Zorrilla and Koob 2010). All small molecule CRHR1 
antagonists share several common pharmacophoric features (Figure 8).  
A five- or six-membered nitrogen heterocyclic core bears a key hydrogen bond-accepting 
nitrogen atom (HBA). A pendant aryl group (bottom aryl) is attached to the core at the position 
adjacent to the HBA via a one atom spacer, which is frequently part of a fused ring. The bottom aryl 
group is typically 2,4-disubstituted or 2,4,6-trisubstituted, with methyl, chloro, and methoxy groups 
common at both the ortho and para positions. The ortho substituent enforces an orthogonal 
orientation between the bottom aryl and the core ring. The HBA-containing core heterocycles bears 
a small lipophilic group, which is typically methyl for six-membered rings and ethyl for five-
membered rings. Finally, a “top-group”, often a lipophilic alkylamino or branched alkyl group, is 
appended to the core heterocycles (Tellew and Luo 2008). 
The molecular details of the nonpeptide ligand interaction with CRHR1 are not well characterized 
at present. However, evidences indicate that nonpeptide antagonists bind an allosteric site in the 
J-domain of the CRHR1 exclusively (Hoare 2005; Hoare et al. 2006). The nonpeptide ligands bind a 
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J-domain fragment with the same affinity as the whole receptor; moreover mutations within the J-
domain (H199V and M276I) affect the binding of nonpeptide ligands but not peptide interaction. A 
functional model for the nonpeptide antagonism at the CRHR1 was proposed: the nonpeptide 
antagonist binds the J-domain, producing a conformational change that blocks the peptide agonist 
binding site on the J-domain (Figure 9). Because the peptide can no longer bind the J-domain, it is 
not able to induce receptor activation (Hoare 2005; Hoare et al. 2008). Recently, computer-based 
approaches have given a more precise insight into the binding mechanism of small molecules 
antagonists of class B GPCRs (Bhattacharya et al. 2010; de et al. 2011). 
 
Figure 8. Notable CRHR1 antagonists reported to have reached clinical trials. 
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Figure 9. Mechanism of the nonpeptidic CRHR1 antagonism. Nonpeptide CRHR1 antagonists bind an 
allosteric binding site within the receptor TMD. It induces a conformational change that hinders the 
peptide agonist to bind its orthosteric binding site and trigger G protein signalling. 
Early CRHR1 nonpeptide antagonists were very potent in vitro and demonstrated efficacy in 
animal models (Chen et al. 1997a; Schulz et al. 1996a). However, they were highly lipophilic 
(cLogP > 7) and poorly water-soluble. Clinical development of such compounds, especially as CNS 
drugs, has been hindered because of unattractive pharmacokinetics, extensive tissue accumulation 
and long elimination half-lives. Recently, efforts have been focused on adding drug-like properties to 
these molecules and turn it into suitable CNS drugs (Chen 2006).  
Although limited clinical results and data are currently available, a number of CRHR1 antagonists 
have been reported to have entered clinical trials for depression and anxiety related disorders 
(Kehne and Cain 2010) (Figure 8). Notably, NBI-30775/R121919 demonstrated efficacy in treating 
patients with depression in a small open-label phase IIa clinical trial, although further development 
was discontinued due to hepatotoxicity issues (Kunzel et al. 2003; Zobel et al. 2000). In a placebo-
controlled clinical study with NBI-34041, improved resistance to psychological stress was observed 
(Ising et al. 2007). However, in a double-blind, placebo-controlled clinical trial for the treatment of 
major depressive disorder, CP-316311 was declared not efficacious (Binneman et al. 2008; Chen et 
al. 2008a). Likewise, pexacerfont (BMS-562086) was also declared not efficacious in generalized 
anxiety disorder (Coric et al. 2010). In a recent press release dated 9/14/10, Neurocrine Biosciences 
Inc. (www.neurocrine.com) announced top-line efficacy and safety results from a Phase II, double-
blind, placebo-controlled clinical trial with CRHR1 antagonist NBI-77860/GSK561679 in patients with 
major depressive disorder.  
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While the clinical results to date have been disappointing, a complete evaluation requires 
consideration of a number of factors, including the potential need to target clinical subpopulations 
with demonstrated CRHR1 hyperactivation in stress response pathways (Kehne and Cain 2010). 
Additional compounds have been reported to enter clinical trials (Chen et al. 2008b; Gilligan et al. 
2009b; Tellew et al. 2010), the results of these trials and clinical studies may further define the role 
of CRH antagonism for the treatment of human illnesses. 
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2 Objective of the study 
The CRH/CRHR1 system orchestrates the neuroendocrine and behavioral responses to stress has 
attracted major interest as a potential novel target for the therapeutic intervention in psychiatric 
disorders (Holsboer and Ising 2008; Ising et al. 2007; Zobel et al. 2000). Generally, transmembrane 
receptors of the class B GPCR subtype have a huge clinical potential to ameliorate numerous of 
diseases of high severity and prevalence. Nonetheless, the development of drugs targeting these 
receptors has been hampered by the difficulty to identify tractable leads as well as by a limited 
biochemical understanding. Moreover, the molecular determinants involved in the recognition of 
CRH peptide ligands and in the modulation of the CRHR1 signaling cascade are not well characterized 
at present. Therefore, a more precise understanding of the involved interaction mechanisms is an 
essential prerequisite towards the development of more efficient CRHR1-specific modulators. 
The aim of this study was the development of tools to pharmacologically address class B GPCRs in 
tractable and relevant biological systems. In particular, we aimed to address the following questions: 
a) How do peptide ligands bind and activate the CRHR1 and class B GPCRs? In particular, what are 
the specific ligands domains involved in receptor binding and modulation? 
b) What are the role and contribution of individual amino acid residues of the peptide ligands for 
CRHR1 binding and modulation? 
c) Can the structure-activity-relationship analysis of the CRHR1 ligands give an insight into the 
activation mechanism of class B GPCRs?  
d) Can the structure-activity-relationship informations be used for the design of novel and 
tailored CRHRs ligands, agonists or antagonists? 
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3 Results and discussion 
3.1 Peptide-peptide conjugates as CRH mimics 
Several structure-activity-relationship studies have investigated the amino acid sequence of CRHR 
peptide ligands. In particular, Beyermann et al. have successfully shown the existence of two 
segregated receptor binding sites in the sequence of CRHRs ligands (Beyermann et al. 2000). CRHR1 
peptide ligands bind and activate their cognate class B GPCR thanks to a low resolution “two 
domain” mechanism. Stepwise, the C-terminal part of the hormone binds the CRHR1 extracellular 
domain (CRHR1-ECD1) with high-affinity, an interaction that directs the N-terminal part of the 
hormone to interact with the CRHR1 transmembrane domain (CRHR1-TMD) leading to G-protein 
signaling. In particular, the middle domain of the CRH hormone, which connects the two functional 
sites of the peptide hormone, was successfully replaced by a helical “connector”, thereby 
reconstituting a potent peptide agonist (Beyermann et al. 2000). Based on this work, we developed a 
peptide-peptide conjugation strategy to chemically probe the molecular interactions of CRH-like 
peptide ligands with their cognate receptor. We propose that the coupling of a CRHR1-ECD1 specific 
C-terminal peptide with an N-terminal peptidic fragment could produce high potency agonists. 
3.1.1 Choice of a ligation technique for the synthesis of biomimetic probes 
The conjugation consists in the linking of two biomolecules to form a hybrid, the bioconjugate, 
which retains the properties of each individual component. The coupling of two peptide fragments 
logically begins with the choice of a suitable ligation chemistry. Many criteria have to be fulfilled to 
produce an adapted conjugation technique: in optimal conditions, the conjugation method should 
be fast and quantitative, highly selective and insensitive to the chemical environment. Moreover the 
functional groups required for the conjugation reaction should be mildly and easily incorporated, 
preferentially during solid phase peptide synthesis (SPPS). Finally, the conjugation reaction should 
provide a robust and stable linkage that remains neutral toward ligand binding to its target receptor. 
For its versatility and broad applicability, we chose the Copper-Catalyzed Azide-Alkyne Cycloaddition 
(CuCAAC) as a starting point for our study. This 1,3-dipolar cycloaddition has such a large scope that 
it has been defined as “the cream of the crop” of “click” chemistry by K. Barry Sharpless himself 
(Kolb et al. 2001). Lately, the CuCAAC was extensively applied to small molecules for drug discovery 
purposes but to our knowledge, only few examples of peptide-peptide CuCAAC-mediated 
conjugations have been reported. 
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Figure 10. Biomimetic probe principle for the investigation of Class B GPCR-ligand interaction. 
An alkyne-tagged peptide (light green) is conjugated to a constant peptide fragment (dark green) 
that has high-affinity for the extracellular domain of the class B GPCR. The peptide-peptide 
conjugate is tested for modulation of the GPCR transmembrane domain activity in a cell-based 
functional assay. 
The CuCAAC is quantitative, robust and insensitive, thereby fulfilling most of our chemical 
requirements. Importantly, the 1,2,3-triazole linkage obtained is known to be insensitive and stable 
in most pH conditions. The copper(I) catalyzed variant of the CuCAAC afford exclusively 
1,2,3-triazoles as 1,4-regioisomers (Tornoe et al. 2002). Moreover, the conjugation can be performed 
under a wide variety of conditions and with almost any source of solvated Cu(I). For the 
reconstitution of CRH-like peptide hormone mimics, the CuCAAC is better suited than the commonly 
used native chemical or Staudinger ligations, which require N-terminal cysteine residues and 
detrimentally produce native amide bonds. Many arguments making us believe that the CuCAAC can 
be successfully applied to the reconstitution of CRH hormone mimics (Figure 10). As an alternative 
conjugation technique, we chose to apply and investigate the hydrazone bioconjugation of peptides. 
The hydrazone ligation occurs spontaneously and does not require additives such as oxidant or 
metal, making it attractive for the testing of crude peptide conjugates in vitro and in vivo. 
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3.1.2 Synthesis and characterization of CRHR1-ECD1 high affinity probes 
The peptides 1-3 were designed as CRHR1-ECD1 high-affinity peptide carriers based on known 
optimized C-terminal CRH analogs (Yamada et al. 2004) and were synthesized using standard Fmoc-
SPPS (Figure 11). The high-affinity carrier peptides 1-3 share common and specific structural 
features: all three possess an intramolecular lactam bridge. This conformational constrain is well 
characterized and has been shown to stabilize the peptide’s helical conformation thus enhancing its 
affinity for the CRHR1-ECD1 (Gulyas et al. 1995; Hernandez et al. 1993; Koerber et al. 1998; Miranda 
et al. 1994; Rivier et al. 1998b). Similarly, recent structure-activity-relationship studies have 
identified the cyclohexyl-alanine (X) substitution to be greatly potency enhancing (Yamada et al. 
2004). This led to the synthesis of N-terminally acetylated peptide 1 (Figure 11a). Peptide 1 was 
designed as a high-affinity CRHR1-ECD1 peptide antagonist and was successfully used for the 
pharmacological characterization of the CRHR1-ECD1 (Gordon et al. 2010). 
Peptides 2 and 3 were designed for the use in CuCAAC and hydrazone ligation reactions, 
respectively. Peptide 2 bears a fluorescent tag (NBD, 4-(7-nitro)benzofurazanyl) for quantification 
and analytical purposes (Figure 11b). The fluorophore was selectively introduced on the side chain of 
lysine8 during SPPS. This residue was shown to point out of the CRHR1-ECD1 binding cavity, thus it 
does not contribute to the binding of the peptide to the CRHR1 (Grace et al. 2007). An azide-
functionalized polyethylene glycol spacer was introduced at the N-terminus of the high-affinity 
peptide sequence for use in CuCAAC conjugation reactions. Moreover, the flexibility of this spacer 
allows optimal positioning of the ligands binding domains towards the receptors ECD1 and TMD 
(Beyermann et al. 2000). The synthesis of the spacer was straightforward and achieved in four steps 
with an overall 51 % yield (Figure 12a). Gratifyingly, the triethylene glycol spacer greatly improved 
the solubility of the high-affinity peptide 2 in aqueous solvents, thereby facilitating chromatographic 
purification. 
Similarly, peptide 3 was designed for hydrazone ligations (Figure 11c). We synthesized a 
Boc-protected hydrazinonicotinic acid (HNA, Figure 12b) which was coupled to the peptides N-
terminus during SPPS (Abrams et al. 1990). In contrast with peptide 2, peptide 3 was not 
fluorescently tagged as the aryl-hydrazone conjugation product was shown to yield a constitutive 
chromophore. 
The affinity of peptides 1-3 for the CRHR1-ECD1 was tested in a radioactive competition assay 
using I125(Tyr0)-sauvagine as a tracer (Figure 13 and Table 3). 
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Figure 11. SPPS scheme for the synthesis of high-affinity peptide carriers. a) SPPS of the 
N-terminally acetylated peptide 1. b) SPPS of the N-terminally azide-functionalized carrier 2. c) SPPS 
of the N-terminally hydrazine-functionalized carrier 3. X = cyclohexyl alanine; EAEK = lactam bridge, 
NBD = 4-(7-nitro)benzofurazanyl. 
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Figure 12. Synthesis of functionalized modification reagents. a) Synthesis of the triethylene glycol 
based azide-functionalized spacer 7. b) Synthesis the Boc-protected hydrazinonicotinic acid 9. 
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Figure 13. Binding of CRHR1-ECD1 high-affinity peptide probes 1-3. Radioactive competition assay 
using I125(Tyr0)-sauvagine and membrane preparations from HEK293 cells stably overexpressing 
CRHR1. 
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IC50 [nM] 
(s.e.m.) 
 
CRH 22.1 ± 4.5 
 
1 52.2 ± 8.3 
 
2 18.8 ± 2.8 
 
3 52.6 ± 13.3 
Table 3. Characterization of CRHR1-ECD high-affinity peptide probes. 
Gratifyingly, we observed that peptide carriers 1-3 retain high-affinity for the CRHR1-ECD1 and 
show affinities similar to the endogenous hormone CRH (Figure 13 and Table 3). The azide-
functionalized peptide 2, which bears the N-terminal spacer showed the highest affinity for the 
CRHR1-ECD1. This proves that the presence of a highly flexible spacer and the NBD fluorescent tag do 
not disturb or influence the binding to the CRHR1-ECD1. Peptides 1 and 3 showed slightly weaker 
affinities than peptide 2. This might be due to the presence and binding contributions of the acetyl 
or HNA N-terminal functional groups respectively. Although the affinities of the carriers 2 and 3 were 
two-fold lower than that of the endogenous ligand CRH, the peptides 1-3 were considered as 
efficient CRHR1-ECD1 high-affinity probes and were used for further investigations. 
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3.1.3 Synthesis of a “clicked” biomimetic probe: proof of concept 
The synthesis of C-terminally modified peptides was achieved by using the Backbone Amide 
Linker (BAL) approach whereby the growing peptide is anchored through a backbone nitrogen 
(Figure 14). The synthesis of the required 4-(3-methoxy-4-([(9H-fluoren-9-ylmethoxycarbonyl)(prop-
2-ynyl)-amino]methyl)(1)phenoxy)butanoic acid linker 11 (FMPB) was achieved by reductive 
amination using propargylamine and sodium cyanoborohydride, followed by 
fluorenylmethyloxycarbonyl (Fmoc) protection of the resulting secondary amine. The synthesis of 
the FMPB linker 11 was first optimized, and then performed in a “one-pot” reaction. This building 
block was then attached to a poly-(ethylene glycol)-polystyrene (PEG-PS) support and used to 
assemble peptides by standard Fmoc solid-phase chemistry. The final cleavage from the resin yield 
the C-terminally modified peptide 14 (Devigny et al. 2011). 
Figure 14. BAL strategy for the synthesis of C-terminally propargylated peptides. Briefly, the 
synthesis of the FMPB linker 11 was performed in a “one-pot” reaction. The linker 11 was then 
attached to a PEG-PS solid support yielding resin 12 that was used for SPPS. Cleavage of the peptide 
from the resin afford the desired N-terminally propargylated peptide 14. 
In the next step, we investigated if the coupling of an N-terminal “activation” fragment with 
peptide 2 could reconstitute a CRH-like hormone mimic. The endogenous peptide agonist Urocortin1 
(UCN) was chosen as a starting point for the investigation of ligand-CRHR1 interactions. UCN is 
closely related to the CRH hormone and a highly potent nonselective CRHR1 and CRHR2 agonist (see 
Introduction, figure 3 and table 2). Based on several structure-activity-relationship (SAR) studies of 
the full length CRH peptide hormone, we chose to first investigate whether the fragment 1-15 of the 
UCN hormone could provide the required amino acid residue sequence that leads to CRHR1 
activation (Beyermann et al. 2000; Kornreich et al. 1992).  
RESULTS & DISCUSSION 
40 
a) 
 
b) 
Peptide (nM)
0.00001 0.0001 0.001 0.01 0.1 1 10 100 1000 10000 100000
c
A
M
P
 S
ti
m
u
la
ti
o
n
 (
%
)
-20
0
20
40
60
80
100
120
16
15
CRH
 
Figure 15. Stimulation of CRHR1 by a peptide conjugate. a) Synthesis of the activation segment 15 
(light green) using BAL resin 12 and “click” conjugation with membrane recruition segment 2 that is 
derived from CRHR1 ligands (dark green). X = cyclohexyl alanine; EAEK = lactam bridge; NBD = 4-(7-
nitro)benzofurazanyl. b) Stimulation of cAMP production in HEK293 cells stably over-expressing 
CRHR1 by the C-terminally propargylated peptide 15 (blue), peptide conjugate 16 (red) and CRH 
(black). 
For this purpose, the N-terminal fragment peptide 15, corresponding to the fragment (1-15) of 
UCN, was synthesized using the BAL strategy in order to introduce the alkyne moiety at the peptide 
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C-terminus (Figure 15a). After HPLC purification, the peptide 15 was conjugated to the high-affinity 
peptide 2 by CuCAAC. The specific reaction conditions required for the CuCAAC were investigated by 
Francisco Perez-Balderas during his post-doctoral work in our laboratory. Notable features of the 
reaction conditions are: tert-butanol, a solvent in which the peptides are readily well-soluble; a six-
fold excess of the C-terminally propargylated peptide counterpart; a large excess of copper sulfate 
and a sufficient reaction time. The obtained conjugate 16 was purified by HPLC, quantified by 
fluorescence, and tested for CRHR1 stimulation in a cell-based cAMP assay (Figure 15b). 
The isolated peptide fragment 15 did not show any activity at the CRHR1 by itself up to a 
concentration of 10 µM in the cellular cAMP stimulation assay. The conjugation of peptide 15 with 
peptide carrier 2 by CuCAAC, however, reconstituted a full agonist with a potency of 2.82 ± 0.23 nM 
(Figure 15b and Table 4). Although the potency of conjugate 16 was much weaker than the CRH full 
hormone, it was a full agonist in the low nanomolar range thus proving that the fifteen UCN 
N-terminal residues contain a sequence motif sufficient to induce CRHR1 full-stimulation. This 
experiment established the peptide-peptide conjugation methodology as a fast and efficient 
alternative to the synthesis of full length peptide hormones. Importantly, the conjugation to the 
high-affinity carrier 2 dramatically enhanced the detection limits for very weak agonists such as 
fragment 15, which would have been inactive otherwise. 
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3.1.4 Urocortin11-15 C- and N-terminal truncation: characterization of a 
minimal CRHR1 stimulation sequence 
Having proven that a “clicked” conjugate can act as high potency agonist, we went on to 
determine the minimal N-terminal peptide sequence that is necessary to fully activate the CRHR1. 
Bidirectionally truncated derivatives of peptide 15 were synthesized using the BAL strategy. As 
previously described, the purified truncated peptides were coupled to peptide 2 by CuCAAC. 
Interestingly, after the reactions were shaken for two days, the presence of a fine yellow-colored 
precipitate was observed. The precipitate was easily isolated by centrifugation and analyzed. 
Gratifyingly, HPLC and mass spectrometry analysis identified the precipitate as the conjugation 
product while unreacted counterparts stayed in solution (Figure 17). Peptide conjugates 17-22 were 
thus isolated as precipitates and further purified by HPLC. After fluorescence quantification, the 
obtained conjugates were tested for CRHR1 stimulation in a cell-based cAMP assay (Figure 16 and 
Table 4). 
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Figure 16. cAMP stimulation curves corresponding to the truncated peptide conjugates listed in 
Table 4. a) Curves of the C-terminally truncated conjugates. b) Curves of the N-terminally truncated 
conjugates. 
 
Peptide sequence 
R = carrier 2 
EC50 [nM] 
(s.e.m.) 
 
CRH - - 0.0048±0.0002 
 
16 Ac-UCN
1-15
 Ac-DNPSLSIDLTFHLLR-R 2.82±0.23 
 
17 Ac-UCN
1-14
 Ac-DNPSLSIDLTFHLL-R 12.88±0.75 
 
18 Ac-UCN
2-15
 Ac-NPSLSIDLTFHLLR-R 1.14±0.06 
 
19 Ac-UCN
3-15
 Ac-PSLSIDLTFHLLR-R 0.26±0.01 
 
20 Ac-UCN
4-15
 Ac-SLSIDLTFHLLR-R 0.98±0.03 
 
21 Ac-UCN
5-15
 Ac-LSIDLTFHLLR-R 2.07±0.24 
 
22 Ac-UCN
6-15
 Ac-SIDLTFHLLR-R Inactive 
Table 4. Characterization of truncated analogs of the human UCN1-15 N-terminal fragment. 
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CuSO4          +        - 
b) 
 
Figure 17. Cycloaddition and workup of an exemplary conjugate. a) Fluorescence visualization 
(Excitation: 480 nm) of the conjugation mixture after centrifugation in the presence (left reaction 
tube) or absence (right reaction tube) of CuSO4. b) HPLC trace of an exemplary CuCAAC conjugation 
reaction, N-terminally propargylated peptide 15 (blue trace) was coupled to the high-affinity peptide 
carrier 2 (red trace) yielding peptide conjugate 16 (green trace) as a precipitate. 
We observed that the C-terminal deletion of Arg15 led to a five-fold decrease in potency 
(Figure 16a and Table 4), indicating that Arg15 seem to be important for activation. Surprisingly, the 
N-terminal truncation of the UCN1-15 fragment initially increased potency. Truncation beyond Leu5, 
however, completely abrogated the stimulating potency of the conjugates (Figure 16b and Table 4). 
Although the UCN3-15 conjugate 19 was the most potent of all conjugates, we considered that the 
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UCN4-15 sequence motif presented a better balance between size and potency. With a potency of 
0.98 ± 0.03 nM, the conjugate 20 established the 12 amino acid UCN4-15 sequence motif as a 
minimized activation fragment. This minimized template was used as a starting point for the further 
SAR investigation of individual amino acid residues, the UCN4-15 native sequence of conjugate 20 
being used as a potency control. 
Based on our observations that peptide conjugates precipitated out of solution, a fast and 
efficient procedure for the work-up of peptide conjugates was established: after the reaction was 
shaken for two days at 37 °C, the mixture was cooled to room temperature and centrifugated 
(Figure 17a). The supernatant containing the soluble unreacted counterparts as well as conjugation 
reagents was removed; the isolated precipitate was then further washed with tert-butanol. Finally, 
the precipitate was dried and subsequently dissolved in DMSO. This easy procedure allowed us to 
quantitatively isolate the truncated conjugates 16-22 with acceptable crude purities (Figure 17b). In 
the following, this workup procedure was systematically used for the isolation of CuCAAC-coupled 
crude conjugates. 
3.1.5 Alternative ligation method: the hydrazone bioconjugation of a UCN4-15 
biomimetic probe 
The UCN4-15 minimized activation template was used to test the suitability of the hydrazone 
bioconjugation as an alternative ligation method to the CuCAAC. The ligation chemistry is based on 
the reaction of an aromatic hydrazine with an aromatic aldehyde, yielding a stable bis-arylhydrazone 
conjugate bond (Figure 18). The aromatic hydrazine is based on 6-hydrazino-nicotinic acid (HNA) and 
is incorporated on the peptide N-terminus during SPPS using its N-Boc protected derivative 9 
(Figure 11c and Figure 12b). The aromatic aldehyde is incorporated on the desired biomolecule in 
solution on a lysine side chain using the succinimidyl 4-formylbenzoate 24 (SFB, Figure 18). Simple 
addition of a HNA-modified peptide to a SFB-modified peptide in a mildly acidic buffer, i.e., pH 5.0-
6.0, yields spontaneously the desired conjugate. Another useful feature of the bis-arylhydrazone 
ligation is that it forms a characteristic chromophore which absorbs at 354 nm. This unique property 
allows following of the conjugation reaction as well as easy UV quantification of the products. 
For the hydrazone ligation, we synthesized, modified and purified peptide 27 (Figure 19a). In 
particular, peptide 27 incorporates several structural features: first, the N-terminus contains the 
UCN4-15 CRHR1 minimized CRHR1 activation motif; it includes a triethylene glycol (TEG) moiety that 
was introduced directly on the UCN4-15 C-terminus, and that plays the role of “connector” between 
the CRHR1-ECD1 recruition segment (peptide 3) and activation segment (UCN
4-15). Finally, a lysine 
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residue is coupled to the C-terminus of the TEG spacer. This residue is subsequently used to 
selectively introduce the SFB modification reagent and thus plays a crucial role in the whole 
synthetic sequence, but not for the potency of the conjugate. Notably, the TEG spacer ensures that 
the lysine residue does not disturb the interaction of the UCN4-15 activation motif with the 
CRHR1-TMD. 
 
Figure 18. Reaction scheme used for the incorporation of modification reagents and hydrazone 
bioconjugation of peptide fragments. The peptide N-terminal fragment is synthesized by SPPS (left). 
Upon cleavage from the solid support, a C-terminal lysine residue is modified with the SFB reagent 
24. The peptide C-terminal fragment is synthesized by SPPS (right). The N-terminus of the peptide is 
modified with the HNA reagent during SPPS and upon cleavage from the solid support; the 
hydrazine-functionalized peptide 3 is obtained. SFB and HNA modified peptides are mixed in 
conjugation buffer to afford the arylhydrazone conjugate 26. 
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Peptide 27 was coupled to the high-affinity peptide carrier 3 by hydrazone ligation (Figure 19a). 
The conjugate 28 was purified by HPLC, quantified by UV absorption spectroscopy, and tested for 
CRHR1 stimulation in cAMP assay (Figure 19b and Table 5). 
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Figure 19. Stimulation of CRHR1 by a hydrazone-coupled peptide conjugate. a) Synthesis of the 
activation segment 27 (light green) and hydrazone conjugation with membrane recruition segment 3 
(dark green). X = cyclohexyl alanine; EAEK = lactam bridge. b) Stimulation of cAMP production in 
HEK293 cells stably over-expressing CRHR1 by peptide conjugates 20 and 28. 
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Peptide 
carrier 
EC50 [nM] 
(s.e.m.) 
 
20 2 0.63±0.08 
 
28 3 0.25±0.03 
Table 5. Characterization of “clicked” and hydrazone coupled peptide analogs of the N-terminal 
fragment of human UCN4-15. 
The hydrazone ligation of the UCN4-15 activation motif with the high-affinity peptide carrier 3 
reconstituted a full agonist with a potency 0.25 ± 0.03 nM. Although the hydrazone conjugate 28 
was slightly more potent than its “clicked” counterpart 20, it does not seem that the linkage plays 
any role in CRHR1 binding. This observation is again, in full agreement with the two-domain model of 
activation for Class B GPCRs. Thereby, the hydrazone ligation is a fast and efficient method for the 
synthesis of CRH hormone mimics. Advantageously, the hydrazone ligation does not require 
additives such as metal or oxidant, thus decreasing the risk for contaminations in the testing of 
crude conjugates.  
 
Figure 20. A novel linker for the synthesis of C-terminally formylbenzoate modified peptides. 
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The hydrazinonicotinic acid (HNA) moiety is easily incorporated at the N-terminus of the peptide 
carrier during SPPS; the 4-formylbenzoate (SFB) modification, however, requires an additional 
synthetic step which includes the HPLC purification of the peptide intermediates and products. This 
is a major limitation for the application of the method to a broader context, such as the synthesis of 
libraries of peptides. To overcome this problem, we designed a novel linker for the synthesis of 
C-terminally formylbenzoate-modified peptides (Figure 20). The approach is based on the work of 
Dubs et al. (Dubs et al. 2007) and shall provide a readily SFB-modified peptide upon cleavage from 
the solid support. The linker 29 was successfully synthesized under my supervision by Stephanie 
Finsterbusch during her Master’s degree practical work in our laboratory. Despite many trials, the 
coupling of linker 29 to a solid support could not be achieved due to its poor solubility in the solvents 
used for SPPS (e.g., CH2Cl2, DMF, and NMP).  
Although the hydrazone ligation method is advantageous in terms of reaction conditions, the lack 
of suitable linker chemistry for the direct synthesis of C-terminally formylbenzoate-modified 
peptides was detrimental towards the synthesis of conjugates in higher throughput. In contrast, the 
synthesis of C-terminally propargylated peptides using the BAL linker strategy is straightforward. 
Moreover, the easy isolation and purification of the “clicked” conjugates by precipitation makes the 
CuCAAC methodology applicable in a medium-throughput-screening (MTS) fashion. Given that both 
ligation methods afford CRHR1 agonists with similar potencies, we chose to continue our 
investigations by using the CuCAAC conjugation. 
3.1.6 Role of the ethylene glycol connector between the two ligands binding 
domains 
Our conjugation methodology uses two segregated receptor binding sites at the N- and C-termini 
of UCN to reconstitute a full hormone mimic. The UCN hormone “middle” domain was successfully 
replaced by a TEG spacer that was introduced at the N-terminus of high-affinity carrier 2 during 
SPPS. However, the length of this functionalized ethylene glycol chain might play an important for 
the final potency of the conjugates. We thus decided to investigate whether an optimal spacer 
length could afford conjugates with optimized potencies. In other words, the PEG spacer could be 
used as a molecular “ruler” to determine the optimal distance between the two CRHR1 binding sites 
within the conjugate. For this purpose, we synthesized a series of azide-functionalized spacers with 
increasing ethylene glycol lengths (Figure 21). 
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a) 
 
b) 
c) 
 
d) 
 
Figure 21. Overview of the synthesis routes used for the azide spacers used in the study. 
The synthesis of azide 34 (n = 0) was straightforward and performed as described (Bouzide and 
Sauve 2002). Azides 37, 45 and 46 (n = 1, 4 and 5 respectively) were obtained in few steps as 
previously described (Figure 12a and 21). The synthesis of azide 38 (n = 2), for which the tosylated 
derivative easily cyclizes to form a six-membered ring, was achieved by Jones oxidation of azide 5. 
Thereby, the ethylene glycol chain of the spacer varies in length between “short” (no ethylene glycol 
moiety, n = 0 in compound 34) and “long” (n = 5 in compound 46). The azide-PEG spacers were 
subsequently introduced on the CRHR1-ECD1 high-affinity carrier N-terminus during SPPS. 
Additionally, the carriers were tagged with the NBD fluorophore for quantification purposes. After 
cleavage and HPLC purification, we obtained the complementary high-affinity peptide carriers with 
N-terminal PEG lengths 48-52 (n = 0  n = 5). These carriers were coupled to the minimized 
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activation motif UCN4-15 by CuCAAC (Figure 22a). After HPLC purification and fluorescence 
quantification, the conjugates were tested for CRHR1 stimulation in cAMP assay (Figure 22b and 
Table 6). 
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Figure 22. Stimulation of CRHR1 by “clicked” UCN
4-15 peptide conjugates listed in Table 6. 
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N-term. 
Peptide carrier 
n = 
EC50 [nM] 
(s.e.m.) 
 
53 Ac-UCN
4-15
 0 2.59±0.28 
 
54 Ac-UCN
4-15
 1 1.00±0.08 
 
55 Ac-UCN
4-15
 2 0.78±0.06 
 
20 Ac-UCN
4-15
 3 0.47±0.02 
 
56 Ac-UCN
4-15
 4 0.63±0.02 
 
57 Ac-UCN
4-15
 5 0.68±0.06 
Table 6. Characterization of clicked UCN4-15 conjugates. 
Surprisingly, the peptide conjugates 20 and 53-57 show high and similar potencies for stimulation 
of CRHR1 (Figure 22b and Table 6). The TEG conjugate 20 (n = 3) was the most potent (pink curve, 
0.47 ± 0.02 nM) while the conjugate 53 bearing the shortest linker (n = 0) was the weakest (dark red 
curve, 2.59 ± 0.28 nM). Gratifyingly, the spacer length which provided the most potent agonist 
(peptide 20, n = 3) corresponds to the high-affinity carrier 2.  
The replacement of the middle portion (16-27) of UCN by ethylene glycol spacers of various 
lengths reconstituted full low nanomolar agonists which exhibited similar biopotencies, thus 
confirming that the amino acid residues of the middle portion (16-27) of UCN are individually not 
essential for activation (Table 6). This is consistent with the results of Beyermann et al. (Beyermann 
et al. 2000). The length of the spacers between the two receptor binding sites had only a little effect 
on receptor activation. This shows that an appropriate distance between both C-terminal and 
N-terminal binding sites in UCN, although advantageous (e.g., for conjugate 20), is not essential for 
receptor binding and activation. As suggested by Beyermann et al., the relative orientation of the 
two binding sites rather than the maintenance of a distinct distance between them seems to be 
essential for a high potency. Moreover, these results also suggest a remarkable flexibility of the 
receptor domains toward ligand binding. Importantly, a helical connector between the two ligand 
binding sites may contribute to confer an optimized conformation and orientation of the ligands; 
however, the high potencies of the UCN4-15 conjugates listed in Table 6 indicate that a helical middle 
domain is not essential for receptor binding and activation. The ten-fold difference in potency 
between conjugates and full length hormones also indicates that the UCN middle portion (16-27) 
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may not only influence the conformation of the ligand, but provide important additional receptor-
ligand interactions. 
Taken together, these results allow us to propose a three-step “low resolution” mechanism for 
the binding events of our UCN4-15 “clicked” conjugates. The peptide carrier 2 first binds the 
CRHR1-ECD1 with high-affinity. The UCN
4-15 N-terminal portion of the conjugate then freely rotates 
around the ethylene glycol spacer to adopt an optimized orientation for binding the CRHR1-TMD. At 
the same time, both the flexibilities of the receptor’s domains and the ethylene glycol spacer help 
the N-terminal segment of the ligand to adjust its position for binding. Finally, the UCN4-15 N-terminal 
segment binds the CRHR1-TMD, an event which activates the receptor and triggers G protein 
signaling. The limited flexibility conferred by the “short” spacer in conjugate 53 may explain its lower 
potency compared to the others UCN4-15 conjugates. Hereby, we established the triethylene glycol 
(n = 3) spacer of conjugate 20 as offering optimized flexibility and distance between the two ligands 
binding sites. 
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3.2 Urocortin14-15 biomimetic screening 
The use of CuCAAC “clicked” conjugates allowed us to characterize the 12 amino acid minimal 
template required for the full CRHR1 activation. To explore the contribution of individual residues to 
CRHR1 stimulation in more detail, we engaged on a medium throughput screening (MTS) of peptide-
peptide conjugates.  
3.2.1 Synthesis and potency evaluation of a Urocotin14-15 peptide conjugate 
library 
Based on the previously characterized minimal activation template UCN4-15, a library of 96 
C-terminally propargylated peptidic fragments containing a series of single amino acid substitutions 
was synthesized (Table 7). Conveniently, the synthesis of this peptide library was achieved using the 
BAL strategy in the FlexChem® parallel synthesis system (see Methods). Standard SPPS was 
performed in a 96 deep-well plate allowing the fast and parallel synthesis of the 96 C-terminally 
propargylated activation fragments. Each position of the UCN4-15 peptide sequence was 
systematically changed to alanine, aminoisobutyric acid (Aib), the corresponding D-amino acid, as 
well as five structurally related natural or unnatural amino acids. Thereby, the systematic amino acid 
replacements shall provide a complete SAR and activity profile of the UCN4-15 activation segment 
(Devigny et al. 2011). 
After SPPS, the propargylated peptides were cleaved from the solid support and the cleavage 
mixture was collected in a 96-deep-well plate. All 96-propargylated peptides were dried and 
weighted, then redissolved in a mixture of acetonitrile/water (50/50, v/v). At this point, we 
performed a first analysis round in order to estimate the quality of our library synthesis. HPLC and 
mass spectrometry analysis were performed for all 96-propargylated peptides. The estimation of the 
library quality is important because such parallel SPPS requires training and needs to be optimized. 
In addition, the FlexChem® system often leaks or breaks down, threatening the growing peptides of 
contamination. The crude UCN4-15 analogs were then coupled via their C-terminal alkyne group to the 
purified high-affinity carrier 2 by CuCAAC (Figure 23).  
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G-protein
N3 1. Conjugation
2. Screening
 
Figure 23. Biomimetic screening principle for the investigation of Class B GPCR ligand interactions.  
A library of alkyne-tagged peptides (light green) is conjugated to a constant peptide fragment (dark 
green) that has high-affinity for the extracellular domain of the class B GPCR. These conjugates are 
probed for modulation of the GPCR transmembrane domain. 
Gratifyingly, the peptide-peptide conjugates were routinely found to be much less soluble than 
their precursors allowing simple precipitation for their purification as previously described. The easy 
isolation of conjugates is a crucial feature of the biomimetic screening approach. Indeed, the 
systematic isolation or purification of individual conjugates is typically the rate limiting step in a 
medium throughput synthesis and can be extremely laborious. HPLC analysis showed complete 
conversion of the carrier peptide 2 for all the 96 conjugation reactions. The integration of the HPLC 
traces showed acceptable purities (≥ 65 %) for most crude conjugates (89 out of 96). At this stage we 
decided to test these crude peptide-peptide conjugates directly in a cellular assay without any 
further purification. This was possible as any residual reaction components (e.g., Cu+, t-butanol, or 
any remaining unconjugated peptide fragment) were minimal and were found not to disturb the 
cellular assay. The activities of the conjugates were compared with the purified conjugate 20 at 2 nM 
(Figure 24 and Table 7). 
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Ser4 Leu5 Ser6 Ile7 Asp8 Leu9 Thr10 Phe11 His12 Leu13 Leu14 Arg15 
Ala Ala Ala Ala
(a)
 Ala Ala Ala Ala Ala Ala Ala Ala 
Aib Aib Aib Aib Aib Aib Aib Aib Aib Aib Aib Aib 
D-Ser D-Leu D-Ser D-Ile D-Asp
(a)
 D-Leu D-Thr D-Phe
(a)
 D-His D-Leu D-Leu D-Arg 
Thr
(a)
 Ile Thr Leu Asn Ile Ser Tyr
(a)
 Arg Ile Ile Gln 
Glu Glu Glu Val
(a)
 Glu Val Glu Trp Glu Val
(a)
 Val Glu 
Lys Lys Lys Thr
(a)
 Thr Phe Lys Lys Lys Phe Phe Lys 
Dap Cha
(a)
 Dap Chg
(a)
 Dab Cha Dap pI-Phe Cha Cha
(a)
 Cha Cit 
h-Ser Nle h-Ser tBuGly h-Ser tBuAla
(a)
 h-Ser PhGly
(a)
 h-Ser
(a)
 tBuAla tBuAla Orn 
Table 7. Summary of single-point substitutions of the UCN4-15 sequence. Crude peptide-peptide 
conjugates carrying the indicated amino acid modification were assayed at 2 nM for cAMP 
stimulation of HEK293 cells stably overexpressing CRHR1. Inactive sequences are indicated in red, 
minimal activity is indicated in orange, equal activity compared to the purified UCN4-15 conjugate 20 
is indicated in yellow and activity-enhancing substitutions are highlighted green. (a) These conjugates 
were additionally HPLC purified and retested for activity (see section 3.2.2). Aib = -aminoisobutyric 
acid; Cha = 3-cyclohexyl-L-alanine; Chg = L- -cyclohexylglycine; Cit = L-citrulline; Dap = L-2,3-
diaminopropionic acid; Dab = L-2,4-diaminobutyric acid; h-Ser = homoserine; Nle = norleucine; Orn = 
ornithine; PhGly = L- -phenylglycine; pI-Phe = para-iodo phenylalanine; tBuAla = -tert-butyl-
L-alanine; tBuGly = L- -tert-butylglycine. 
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Figure 24. Positional MTS of a crude UCN4-15 peptide conjugate library at 2nM. Inactive sequences 
are indicated in red, minimal activity is indicated in orange, equal activity compared to the original 
UCN4-15 conjugate 20 is indicated in yellow, and activity-enhancing substitutions are highlighted in 
green. The difference of potencies between crude conjugates from the library and peptide 20 was 
estimated using a student’s t-test. 
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The biomimetic screening of the peptide conjugate library resulted in 70 conjugates where the 
stimulatory activity for CRHR1 was reduced or completely abolished (Figure 24 and Table 7). For 15 
of these peptide conjugates, the CRHR1 stimulation was not found to be significantly different 
compared to the wild-type sequence of UCN4-15. However, an enhanced CRHR1 stimulation was 
observed for 11 peptide conjugate analogs. Analysis of the activities for the single amino acid 
substitution analogs allows several conclusions about the structure-activity-relationship of CRHR1 
agonists (Devigny et al. 2011). 
First, replacement of Arg15 led to a substantial loss of potency. Consistently with the truncation 
study, the hydrogen bonding pattern of Arg15 seems to contribute importantly to CRHR1 stimulation. 
Replacement of Leu5,9,13,14 residues by similar aliphatic residues such Ile was quite well tolerated. 
Interestingly, the replacement of these residues by the unnatural amino acids such as Cha and 
tBuAla provided conjugates with similar or enhanced potencies. These sterically hindering side 
chains of Cha and tBuAla might constrain the whole N-terminal activation segment in an 
advantageous conformation to bind the CRHR1-TMD. Such substitutions might also optimize the 
hydrophobic interactions between the peptide ligand and the receptor. A similar structure-activity-
relationship was observed at Ile7 that could be advantageously replaced by Leu or bulky Chg 
residues. Generally, it seems that positions 5, 7, 9, 13, and 14 tolerate conservative aliphatic 
substitutions which can partially enhance potency.  
Replacement of His12 was well tolerated and it seems that this residue contribute comparatively 
less to the interaction with the CRHR1 receptor. An L- to D-Phe substitution at position 11 
substantially improved the activity of the peptide conjugate. Interestingly, this substitution is also 
present in the high-affinity CRHR1 peptide antagonist astressin (Gulyas et al. 1995). The replacement 
of Phe11 by Trp also provided an analogue with improved potency. Replacement of polar residues 
Ser6, Asp8, and Thr10 abolished activity. Consistent with our truncation study (section 3.1.4) and with 
prior studies on full length CRH (Beyermann et al. 1996; Kornreich et al. 1992), the side chains of 
these three residues seem to be essential for CRHR1 activation. Ser
4 could be advantageously 
substituted for several amino acids. The potency of the Ala4 conjugate indicates that the Ser4 side 
chain does not play an important role for CRHR1 activation. Again, this is consistent with our 
N-terminal truncation study in which UCN5-15 conjugate 21 showed significant activity (Table 4). 
Interestingly, the Ser4Thr substitution enhanced potency, either by fine-tuning of the hydrophobic 
interactions or by influencing the conformation of the three adjacent residues that are essential for 
activation. 
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The UCN4-15 SAR mentioned above is to compare with several single point mutation studies on the 
full length CRH hormone. In particular, Rivier et al. have performed alanine and D-amino acid scans 
of the whole CRH sequence (Kornreich et al. 1992; Rivier et al. 1993). As CRH and UCN share a high 
degree of homology in the activation segment (e.g., the fragments 4-7 in UCN and the corresponding 
5-8 in CRH are only slightly different, the Ser6 is conserved while Leu residues are exchanged by Ile 
residues and vice versa; the UCN8-15 fragment is completely conserved in CRH9-16; Table 2), the SAR 
between N-termini of the two hormones can be correlated. The results are striking: Ala4UCN4-15 and 
Ala12UCN4-15 were well tolerated, as are Ala5CRH and Ala13CRH. Alanine substitutions at any other 
position within the UCN4-15 or CRH5-16 N termini produced analogues with decreased potencies. 
Similarly, D-Phe11UCN4-15 and D-Phe12CRH substitutions greatly enhanced potency while the latter 
was dramatically reduced by D-amino acid substitutions at other positions. To a lesser extent, a 
single point slight alteration study also identified the potency enhancing Trp12CRH substitution 
(corresponding to Trp11UCN4-15 in our screening) (Beyermann et al. 1996). The mentioned SAR 
studies on the full length CRH required the laborious synthesis of the full length hormone to 
investigate the role of residues located in the N-terminal portion, thus greatly limiting the number of 
analogues within a library. In contrast, our conjugation strategy produced rapidly a complete SAR 
profile at each position within the UCN4-15 sequence. Overall, the activity profiles for SAR studies of 
CRH5-16 match perfectly with the UCN4-15 screening described herein, thus further validating our 
conjugation methodology.  
3.2.2 Purification of exemplary conjugates: validation of the crude 
biomimetic screening 
The precipitation workup procedure allowed the easy and simple isolation of the peptide 
conjugates (see Section 3.1.4). However, HPLC analysis of the crude conjugates revealed that in 
some cases, unreacted propargylated peptide precipitates together with the conjugate. Although 
copper sulfate is soluble in tert-butanol, residual metal might also contaminate the crude 
conjugates. It remained unclear whether these impurities have a detrimental effect on the potency 
of the crude conjugates. To ensure the suitability of the previous screening using crude conjugates, 
fourteen conjugates were purified by HPLC and their activities were compared in the cellular assay 
with their crude counterparts at 2 nM (Figure 25 and Table 8). We especially focused on sequences 
with enhanced activity as well as peptide conjugates with lower purities (≤ 65%). 
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Figure 25. Maximal cAMP stimulation of crude vs. purified single-substituted analogs of human 
UCN4-15 at 2 nM. 
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 Crude Purified 
cAMP stimulation 
(%) Purity (%) 
cAMP stimulation 
(%) Purity (%( 
2
 n
M
 
Thr
4
 90.3±0.6 95 90.9±1.3 100 
Cha
5
 94.5±1.8 82 94.8±0.8 100 
Val
7
 13.9±1.6 42 19.1±6.2 98 
Thr
7
 2.7±2.7 56 1.5±3.0 93 
Chg
7
 77.9±8.9 50 79.8±2.6 90 
D-Asp
8
 3.0±1.2 69 4.8±1.0 98 
tBuAla
9
 42.8±7.8 100 56.7±4.9 100 
D-Phe
11
 91.6±4.5 66 84.4±4.9 92 
Tyr
11
 30.1±4.7 60 40.6±11.8 97 
Chg
11
 -0.7±2.4 51 7.4±0.7 96 
h-Ser
12
 53.3±1.7 67 56.5±6.5 100 
Val
13
 10.7±4.9 61 25.4±2.2 100 
Cha
13
 52.0±10.1 100 46.4±9.5 97 
UCN
4-15
 56.7±8.0 78 68.8±3.5 100 
Table 8. cAMP stimulation of crude vs. purified single-substituted analogs of human UCN4-15 at 
2 nM. 
No differences in potency were observed between crude and purified conjugates of same purities 
(e.g., Thr4, Cha5, tBuAla9 and Cha13), thus confirming that residual conjugation components in the 
precipitate (e.g., copper or unreacted propargylated peptide) do not influence the functional assay. 
Furthermore, this experiment also validates the stimulation enhancing effects of these amino acid 
substitutions. For others conjugates, no major differences in activity were found between the crude 
and the purified conjugates, thus validating the in situ screening approach. Importantly, the 
presence of impurities (unreacted C-terminally propargylated peptide or copper) has only a minimal 
influence on the potency of the crude peptide conjugates. 
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3.2.3 Synthesis and evaluation of optimized UCN4-15 peptide probes 
The next step was to investigate whether the enhancing effects of the single substitutions 
identified in the positional screening were additive. For this purpose, a library of C-terminally 
propargylated UCN4-15 peptides bearing multiple substitutions was synthesized. Notably, the 
substitutions Ser4Thr, Leu5Cha, and Phe11D-Phe provided the greatest individual potency 
enhancement in the MTS and were chosen as a starting point for the elaboration of more potent 
conjugates (Devigny et al. 2011). 
Combination of the first two mutations in conjugate 58a enhanced potency 24-fold compared to 
the native UCN4-15 sequence (Figure 26a and Table 9). The triple mutation in conjugate 59a further 
slightly increased potency to provide a 40 pM agonist. These conjugates were so potent that we 
tested whether they could show any activity, even at a high concentration, without the presence of 
recruition segment 2. An additional library of polysubstituted C-terminally amidated peptides was 
synthesized. Gratifyingly, untethered peptides 58b and 59b showed for the first time a weak but 
detectable CRHR1 agonism (Figure 26b and Table 9). These encouraging results led us to incorporate 
other mutations identified as beneficial in the single substitution screening (Ile7Chg, Leu9tBuAla, and 
Leu13Cha). This further enhanced the potency of untethered peptides to finally provide the 
hexasubstituted peptide 62b as a low nanomolar agonist. Importantly, in both tethered and 
untethered setups, the incorporation of additional substitutions showed cumulative effects for the 
potency. 
From a structural point of view, it seems that this increase in potency was largely achieved by 
fine-tuning the hydrophobic interactions through incorporation of the natural and unnatural amino 
acids side chains (Thr, Cha, Chg and tBuAla). Additionally, these mutations may play an important 
conformational role by constraining the whole activation segment in a helical conformation. 
Intriguingly, these additional substitutions did not further increase the potency in the context of the 
high-affinity carrier. This is in contrast to the cooperative behavior classically expected for 
conjugated two-site binding fragments (Murray and Verdonk 2002). The molecular underpinnings for 
the apparent lower limit of approximately 50 pM for peptide-carrier 2 conjugates are currently 
unknown. 
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Figure 26. Stimulation of CRHR1 by multisubstituted peptide conjugates (a) and C-terminally 
amidated (b) UCN4-15 peptide fragments. 
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Figure 27. Competitive inhibition of the stimulation of CRHR1 by multisubstituted peptide 
conjugates (a) and C-terminally amidated (b) UCN4-15 peptide fragments in the presence of 
peptide 1 (5 µM). 
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The N-terminal part of CRH corresponding to peptide 62b is believed to primarily interact with 
the juxtamembrane domain of CRHR1. To further characterize the pharmacology of peptide 
conjugates 58a-62a and C-terminally amidated peptides 58b-62b, we decided to investigate the 
relevance of peptide CRHR1-ECD1 recruition for the ligands potencies. A competition assay between 
peptides 58-62 and the CRHR1-ECD1 specific high-affinity peptide antagonist 1 was performed 
(Figure 27 and Table 9). The conjugates 20a and 58a-62a were very sensitive to the presence of 
5 µM of peptide 1. The native UCN4-15 sequence of peptide 20a was rendered completely inactive. 
The potency of conjugates 58a-62a was in average 130-fold weaker in the presence of peptide 1, 
indicating that the conjugates compete directly for binding the CRHR1-ECD1 with peptide 1. In 
contrast, this effect was very moderate for untethered peptides 58b-62b. The weak CRHR1 agonist 
58b was rendered inactive and the peptides 59b-62b were in average 2-fold weaker in the presence 
of 5 µM of peptide 1.  
Obviously, peptide 1 was unable to efficiently inhibit CRHR1 stimulation by amidated peptides 
59b-62b. The weak inhibitory effect might reside in the mechanism of peptide 59b-62b. The amino 
acid sequence of peptides 58b-62b relies on the native UCN4-15 sequence and likely interacts with the 
CRHR1 transmembrane domain. It is then not surprising that the ECD1 specific antagonist 1 is unable 
to compete with transmembrane domain agonists. 
To further characterize the pharmacology of peptides 58-62, we performed a radioactive 
competition assay using hot SVG and membrane preparations overexpressing CRHR1 (Figure 28). The 
peptide conjugates 20a and 58a-62a fully competed with I125-SVG showing affinities in the low 
nanomolar range (Figure 31a). Interestingly, the binding affinity of the conjugates slightly increased 
with increasing substitution to reach a lower limit around 2 nM. This non cooperative behavior 
correlates with the lower limit of potency observed in the CRHR1 stimulation assay (Figure 26a and 
Table 9). Consistent with the stimulation assay, peptides 20b and 58b were found to be inactive in 
the binding assay. Likewise, peptides 59b-62b competed weakly with I125(Tyr0)-SVG. At higher 
concentrations, the curves of peptides 59b-62b converge to approximately 400 CPM. Obviously, a 
lower SVG displacement limit was reached indicating that peptides 59b-62b may compete with the 
N-terminus of SVG, displacing it only partially from binding CRHR1. 
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Figure 28. Radioactive competition assay using I125(Tyr0)-SVG and membrane preparations from 
HEK293 cells stably overexpressing CRHR1. a) Competition between I
125(Tyr0)-SVG and peptide 
conjugates. b) Competition between I125(Tyr0)-SVG and C-terminally amidated peptides.
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R = carrier 2
(a) 
R = NH2
(b) 
EC50 (nM)
(c)
 IC50 (nM)
(d) 
EC50 (nM)
(c) 
IC50 (nM)
(d) 
 -1 
+1 
(5 µM) 
+I
125
Svg 
(20 pM) -1 
+1 
(5 µM) 
+I
125
Svg 
(20 pM) 
 
20 Ac-UCN4-15 1.12±0.05 Inact.(e) 5.4±2.6 Inact.(f) Inact.(g) Inact.(h) 
 
58 Ac-[Thr4Cha5]UCN4-15 0.053±0.001 7.1±0.5 3.6±1.8 487±144(I) Inact.(g) Inact.(h) 
 
59 Ac-[Thr4Cha5D-Phe11]UCN4-15 0.040±0.001 5.1±0.5 1.8±0.9 181±15 396±31 10188±6611 
 
60 Ac-[Thr4Cha5,13D-Phe11]UCN4-15 0.074±0.001 8.4±0.5 2.2±1.3 48±2 113±7 3738±1604 
 
61 Ac-[Thr4Cha5,13Chg7D-Phe11]UCN4-15 0.037±0.001 5.5±0.3 1.6±1.0 25±1 50±6 2977±1602 
 
62 Ac-[Thr4Cha5,13Chg7tBuAla9D-Phe11]UCN4-15 0.049±0.001 5.9±0.5 1.6±0.6 4.0±0.1 10.0±1.0 400±190 
Table 9. Binding to or stimulation of CRHR1 by multisubstituted peptide fragments and conjugates 
in a stable CRHR1 overexpressing cell line. 
(a) Propargylated peptides conjugated to peptide 2. 
(b) C-terminally amidated. (c) cAMP stimulation of a stable CRHR1 overexpressing cell line in the 
absence or presence of 5 µM of the extracellular domain-specific antagonist 1. (d) Radioactive binding 
assay using membrane preparations from CRHR1-overexpressing HEK293 cells. 
(e) Inactive up to 50 
nM. (f) Inactive up to 10 µM. (g) Inactive up to 5 µM. (h) Inactive up to 80 µM. (I) Partial agonist. 
The role of the CRHR1-ECD1 for the conjugates or peptide amides potencies was further 
investigated using HEK293 cells transiently overexpressing either the full length wild type CRHR1 
(WT) or a truncated mutant lacking the ECD1 (ΔECD1; Figures 29, 30 and Table 10).  
As expected, the peptide conjugates 20a and 58a-62a were potent in a cAMP stimulation assay 
using a cell line transiently overexpressing the WT-CRHR1 (Figure 29a). Notably, the potency values 
were similar in assays using cell lines stably or transiently overexpressing CRHR1 (Tables 9 and 10). 
The peptide conjugates were inactive in a cAMP stimulation assay using a cell line transiently 
overexpressing a mutant CRHR1 that lacks the ECD1 (ΔECD1-CRHR1, Figure 29b). For conjugates 58a-
62a incorporating the potency enhancing N-terminal amino acid substitutions, it is thus somewhat 
surprising that these conjugates are not able to stimulate CRHR1. Although conjugates 61a and 62a 
starts to weakly stimulate CRHR1 at higher concentrations (dark red and dark green plots 
respectively), their potencies are substantially reduced compared to the untethered analogs 
(compare to Figure 30b). The ligated C-terminal recruition fragment 2 therefore seems to hinder the 
activation segment from binding to the CRHR1-TMD. 
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Figure 29. cAMP stimulation curves of multisubstituted peptide conjugates using HEK293 cells 
transiently overexpressing a) WT-CRHR1 or b) ΔECD1-CRHR1. 
RESULTS & DISCUSSION 
70 
a) 
WT
[Peptide] (nM)
1e-3 1e-2 1e-1 1e+0 1e+1 1e+2 1e+3 1e+4 1e+5
c
A
M
P
 s
ti
m
u
la
ti
o
n
 (
%
)
-40
-20
0
20
40
60
80
100
120
20b
58b
59b
60b
61b
62b
 
b) 
ECD1
[Peptide] (nM)
1e-3 1e-2 1e-1 1e+0 1e+1 1e+2 1e+3 1e+4 1e+5
c
A
M
P
 s
ti
m
u
la
ti
o
n
 (
%
)
-40
-20
0
20
40
60
80
100
120
20b
58b
59b
60b
61b
62b
 
Figure 30. cAMP stimulation curves of C-terminally amidated multisubstituted peptides using 
HEK293 cells transiently overexpressing a) WT-CRHR1 or b) ΔECD1-CRHR1. 
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R = carrier 2
(a) 
R = NH2
(b) 
EC50 (nM)
 
EC50 (nM)
 
 WT ΔECD WT ΔECD 
 
20 Ac-UCN4-15-R 1.20±0.08 Inact. Inact. Inact. 
 
58 Ac-[Thr4Cha5]UCN4-15-R 0.052±0.002 Inact. 429±31 831±86 
 
59 Ac-[Thr4Cha5D-Phe11]UCN4-15-R 0.037±0.001 Inact. 165±8 797±79 
 
60 Ac-[Thr4Cha5,13D-Phe11]UCN4-15-R 0.057±0.001 Inact. 46±3 161±13 
 
61 Ac-[Thr4Cha5,13Chg7D-Phe11]UCN4-15-R 0.018±0.001 Inact. 20.9±0.8 84±2 
 
62 Ac-[Thr4Cha5,13Chg7tBuAla9D-Phe11]UCN4-15-R 0.014±0.001 Inact. 3.4±0.3 15.6±0.5 
Table 10. Stimulation of CRHR1 by multisubstituted peptide fragments and conjugates in a 
transient CRHR1 wild type or ΔECD1 overexpressing cell line. 
(a) Propargylated peptides conjugated 
to peptide 2. (b) C-terminally amidated. 
Similarly, the potencies of untethered peptides 58b-62b correlated perfectly between assays 
using cell lines stably or transiently overexpressing the WT-CRHR1 (Tables 9 and 10). The peptides 
58b-62b, however, all activated the ΔECD1-CRHR1 mutant, albeit with about 4-fold reduced potency 
(Figure 30b and Table 10) and consistently produced partial agonism (58b) or full agonism (59b-62b). 
Notably, the untethered peptides were able to stimulate the ΔECD1-CRHR1 mutant with good 
potency (e.g., 15.6 ± 0.5 nM for peptide 62b), while their conjugated counterparts (e.g., 62a) were 
inactive in the same settings. This observation confirms that the carrier peptide 2 can actually 
negatively affect the conjugation partners when not bound to the ECD1.  
This experiment clearly and directly shows that the transmembrane domain (CRHR1-TMD) is the 
primary interaction site for these N-terminally derived CRH analogs, with only minor contributions 
from the extracellular domain, possibly indirectly by stabilizing the correct conformation of the 
juxtamembrane domain. Incorporation of six amino acid potency-enhancing substitutions identified 
in the single point screening led to the optimized untethered peptide 62b. At this point, we decided 
to rename the peptide 62b in transtressin; “trans” refers to the “transmembrane domain” of the 
CRHR1 and “stressin” refers to the potency of 62b to stimulate the CRHR1.  
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3.2.4 Pharmacological characterization of a CRHR1-TMD specific probe 
The binding mode of the hexasubstituted untethered peptide transtressin (62b) was further 
characterized in several assays. First, we tested the sensitivity of transtressin toward peptide 1, an 
antagonist specific for the CRHR1 extracellular domain, and DMP696, a nonpeptidic antagonist 
specific for the CRHR1 juxtamembrane domain (generous gift of Bristol-Myers-Squibb, see 
Introduction). In a competition assay using the full length CRHR1 construct, the endogenous 
hormone CRH (1 nM) was very sensitive to a saturating concentration of peptide 1 (10 µM), while 
DMP696 (2 µM) had only a weak inhibitory effect (Figure 31, dark brown bars). In contrast, DMP696 
completely abolished CRHR1 stimulation produced by transtressin (100 nM) while peptide 1 had no 
effect (Figure 31, light brown bars) in the same settings. In a similar assay using the truncated CRHR1 
mutant (ΔECD1-CRHR1), CRH was completely inactive even in the absence of DMP696. In contrast, 
transtressin was potent and sensitive to the presence of DMP696 (Figure 31, yellow bars). 
 
Figure 31. Stimulation of CRHR1 and extracellular domain-truncated CRHR1 by an optimized 
peptide agonist. HEK293 cells transiently overexpressing full length CRHR1
24-415 (brown bars), a 
truncated version CRHR1
112-415 (yellow bars), or an empty vector (gray bars) were stimulated with 
CRH (filled) or transtressin (62b, hatched) at the indicated concentration in the absence or presence 
of the antagonists DMP696 (2 µM) or peptide 1 (10 µM). After 30 min, cAMP accumulation was 
determined and normalized. 
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These preliminary results clearly identify the CRHR1-TMD as a primary interaction site for 
transtressin. Interestingly, CRH binds so tightly to the CRHR1 that DMP696 has only a weak inhibitory 
effect. Despite being one of the most potent CRHR1 nonpeptide antagonists, it seems that this 
compound is not potent enough to displace the endogenous hormone in this concentration range. 
Moreover, it seems that DMP696 stabilized an inactive conformation of the mutant CRHR1 
(Figure 31, yellow filled bar). In agreement with our previous experiments, transtressin was slightly 
less potent in an assay using the ΔECD1-CRHR1 than the WT-CRHR1 constructs (Figures 30 and 31). In 
these cell lines transiently overexpressing the WT-CRHR1 or ΔECD1-CRHR1 constructs, the differences 
in potency observed may rise from different receptor expression level, from different functionality of 
the mutant receptor, or both. 
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Figure 32. cAMP inhibition curves of transtressin by the CRHR1-ECD1 specific peptide 1, astressin 
and the CRHR1-TMD specific antagonist DMP696. HEK293 cells stably overexpressing the full length 
CRHR1 were incubated with increasing concentrations of antagonists: peptide 1 (blue), astressin 
(green) and DMP696 (red). After that the cells were incubated for 30 min, a fixed concentration of 
transtressin (3 nM) was added and the cells were further incubated for 30 min. Finally, the cells were 
lysed and the cAMP production was determined. 
Transtressin was further characterized in a dose-response cAMP competition assay. In this setup, 
HEK293 stably overexpressing the full length CRHR1 construct were first incubated with increasing 
concentrations of each antagonists: peptide 1, astressin (AST) and DMP696 respectively; a fixed 
EC50-corresponding concentration of transtressin was then added (EC50 = 3 nM, identified in cAMP 
stimulation assay, Table 10). Consistently, the CRHR1-ECD1 specific peptide antagonist 1 was unable 
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to inhibit the CRHR1 stimulation produced by transtressin (Figure 32, blue plots). DMP696, however, 
competed with transtressin and completely abolished CRHR1 stimulation at higher concentrations 
(red curve). Interestingly, the peptide antagonist astressin also had an inhibitory effect; however at 
higher astressin concentrations the cAMP stimulation reached a lower limit around 30 % (green 
curve). Hence the competition effect of astressin with transtressin suggests that the antagonistic 
potency of this peptide arises not only from CRHR1-ECD1 binding but also from an interaction with 
the CRHR1-TMD. 
The dose-response cAMP competition assays of transtressin with several CRHR1-domains specific 
antagonists clearly establish the latter as a specific CRHR1-TMD peptide agonist. Starting from the 
40-amino acid long sequence of the endogenous UCN hormone, the conjugation methodology 
allowed us to identify and optimize the ligand-CRHR1-TMD interactions in order to obtain a specific 
and highly potent twelve-amino acid CRHR1 agonist. Gratifyingly, transtressin is the first known 
CRHR1 transmembrane domain specific agonist.  
The dose sensitivity of the endogenous hormone CRH, the conjugates 20a, 62a and transtressin 
to the CRHR1-TMD specific nonpeptide antagonist DMP696 was further investigated (Figure 33 and 
Table 11) in a cAMP inhibition assay. Nonpeptidic CRHR1 antagonists such as DMP696 are well 
known to bind an allosteric site within the J-domain, producing a conformational change that blocks 
peptide agonists to bind their orthosteric site. Because the peptide can no longer bind the J-domain, 
it can no longer activate the CRHR1. This effect is concentration-dependent; hence a Schild 
regression analysis may provide crucial details about the molecular activation mechanism of each 
agonist. In this competition setup, HEK293 cells stably overexpressing the CRHR1 were first incubated 
with increasing concentrations of DMP696. Increasing concentrations of the peptide agonists were 
then added and the subsequent cAMP production was determined. 
RESULTS & DISCUSSION 
75 
a) 
CRH
[Peptide] (pM)
1e-3 1e-2 1e-1 1e+0 1e+1 1e+2 1e+3 1e+4 1e+5
c
A
M
P
 s
ti
m
u
la
ti
o
n
 (
%
)
-20
0
20
40
60
80
100
120
@600nM DMP696
@300nM DMP696
@150nM DMP696
@75nM DMP696
@50nM DMP696 
@25nM DMP696 
@ No DMP696
 
b) 
20a-UCN
4-15
-conj.
[Peptide] (nM)
0.01 0.1 1 10 100
c
A
M
P
 s
ti
m
u
la
ti
o
n
 (
%
)
-20
0
20
40
60
80
100
120
@600nM DMP696
@300nM DMP696
@150nM DMP696
@75nM DMP696
@50nM DMP696 
@25nM DMP696 
@ No DMP696
 
RESULTS & DISCUSSION 
76 
c) 
62a
[Peptide] (nM)
0.0001 0.001 0.01 0.1 1 10 100
c
A
M
P
 s
ti
m
u
la
ti
o
n
 (
%
)
-20
0
20
40
60
80
100
120
@600nM DMP696
@300nM DMP696
@150nM DMP696
@75nM DMP696
@50nM DMP696 
@25nM DMP696 
@ No DMP696
 
d) 
62b
[Peptide] (nM)
1e-2 1e-1 1e+0 1e+1 1e+2 1e+3 1e+4 1e+5
c
A
M
P
 s
ti
m
u
la
ti
o
n
 (
%
)
-20
0
20
40
60
80
100
120
@600nM DMP696
@300nM DMP696
@150nM DMP696
@75nM DMP696
@50nM DMP696 
@25nM DMP696 
@ No DMP696
 
Figure 33. Mechanistic analysis of DMP696 inhibition vs peptide agonists CRH, 20a, 62a and 
transtressin. Full dose-response curves for (a) CRH, (b) conjugate 20a, (c) conjugate 62a and (d) 
transtressin (62b) stimulated cAMP production in absence or presence of increasing concentrations 
of DMP696 using HEK293 cells stably overexpressing CRHR1. 
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DMP696 
(nM) 
CRH 20a 62a 62b 
EC50 (pM) % Emax EC50 (nM) % Emax EC50 (nM) % Emax EC50 (nM) % Emax 
600 88.1±4.0 99 n.a. n.a. 1.3±0.1 98 183±55 27 
300 39.1±2.8 100 n.a. n.a. 0.68±0.03 99 172±17 47 
150 15.5±1.0 100 7.1±3.9 17 0.44±0.03 99 104±9 69 
75 6.5±0.2 100 5.1±0.8 39 0.27±0.02 100 51±3 92 
50 3.9±0.2 100 4.8±0.5 65 0.19±0.01 100 30±2 91 
25 2.6±0.1 100 2.6±0.4 79 0.075±0.002 100 17±2 96 
0 2.0±0.2 99 1.4±0.1 87 0.036±0.003 99 4.0±0.3 98 
Table 11. Schild analysis of competitive properties of DMP696 vs. peptide agonists CRH, 20a, 62a 
and transtressin (62b). 
Increasing concentrations of DMP696 incrementally depressed the maximal stimulation (Emax) 
induced by conjugate 20a while only weakly affecting the potency of the latter, consistently with a 
noncompetitive mode of inhibition (Figure 33b). This is in line with the two-domain model where the 
receptor occupancy is largely determined by the extracellular domain and its high-affinity to the 
carrier peptide (unaffected by DMP696), while efficacy is primarily determined by the interaction of 
the transmembrane domain with the N-terminal UCN4-15 segment. Importantly, the two-domain 
model predicts that concentrations of conjugate 20a that fully saturate the extracellular domain 
constitute an upper limit to the effective (“intramolecular”) concentration of the conjugated peptide 
20 that can be “perceived” by the transmembrane domain. Further increasing concentrations of free 
conjugated 20a unligated to the extracellular domain can be neglected in this context. This maximal 
effective concentration of 20 is eventually unable to overcome the increasing concentrations of 
DMP696 thus providing a rationale for the observed noncompetitive mode of inhibition.  
In contrast, increasing concentrations of DMP696 dramatically affected the potency of the 
endogenous hormone CRH. However, DMP696 had no effect on the maximal stimulation (Emax) 
induced by CRH and, at higher concentrations, full CRHR1 stimulation was observed (Figure 33a). 
Increasing concentrations of DMP696 had similar effects on the cAMP dose response of conjugate 
62a (Figure 33c). In both cases, the decrease in potency was directly proportional to the 
concentration of DMP696; however at higher concentrations of the peptide agonists, DMP696 was 
not able to inhibit the CRHR1 stimulation. This effect is consistent with a competitive mode of 
inhibition of DMP696 in which the antagonist competes directly with the peptide N-terminus for 
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binding the CRHR1-TMD. This mode of inhibition is not in line with the two domain model; it seems 
that the effective concentration of agonist N-terminus “perceived” by the CRHR1-TMD does not 
depend of the binding of the peptides to the CRHR1-ECD1. We assume that this mechanism is 
characteristic of highly potent peptide agonists such as CRH and conjugate 62a. In this concentration 
range, the CRHR1-ECD1 is not saturated with peptide C-terminus and allows a direct competition at 
the CRHR1-TMD; it is possible that a higher concentration of DMP696 would reveal a noncompetitive 
mode of inhibition similar to that observed with conjugate 20a. 
The sensitivity of transtressin toward increasing concentrations of DMP696 revealed an 
interaction reminiscent of a mixed competitive mode of inhibition. DMP696 strongly affected the 
EC50 of transtressin even at low concentrations, while at higher concentrations it also reduced the 
Emax of the latter (Figure 33d). This is completely in line with a direct competition between DMP696 
and transtressin for binding at the CRHR1-TMD. Transtressin is able to displace DMP696 from binding 
the CRHR1-TMD up to a concentration of 75 nM of the latter (blue curve). Above this limit, the 
CRHR1-TMD is saturated with DMP696 thus decreasing the transtressin-induced cAMP stimulation 
(Emax level). This mode of inhibition is characteristic of a CRHR1-TMD specific agonist and a unique 
feature of our new CRHR1 modulator transtressin. 
Finally, the specificity of the conjugate 20a and transtressin for CRH receptors was tested in 
collaboration with Serena Cuboni. A cAMP stimulation assay was performed using HEK293 cells 
transiently overexpressing GLPR1, PTHR and CRHR2 (Figure 34). 
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Figure 34. cAMP stimulation curves of peptide conjugate 20a and transtressin in cell lines 
transiently overexpressing (a) GLP1, (b) PTHR and (c) CRHR2. 
Transtressin and conjugate 20a were unable to stimulate the GLP1 and the PTH receptors, 
showing that there is no cross-reactivity for other closely related receptors. However, transtressin 
and the conjugate 20a were active at the CRHR2 (22.04 ± 1.12 nM and 0.57 ± 0.03 nM respectively, 
Figure 34c), the closest homologue of CRHR1 (> 70 % amino acid sequence identity). The low degree 
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of selectivity between the two CRH receptor subtypes is not surprising as CRHR2 is also potently 
stimulated by the endogenous ligand UCN from which transtressin and the conjugate 20a were 
derived. The highest degree of sequence homology between CRHR1 and CRHR2 is found in the 
intracellular loops and the seven transmembrane helices (~ 90 % and ~ 85 % identity respectively), 
while the extracellular domains are conserved to a lesser extent (~ 60 %), thus explaining the slight 
differences of potencies for transtressin and the conjugate 20a between the two receptor subtypes. 
In particular, the ligand selectivity profile of CRHR1 and CRHR2 were well investigated. Dautzenberg 
et al. have shown that the unusual ligand selectivity of the CRHR1 resided completely in its ECD1 
domain; suggesting that the others extracellular loops of CRHRs do not contribute significantly to the 
selectivity of this receptor (Dautzenberg et al. 1999). Hence, transtressin is a nonselective CRHR1 and 
CRHR2 agonist. 
Recently, a transtressin analogue with an N-terminal tyrosine amino acid residue was 
synthesized. This modification retained the agonistic potency of transtressin (data not shown). This 
peptide could be used to obtain a radioactive analogue of transtressin that could be used in binding 
assays; such direct binding experiment would complement the pharmacological characterization of 
this new modulator of the CRHRs. 
Finally, a hallmark of the biomimetic screening is the possibility to target the unmodified native 
receptors. The peptide-carrier conjugates should therefore also be applicable to the endogenous 
receptors in their native environment. This was confirmed in a collaboration with the group of 
Molecular Neurogenetics (Jan Deussing) at the Max-Planck-Institute for Psychiatry in Munich, which 
allowed us to test the effects of conjugates in a physiologically relevant system. Katherine Webb (AG 
Deussing) administered the conjugate 20a and transtressin directly to the brain of wild-type mice via 
intracerebroventricular injection. The CRHR1-mediated modulation of the stress response was then 
evaluated using the acoustic startle response paradigm (data not shown). Gratifyingly, the sensitizing 
effects of the peptide conjugate on the startle response were qualitatively similar to exogenously 
applied CRH controls (Devigny et al. 2011).  
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3.2.5 Synthesis and evaluation of a peptide amide library 
Based on the potency-enhancing amino acid substitutions identified in the screening, we decided 
to complete the SAR of the UCN4-15 sequence by synthesizing a small library of untethered peptides 
(Figure 35 and Table 12). We included combinations of amino acid substitutions suited for the 
untethered template (peptides 63, 64, 65, 66, 67, 73, 75, 76, 77, 78 and 79); in addition we 
incorporated more “exotic” amino acid substitutions such as α-methylated amino acids (peptides 68, 
69, 70 and 75) and unnatural amino acids (peptides 71 and 72). As usual, the library of untethered 
peptides was tested for CRHR1 stimulation in a cAMP cell-based assay. 
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Figure 35. cAMP stimulation curves of an untethered peptide analogs of human UCN4-15. 
A Phe11D-Phe including double amino acid substituted transtressin-analogs 63 and 64 afforded 
weak yet full CRHR1 agonists. In contrast, the untethered peptide 58b was only a partial agonist in 
the same settings, thus confirming the crucial importance of the Phe11-D-Phe substitution for the 
potency of untethered ligands. The substitution of Leu residues to tBuAla at positions 5 and 13 
consistently improved the potency but afforded untethered peptides that were not as potent as 
their Cha-substituted analogs (peptides 65, 66 and 67). Similarly, the Ile7tBuGly peptide 74 was 
dramatically less potent than its Ile7Chg analog 61b. Introduction of a tBuAla residue at position 14 in 
peptide 76 greatly improved the potency. However, the Cha14-substituted analog 77 was found to be 
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10-fold less potent then 76 and 2-fold less potent than its native Leu14 analog 60b. A similar trend 
was observed at position 9; the Cha9-substituted peptide 78 was dramatically less active than its 
tBuAla9 analog: transtressin. Finally, the tBuAla heptasubstituted peptide 79 was only slightly less 
potent than transtressin (5.3 ± 0.2 nM and 4.0 ± 0.1 nM respectively).  
 
 Sequence 
Subst. 
# EC50 (nM) 
Rel. 
Pot./transtressin 
 63 Ac-[Cha5D-Phe11]UCN4-15 2 509±28 0.006 
 64 Ac-[Thr4D-Phe11]UCN4-15 2 3135±103 0.001 
 65 Ac-[Thr4tBuAla5D-Phe11]UCN4-15 3 1352±50 0.002 
 66 Ac-[Thr4tBuAla5D-Phe11Cha13]UCN4-15 4 46±2 0.07 
 67 Ac-[Thr4tBuAla5,13D-Phe11]UCN4-15 4 556±28 0.005 
 68 Ac-[Thr4Cha5D-Phe11α-MeLeu13]UCN4-15 4 605±61 0.005 
 69 Ac-[Thr4Cha5,13α-MeD-Phe11]UCN4-15 4 Inact. - 
 70 Ac-[Thr4α-MeLeu5D-Phe11Cha13]UCN4-15 4 Inact. - 
 71 Ac-[alloThr4Cha5,13D-Phe11]UCN4-15 4 42±4 0.07 
 72 Ac-[β-PheSer4Cha5,13D-Phe11]UCN4-15 4 13±1 0.23 
 73 Ac-[Thr4Cha5,13,14D-Phe11]UCN4-15 5 184±9 0.02 
 74 Ac-[Thr4Cha5,13tBuGly7D-Phe11]UCN4-15 5 284±26 0.01 
 75 Ac-[Thr4Cha5,13α-MeLeu9D-Phe11]UCN4-15 5 9.4±0.5 0.11 
 76 Ac-[Thr4Cha5,13D-Phe11tBuAla14]UCN4-15 5 7.4±0.5 0.41 
 77 Ac-[Thr4Cha5,13,14Chg7D-Phe11]UCN4-15 6 83±5 0.04 
 78 Ac-[Thr4Cha5,9,13Chg7D-Phe11]UCN4-15 6 157±11 0.02 
 79 Ac-[Thr4tBuAla5,9,13,14Chg7D-Phe11]UCN4-15 7 5.3±0.2 0.57 
Table 12. Stimulation of CRHR1 by multisubstituted untethered peptides in a stable CRHR1 
overexpressing cell line. 
The incorporation of α-methylated amino acid residues is well known to influence the 
conformation of peptides by enhancing their ellipticity (Altmann et al. 1988). In our template, 
transtressin analogs 68, 69 and 70 including α-MeLeu or α-MeD-Phe amino acid substitutions were 
only poorly active. In contrast, the Leu9α-MeLeu substitution in peptide 75 was surprisingly well 
tolerated and delivered a low nanomolar agonist.  
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These results clearly reveal that the role of each substituted amino acid residue directly depends 
on the neighboring context. Generally, the side chain of hydrophobic residues such as Leu and Ile 
can be positively substituted by another bulkier hydrophobic side chain. However, the size and 
nature of such substitutions seem to be position-dependent. These side chains can play major roles 
having an influence on the potency of the peptide ligands: the strength of hydrophobic interactions 
that naturally occur between ligand and receptor residues may be enhanced; and the bulkiness of 
the side chain might confer to the peptide a conformation that optimizes ligand-receptor 
interactions (e.g., by enhancing ellipticity). Although the individual contribution of each amino acid 
residue to these phenomena remains unclear at the moment, the importance relies in finding the 
amino acid combinations that confer an optimized potency. 
3.2.6 Structure-Activity-Relationship at [Phe11]UCN4-15 
By screening the minimized UCN4-15 activation segment, we identified the Phe11D-Phe substitution 
as one of the most potency enhancing (Table 7 and Figure 24). Our findings in the UCN4-15 template 
correlate perfectly with an early single point D-substitution study on the full length CRH endogenous 
hormone (Rivier et al. 1993). It is noteworthy that the D-Phe substitution was systematically used for 
the synthesis and SAR studies of CRHR1 peptide agonists and antagonists (Cervini et al. 1999; Gulyas 
et al. 1995; Hernandez et al. 1993; Koerber et al. 1998; Miranda et al. 1994; Miranda et al. 1997; 
Rivier et al. 1998a; Rivier et al. 1998b). To further probe the role of the Phe11 residue for the potency 
of ligands, we decided to synthesize a library of UCN4-15 conjugates bearing Phe11 substitutions. We 
especially focused on D-Phe11-substituted derivatives depending on the aryl substituents and the 
commercial availability of the Fmoc-protected amino acid building blocks. The obtained conjugates 
were tested in a cAMP stimulation assay (curves not shown) and the potencies were compared to 
the native UCN4-15 sequence of conjugate 20a (Table 13). 
As previously determined, the Phe11D-Phe-substituted UCN4-15 conjugate 80 was five-fold more 
potent than the native UCN4-15 sequence of conjugate 20a. The close Phe11D-Pal (3-pyridyl) analog 83 
also enhanced the potency of the UCN4-15 template. All other Phe11 substitutions were detrimental 
for the potency of the conjugates. The Phe11D-Trp substitution was well tolerated and the conjugate 
remained highly potent (conjugate 88). Similarly, the 1-naphtyl substitution was well-tolerated 
(conjugate 81) while its 2-naphtyl related analogue was inactive (conjugate 82), suggesting that aryl-
substitutions at the para-position are detrimental for the potency of the ligands. Consistently, 
Phe11Tyr and Phe11pI-Phe analogues were rendered completely inactive in our UCN4-15 screening 
(Figure 24). Additional chemical substitutions around the Phe-aryl ring were poorly tolerated 
(conjugates 81, 82 and 84). The inactive Phe11Acp and Phe11Ach (backbone cyclopentyl and 
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cyclohexyl amino acids respectively) conjugates 85 and 86 pointed out the importance of the aryl 
moiety for the potency. Consistently, this effect could be reversed by the introduction of an aryl 
moiety in the Phe11-indane substituted conjugate 87. 
 [Phe
11
] 
Side chain 
structure EC50 (nM) Rel. Pot./20 
 20a - - 3.10±0.57 - 
 
80 D-Phe  0.60±0.05 5.2 
 
81 D-Nal(1)  12.25±1.69 0.3 
 
82 D-Nal(2)  Inactive - 
 
83 D-Pal  1.20±0.13 2.6 
 
84 D-pNO2-Phe  5.52±0.43 0.6 
 
85 Ach  Inactive - 
 
86 Acp  Inactive - 
 
87 Aic  15.75±0.20 0.2 
 
88 D-Trp  3.84±0.20 0.8 
Table 13. Stimulation of CRHR1 by Phe
11-substituted UCN4-15 peptide conjugates. 
The SAR profile at the UCN4-15Phe11 gives complementary details about the role of this amino acid 
residue for ligand-receptor interaction. The aryl moiety of Phe11 seems to interact directly with the 
CRHR1-TMD. Interestingly, the potency of the UCN
4-15 segment is greatly enhanced by the presence 
of a Phe11D-Phe substitution. This D-amino acid substitution suggests that a helical conformation for 
this peptide is not favored for an optimized binding.  
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3.2.7 Summary of the UCN biomimetic screening 
A rapid approach to chemically probe the interaction domain of class B GPCRs was developed. 
The conjugation of a high-affinity carrier resulted in a dramatic enhancement in the activity of 
peptide ligands and allowed the initial testing of peptides whose activity would otherwise have been 
too weak to be detectable. The synthesis and coupling of short length peptides to reconstitute a fully 
functional CRHR1 modulator has several advantages compared to the classical synthesis of whole, 
full length peptide ligands. For example, it is quicker with higher product purities. Importantly, the 
fragment conjugation approach obviated the need for HPLC purification of the initial test peptides, 
thereby enabling a substantially higher screening throughput. Thanks to the exquisite receptor 
specificity of the conjugates imparted by the carrier segment, the crude peptide conjugates were 
compatible with functional assays in living cells (Devigny et al. 2011). 
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Figure 36. Urocortin1 biomimetic screening overview: sequence optimization of a typical class B 
GPCR peptide hormone. 
By application of this methodology to the class B GPCR CRHR1 we discovered a low nanomolar 
agonist, named transtressin (Figure 36). This 12-mer peptide is the first known agonist specific for 
the activation domain of the receptor. The activation mechanism of transtressin is independent of 
the extracellular domain and resembles the signaling mechanism of canonical class A GPCRs. We 
assume that transtressin binds at the endogenous hormone orthosteric site and derives its activity 
from optimized hydrophobic interactions. Our results are inconsistent with a necessary allosteric 
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change of the extracellular domain which had been postulated as the initiating step of signal 
transduction for other class B GPCRs (Dong et al. 2006; Dong et al. 2008). CRHR1 therefore resembles 
more closely the parathyroid hormone receptor 1, the only other class B GPCR for which 
juxtamembrane-specific agonists have been described (Carter et al. 2007; Shimizu et al. 2000). 
Whether transmembrane-specific agonists for other class B GPCRs can be identified by this 
methodology remains to be determined. The CRHR1 domain-specificity of transtressin can be 
advantageously used in competition assays and allows to address the specificity of CRHR1 ligands 
(e.g., antagonists) for modulating the CRHR1 functions. The key principle of this work, testing class B 
ligands after membrane recruitment, is related in some aspects to a recently published “mammalian 
class B ligand display” (Fortin et al. 2009). However, while potentially superior in the number of 
tested peptides, the latter approach is inherently limited to genetically encoded amino acids. It is 
noteworthy that for transtressin, five unnatural amino acids substitutions were necessary to achieve 
low nanomolar, juxtamembrane-specific ligands. As such the “carrier-conjugate” approach 
presented in this study might be better suited to produce hits for drug development, as this method 
can be readily adapted to unnatural or even nonpeptidic substances (Devigny et al. 2011). 
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3.3 Biomimetic screening of a synthetic CRHR1 modulator: 
astressin 
The CuCAAC conjugation of peptide fragments is an efficient strategy for the SAR investigation of 
UCN-like peptide hormones. Ultimately, this powerful approach has led to the discovery of 
transtressin, the first CRHR1-TMD specific peptide agonist. These results encouraged us to apply the 
conjugation methodology to others CRHR peptide modulators. Beyond endogenous CRHRs peptide 
agonists such as UCN and CRH, a plethora of synthetic CRHR1 peptides have been disclosed. All of 
the non-natural peptide ligands, both agonists and antagonists, have been developed from SAR work 
and derivatisation of the natural ligands (see Introduction). Chain shortening, residue substitution 
and cyclization studies have led to the peptide antagonist astressin, a highly potent α-helical peptide 
using a lactam bridge constrain. Consistently with the two-domain model, peptide antagonists such 
as astressin bind the CRHR1-ECD1 with high-affinity, the absence of the truncated amino terminus 
end of the antagonists means inability to initiate the activation of the receptor but effectively blocks 
the endogenous ligand from binding the receptor (Grace et al. 2004; Hoare 2005).  
The competition assay between transtressin and astressin revealed that astressin binds not only 
to the CRHR1-ECD1 but unexpectedly seem to interact to some degree also directly with the CRHR1-
TMD (Figure 32). Indeed, astressin inhibits the CRHR1 cAMP stimulation induced by transtressin, 
suggesting that both peptides compete for the same binding site within the CRHR1-TMD. Moreover, 
the inhibition induced by a high dose of astressin reached a minimum (Emin) and did not completely 
abrogate the transtressin-induced stimulation, indicating the weak basal agonism of astressin. 
Thereby, we assume that the C-terminus of astressin binds with high-affinity to the CRHR1-ECD1, 
while the N-terminus weakly interacts with the CRHR1-TMD thereby partially inhibiting transtressin. 
Astressin is particularly well-suited for the biomimetic screening approach: the twelve C-terminal 
amino acid residues of astressin correspond to the sequence of the peptide carrier 2, thereby similar 
CRHR1-ECD1 affinities can be expected. Additionally, the five N-terminal amino acid residues of 
astressin (AST1-5) correspond to the fragment (11-15) of UCN; hence similar SARs can be expected for 
the screening of this fragment. Investigating the interactions between the N-terminus of astressin 
and the CRHR1-TMD may provide important details about the working mechanism of peptide 
antagonists; also the biomimetic screening approach may lead to the discovery of new CRHR1 
modulators. We thus engaged on a biomimetic screening of astressin analogs; briefly it consists of: 
1) reconstitution of an AST biomimetic conjugate  proof of concept; 2) truncation study  
characterization of a minimal CRHR1-TMD amino acid sequence; 3) positional MTS of a peptide 
conjugate library  SAR of the AST-minimized template. 
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3.3.1 Evaluation of astressin conjugates: rationale and proof of concept 
We first tested whether a “clicked” astressin analogue inhibit the CRHR1 stimulation induced by 
transtressin, and thus reconstitute a peptide antagonist. A focus on the interaction between the 
peptide antagonist and the CRHR1-TMD was chosen. The use of the CRHR1-TMD specific peptide 
agonist transtressin in a competition setup may address efficiently this interaction. As a starting 
point, the N-terminal (1-14) fragment of astressin was used, assuming that this segment contains the 
amino acid sequence interacting with the CRHR1-TMD and which leads to a potential partial 
agonism.  
For this purpose, the N-terminal fragment peptide 89 was synthesized using the BAL strategy, and 
after HPLC purification, it was conjugated to the high-affinity peptide 2 by CuCAAC (Figure 37a). 
Gratifyingly, the AST1-14 conjugate 90 precipitated out of solution, thus validating the centrifugation 
workup which was established for the UCN screening. The conjugate 90 was tested for CRHR1 
inhibition in a transtressin stimulated cell-based cAMP assay (Figure 37b). In this agonist dose-
response assay setup, the cells were first incubated with a high concentration of antagonist, 
astressin itself being used as control; increasing concentrations of transtressin are then added and 
the resulting cAMP production is determined. Although this assay setup does not allow comparing 
potencies of antagonists between each other, it uses a “saturating” concentration of the peptide 
antagonist to determine whether the latter has any inhibitory effect. 
The isolated peptide fragment 89 did not show any inhibitory activity at the CRHR1 by itself in the 
cellular cAMP inhibition assay. The conjugation of peptide 89 with peptide carrier 2, however, 
reconstituted a weak antagonist (Figure 37b and Table 14). Although, the efficacy of conjugate 90 in 
inhibiting transtressin was much weaker than AST at the same concentration, it produced a 
significant antagonistic effect thus proving that the fourteen AST N-terminal residues contain a 
template that interact with the CRHR1-TMD and compete with transtressin. The conjugation to the 
high-affinity carrier 2 consistently enhanced the detection limits for fragments such as peptide 89. 
Hence, the CuCAAC conjugation of AST-derived peptide fragments reconstitutes a peptide 
antagonist, proving that the approach is suitable for investigating the astressin-CRHR1-TMD 
interface. 
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Figure 37. Inhibition of transtressin-stimulated CRHR1 by a peptide conjugate. a) Synthesis of the 
inhibition segment 89 (pink) using BAL resin and “click” conjugation with membrane recruition 
segment 2 (dark green). B = norleucine; f = D-phenylalanine. b) Inhibition of transtressin-induced 
cAMP production in HEK293 cells stably over-expressing CRHR1 by peptide conjugate 90 and AST. 
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3.3.2 Astressin1-14 truncations: characterization of a minimal inhibition 
sequence 
Having proven that a “clicked” AST conjugate can act as an antagonist, we went on to determine 
the minimal N-terminal AST-derived peptide sequence necessary to inhibit the transtressin-induced 
CRHR1 stimulation. Bidirectionally truncated derivatives of peptide 89 were synthesized using the 
BAL strategy. The purified truncated peptides were then coupled to peptide 2 by CuCAAC, isolated 
by centrifugation and further purified by HPLC. After fluorescence quantification, the truncated 
conjugates were tested for CRHR1 inhibition in an agonist (transtressin) dose-response setup. The 
inhibition potencies of the conjugates were normalized to a maximal (astressin, 100 %) and a 
minimal inhibition (DMSO, 0 %). The C-terminal deletion of amino acid residues led first to a 
decrease and then to a substantial increase in inhibitory potency (Figure 38 and Table 14). The 
C-terminal deletion of Arg12 led to the conjugate 93 for which the relative inhibitory efficacy reached 
30% of that of astressin. Truncation beyond Ala11, however, completely abrogated the inhibitory 
potency of the conjugates. The AST1-5 fragment corresponding to the five C-terminal amino acids of 
the UCN4-15 “activation” template were also completely inactive for inhibition of the CRHR1, 
suggesting that additional ligand-receptor contacts are necessary for inhibiting transtressin. To 
confirm the importance of the N-terminal amino acid residues (and especially D-Phe1) for the 
interaction between astressin and the CRHR1-TMD, we also synthesized and tested N-terminally 
truncated AST1-11 conjugates.  
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Figure 38. cAMP inhibition curves corresponding to C-terminally truncated AST1-14 peptide 
conjugates listed in Table 14. 
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 Peptide sequence 
R = carrier 
EC50 [nM]
 (a) 
(s.e.m.) 
Inhib. efficacy 
(b) 
(%) 
  DMSO - - 3.28±0.08 0 
2
5
0
 n
M
 
 AST - - 34.9±1.2 100 
 90 Ac-AST(1-14) Ac-fHLLREVLEBARAE-R 9.31±0.28 19 
 91 Ac-AST(1-13) Ac-fHLLREVLEBARA-R 7.56±0.29 15 
 92 Ac-AST(1-12) Ac-fHLLREVLEBAR-R 6.04±0.31 9 
 93 Ac-AST(1-11) Ac-fHLLREVLEBA-R 12.7±0.7 30 
 94 Ac-AST(1-10) Ac-fHLLREVLEB-R 8.16±0.38 15 
 95 Ac-AST(1-9) Ac-fHLLREVLE-R 5.31±0.08 6 
 96 Ac-AST(1-8) Ac-fHLLREVL-R 4.57±0.07 4 
 97 Ac-AST(1-7) Ac-fHLLREV-R 5.21±0.22 6 
 98 Ac-AST(1-6) Ac-fHLLRE-R 4.55±0.19 4 
 99 Ac-AST(1-5) Ac-fHLLR-R 5.13±0.11 6 
Table 14. Characterization of C-terminally truncated analogs of the AST1-14 N-terminal fragment. 
(a) EC50 of transtressin. 
(b) Inhibitory efficacy normalized to astressin (100 %) and DMSO (0 %). 
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Figure 39. cAMP inhibition curves corresponding to the N-terminally truncated AST1-11 peptide 
conjugates listed in Table 15. 
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 Peptide sequence 
R = carrier 
EC50 [nM] 
(a)
 
(s.e.m.) 
Inhib. Efficacy
 (b) 
(%) 
  
DMSO - - 0.124±0.004 0 
2
5
0
 n
M
 
 
AST - - 1.85±0.18 100 
 93 Ac-AST(1-11) Ac-fHLLREVLEBA-R 0.427±0.001 18 
 100 H2N-AST(1-11) H2N-fHLLREVLEBA-R 0.374±0.034 15 
 101 Ac-AST(2-11) Ac-HLLREVLEBA-R 0.219±0.008 6 
Table 15. Characterization of N-terminally truncated analogs of the AST1-11 N-terminal fragment. 
(a) EC50 of transtressin. 
(b) Inhibitory efficacy normalized to astressin (100 %) and DMSO (0 %). 
The inhibition efficacies for the conjugates were normalized between DMSO and astressin; 
however, the EC50 values for transtressin in the presence of astressin and DMSO in Table 15 are 
substantially different compared to Table 14 because the reproducibility in inhibition assays is 
difficult to achieve. Removal of the N-terminal acetyl moiety of the AST1-11 template resulted in a 
slight decrease in inhibitory efficacy; however the conjugate 100 retained a good inhibitory efficacy 
compared to 93. Further truncation of the D-Phe1 amino acid residue resulted in a complete loss of 
efficacy, thus confirming the crucial role of this N-terminal residue for the interaction between the 
N-terminus of astressin and the CRHR1-TMD. Importantly, for both C- and N-terminal truncated 
conjugates as well as astressin, the CRHR1-TMD specific peptide transtressin displaced completely 
the N-terminus of the antagonists and produced full CRHR1 stimulation at higher concentrations. 
These data are fully consistent with a weakly TMD-interacting conjugate. Hereby, the bidirectional 
truncations established the 11 amino acid AST1-11 sequence motif as a minimized fragment for the 
inhibition of the transtressin induced CRHR1 stimulation.  
3.3.3 Role of the Astressin1-11 conjugate middle domain 
In the previous UCN4-15 biomimetic screening study, the TEG (n = 3) ethylene glycol appeared to 
offer the best compromise between flexibility and distance for the two ligand domains to bind the 
CRHR1. Hence, we decided to investigate if a similar mechanism could be observed using the 
minimized astressin-derived N-terminal fragment. The C-terminally propargylated AST1-11 fragment 
was coupled to the peptide carriers which were N-terminally modified with azide-functionalized 
ethylene glycol spacers of various lengths (n = 0 to 5). The HPLC purified conjugates 93, 102-106 
were then tested in an inhibition assay. In order to directly compare the potencies of the conjugates 
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for CRHR1 inhibition, an antagonist dose-response assay setup was used. HEK293 cells stably over-
expressing the CRHR1 were first incubated with increasing concentrations of the peptide antagonists 
(AST, 93 and 102-106 respectively). A fixed EC50-corresponding concentration of transtressin was 
then added and the resulting cAMP production was determined. 
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b) 
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Figure 40. Inhibition of CRHR1 by “clicked” AST
1-11 peptide conjugates listed in table 16. 
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N-term. 
Peptide carrier 
n = 
EC50 [nM] 
(s.e.m.) 
Emin 
(%) 
 
AST - - 3.11±82887 30 
 102 Ac-AST(1-11) 0 25.3±7.1 40 
 103 Ac-AST(1-11) 1 25.8±394133 43 
 
104 Ac-AST(1-11) 2 50.8±39.6 38 
 
93 Ac-AST(1-11) 3 19.4±7.6 35 
 
105 Ac-AST(1-11) 4 21.4±5.9 40 
 
106 Ac-AST(1-11) 5 - - 
Table 16. Characterization of “clicked” AST1-11 conjugates. 
The replacement of the middle portion of astressin by ethylene glycol spacers of various lengths 
reconstituted potent antagonists, thus confirming that the amino acid residues of the middle portion 
of AST are not important for the ligand-receptor interaction (Table 16). These results are consistent 
with our similar study on the UCN4-15 fragment, indentifying the triethylene glycol spacer (n = 3) as 
offering the best compromise for the N-terminal AST1-11 fragment to bind the CRHR1-TMD. In a lesser 
extent than for the peptide agonist conjugates, the proposed “three-step” CRHR1 binding 
mechanism for peptide conjugates is still relevant: the peptide carrier 2 first binds the CRHR1-ECD1 
with high-affinity. The AST1-11 N-terminal portion of the conjugate then freely rotates around the 
ethylene glycol spacer and takes advantage of both spacer and receptor domains flexibilities to bind 
the CRHR1-TMD in an optimal orientation. Presumably, the AST
1-11 fragment binds to the same 
orthosteric site than transtressin within J-domain and thus hinders the latter to bind its orthosteric 
site and trigger G protein signaling. Thereby, the triethylene glycol spacer (n = 3) of conjugate 93 
showed the highest inhibitory potency and was used systematically in the following study. 
RESULTS & DISCUSSION 
96 
3.3.4 Astressin1-11 stimulation biomimetic screening 
The use of CuCAAC “clicked” conjugates allowed us to characterize the 11 amino acid minimal 
template required for the CRHR1-TMD interaction. Since astressin is also a weak partial agonist, we 
evaluated the AST1-11 template for CRHR1 stimulation. We went on to determine the contribution of 
individual residues to CRHR1 stimulation in more details using a MTS with AST
1-11 peptide conjugates 
(Figure 41). 
N3 1. Conjugation
2. Screening
G-protein
 
Figure 41. Biomimetic screening strategy for the investigation of the CRHR1-astressin stimulation. 
A library of alkyne-tagged AST1-11 peptide fragments (pink) is conjugated to a constant peptide 
fragment (dark green) that has high-affinity for the CRHR1-ECD1. These conjugates are probed for 
modulation of the GPCR transmembrane domain. 
Based on the previously characterized minimal activation template AST1-11, a library of 96 
C-terminally propargylated peptidic fragments containing a series of single amino acid substitutions 
was synthesized (Table 17). Each position of the AST1-11 peptide sequence was systematically 
changed to alanine, Aib, the corresponding enantiomeric amino acid, as well as structurally related 
natural and unnatural amino acids. A particular focus was given on the SAR of the N-terminal D-Phe1 
residue. After cleavage from the solid support, the C-terminally propargylated AST1-11 peptides were 
analyzed by HPLC and mass spectrometry (data not shown). Gratifyingly, the first estimation of 
quality revealed that most of the propargylated AST1-11 peptides presented crude purities above 
80%. (89 out of 96, table 28) The purity of the crude propargylated library is the bottleneck of the 
conjugation approach, because the crude purities are subsequently transferred to the conjugates. 
The crude C-terminally propargylated AST1-11 peptides were then coupled to the peptide carrier 2 
and isolated by precipitation as previously described. Similarly to the UCN4-15 screening, the easy 
isolation of the crude conjugates by simple centrifugation was a crucial feature of the conjugation 
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methodology. We decided to first test the activity of the single-substituted AST1-11 conjugates as such 
in a cAMP stimulation assay at 250 nM (Figure 42 and Table 17). 
D-Phe
1
 D-Phe
1
 His
2
 Leu
3
 Leu
4
 Arg
5
 Glu
6
 Val
7
 Leu
8
 Glu
9
 NLeu
10
 Ala
11
 
Ala D-pNO2-Phe Ala Ala Ala Ala Ala Ala Ala Ala Ala Ala 
Aib D-Nal(1) Aib Aib Aib Aib Aib Aib Aib Aib Aib Aib 
Phe D-Nal(2) D-His D-Leu D-Leu D-Arg D-Glu D-Val D-Leu D-Glu D-NLeu D-Ala 
D-Tyr D-αMe-Phe Glu Ile Ile Asn Asp Ile Ile Asp Leu Ser 
D-Trp Th-pheSer Trp Val Val Gln Gln Leu Val Gln Ile Leu 
D-His Aic Phe Phe Phe Lys His Phe Phe Lys Lys Val 
D-3-Pal Cha Cha Cha Cha Cit Dab Chg Cha Dab Cha tBuGly 
D-pBr-Phe D-Cha Dab tBuAla tBuAla Orn Orn tBuGly tBuAla Orn tBuAla NVal 
Table 17. Summary of CRHR1 stimulation by single-point substituted AST
1-11 conjugates. Crude 
N-terminally acetylated peptide-peptide conjugates carrying the indicated amino acid modification 
were assayed at 250 nM for cAMP stimulation of HEK293 cells stably overexpressing CRHR1. 
Sequences with no stimulatory activity are indicated in red, minimal activity is indicated in orange 
(10 – 20 %), substantial activity is indicated in yellow (20 – 30 %) and significant activity is indicated 
in green (> 30 %). Aic = 2-aminoindane-2-carboxylic acid; Nal(1) = 1-naphtylalanine; Nal(2) = 2-
naphtylalanine; NLeu = norleucine; NVal = norvaline; 3-Pal = 3-pyridylalanine; pBr-Phe = para-bromo 
phenylalanine; pNO2-Phe = para-nitro phenylalanine; Th-pheSer = threo-β-phenylserine. 
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Figure 42. Positional stimulatory MTS of a crude AST1-11 peptide conjugate library at 250nM. 
Inactive sequences are indicated in red, minimal stimulatory activity is indicated in orange, 
substantial activity is indicated in yellow and significant activity compared to the original AST1-11 
conjugate 93 is indicated in green. 
The biomimetic screening of the AST1-11 peptide conjugate library resulted in 86 conjugates where 
the stimulatory activity was very low and not significantly different compared to the AST1-11 
sequence (red and orange, < 20 %). For five of these peptide conjugates, the CRHR1 stimulatory 
activity was found to be slightly improved (yellow, 20 – 30 %) and for five others it was greatly 
enhanced (green, > 30 %). Surprisingly, for two of these conjugates, CRHR1 full activation was 
observed (D-Phe1D-Trp and Val7tBuGly). Several D-Phe1 amino acid substitutions enhanced weakly 
the potency of the AST1-11 conjugate; in particular the D-Phe1D-His, D-Phe1D-Pal and 
D-Phe1D-αMePhe substitutions showed substantially increased potencies, presumably due to their 
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close structural resemblance to D-Phe. The D-Phe1D-Trp substitution afforded a surprisingly potent 
conjugate and reconstituted a full agonist at 250 nM. Several other positions were found to be 
positively sensitive to amino acid substitutions, in particular Leu4, Arg5, Val7 and Leu8. The Arg5Aib 
and Arg5Orn substitutions greatly improved the potency of the conjugates. Consistently with the 
UCN4-15 screening, replacement of Val7 and Leu8 residues by similar aliphatic residues such tBuGly 
and tBuAla respectively provided conjugates with improved stimulatory activity. Noteworthy, the 
latter concentration applied to the cells in this assay being extremely high, these results have to be 
taken with care and the potency of such ligands should be further assessed with dose-response 
stimulation curves. 
3.3.5 Astressin1-11 inhibition biomimetic screening 
Having investigated the potential CRHR1 stimulatory activity of the AST
1-11 conjugates, we went on 
to assess the ability of these conjugates to inhibit the CRHR1 stimulation induced by the CRHR1-TMD 
specific peptide transtressin (Figure 43). For this single-point inhibition assay, HEK293 cells over-
expressing the CRHR1 were first incubated with 250 nM of the AST
1-11 conjugates; an EC50-
corresponding concentration of transtressin (5 nM) was then added and the resulting cAMP 
production was determined. 
N3 1. Conjugation
2. Screening
 
Figure 43. Biomimetic screening strategy for the investigation of the CRHR1-astressin analog 
inhibition. A library of alkyne-tagged AST1-11 peptide fragments (pink) is conjugated to a constant 
peptide fragment (dark green) that has high-affinity for the CRHR1-ECD1. These conjugates are 
probed for inhibition of the CRHR1-TMD specific transtressin-induced CRHR1 stimulation. 
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D-Phe
1
 D-Phe
1
 His
2
 Leu
3
 Leu
4
 Arg
5
 Glu
6
 Val
7
 Leu
8
 Glu
9
 NLeu
10
 Ala
11
 
Ala D-pNO2-Phe Ala Ala Ala Ala Ala Ala Ala Ala Ala Ala 
Aib D-Nal(1) Aib Aib Aib Aib Aib Aib Aib Aib Aib Aib 
Phe D-Nal(2) D-His D-Leu D-Leu D-Arg D-Glu D-Val D-Leu D-Glu D-NLeu D-Ala 
D-Tyr D-αMe-Phe Glu Ile Ile Asn Asp Ile Ile Asp Leu Ser 
D-Trp Th-pheSer Trp Val Val Gln Gln Leu Val Gln Ile Leu 
D-His Aic Phe Phe Phe Lys His Phe Phe Lys Lys Val 
D-3-Pal Cha Cha Cha Cha Cit Dab Chg Cha Dab Cha tBuGly 
D-pBr-Phe D-Cha Dab tBuAla tBuAla Orn Orn tBuGly tBuAla Orn tBuAla NVal 
Table 18. Inhibition summary of transtressin-stimulated CRHR1 by single-point substituted AST
1-11 
conjugates. Crude peptide-peptide conjugates carrying the indicated amino acid modification were 
assayed at 250 nM for cAMP inhibition of HEK293 cells stably overexpressing CRHR1 stimulated by 
5 nM of transtressin. Sequences with additional stimulatory activity are indicated in red (> 75 %), 
equal activity compared to the purified AST1-11 conjugate 93 are indicated in orange (65 – 75 %), 
substantial enhanced inhibition is indicated in yellow (60 – 65 %) and significant enhanced inhibition 
is indicated in green (< 60 %).  
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Figure 44. Positional inhibitory MTS of a crude AST1-11 peptide conjugate library. Sequences with 
stimulatory activity are indicated in red, equal activity compared to the purified AST1-11 conjugate 93 
are indicated in orange, substantial enhanced inhibition is indicated in yellow and significant 
enhanced inhibition is indicated in green.  
The inhibitory biomimetic screening of the AST1-11 peptide conjugate library resulted in 
71 conjugates where the inhibitory activity for CRHR1 was not significantly different compared to the 
native sequence of the purified AST1-11 conjugate 93 (orange, 65 – 75 %, Figure 44 and Table 18). For 
ten of the conjugates, the inhibitory efficacy was slightly increased (yellow) and for eight others, the 
CRHR1 inhibition was significantly improved (green, < 60 %). Eight of the conjugates showed an 
additive stimulatory effect to that of transtressin (red, > 75 %). The effects of the conjugates using 
the inhibition competition assay setup are very low compared to the agonist screening assays 
performed before; this is mostly due to the limited detection range imposed by the intrinsic low 
affinity of the AST1-11 sequence for the CRHR1-TMD. The full length astressin itself was used as 
control and effectively inhibited the transtressin induced CRHR1 stimulation at 250 nM (pink). The 
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differences in inhibitory potency observed between full length astressin and the AST1-11 conjugate 93 
suggests that amino acid residues in the middle portion play a significant role for the N-terminus to 
bind efficiently to the CRHR1-TMD. As previously discussed, the middle segment of CRHR1 peptide 
ligands might not only define the orientation of the N-terminus segment by conformational 
constrain, but it might also provide additional ligand-receptor interactions underlining the “low 
resolution” of the two-domain model. Although the inhibitory effects induced by the AST1-11 
conjugates were weak, the analysis of the activities for the single amino acid substitution AST1-11 
analogs allows several conclusions about the SAR of CRHR1 peptide antagonists.  
Replacement of the D-Phe1 residue by several amino acid residues led to enhancement of the 
inhibitory activity (e.g., D-Phe1D-Pal, D-Phe1D-pBrPhe and D-Phe1D-Cha), suggesting that the side 
chain of this N-terminal residue interacts directly with the CRHR1-TMD. The replacement of Leu
3,8 
and NLeu10 residues by unnatural aliphatic amino acids such as Cha and tBuAla provided conjugates 
with enhanced inhibition. These results are in line with the SAR screening of the UCN4-15 “activation” 
template, indicating that fine-tuning of the hydrophobic interactions in the AST1-11 motif may also 
lead to ligands with optimized affinity for the CRHR1-TMD. The Leu
4Aib substitution also afforded a 
conjugate with enhanced inhibition compared to 93. Importantly, the conjugates showing the 
greatest stimulatory activity (e.g., D-Phe1D-Trp and Val7tBuGly) in the cAMP stimulation screening 
were also found to potently activate CRHR1 using the inhibition setup. The biomimetic screening of 
an antagonistic sequence such as AST1-11 is more challenging compared to UCN4-15. The intrinsic low 
potency of the native sequence limits the assay output limited. In this case, the results obtained with 
both setups complement each other quite well and allowed us to identify amino acid substitutions 
having a modulating effect for the stimulation and for the inhibition of CRHR1. 
3.3.6 Evaluation of multisubstituted Astressin1-11 biomimetic probes 
The next step was to investigate whether the effects of the single substitutions identified in the 
AST1-11 positional screenings were additive. For this purpose, a library of C-terminally propargylated 
UCN4-15 peptides bearing multiple substitutions was synthesized. The focus was given on amino acid 
substitutions having enhancing inhibitory effects (Table 18; e.g., His2Cha, Leu3tBuAla, Leu4Aib, 
Leu8tBuAla, NLeu10Cha and NLeu10tBuAla). Although most of these substitutions showed weak 
effects for inhibiting transtressin, we expected to find optimized antagonistic sequences thanks to 
the cumulative effects of each substitution. In addition, each multisubstituted AST1-11 peptide was 
synthesized either N-terminally acetylated or let as a free amine, thus addressing the role of the N-
terminal acetylation for the efficacy. The multisubstituted AST1-11 conjugates were tested using a 
transtressin dose-response inhibition assay setup (Figures 45, 46 and Table 19). 
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Figure 45. Inhibition of CRHR1 by N-terminally free AST
1-11 peptide conjugates listed in table 19. 
HEK293 cells over-expressing the CRHR1 were incubated with 250 nM of the AST
1-11 conjugates 
bearing multiple amino acids substitutions, increasing concentrations of the CRHR1-TMD specific 
peptide transtressin were then added and the cAMP production determined. 
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Figure 46. Inhibition of CRHR1 by N-terminally acetylated AST
1-11 peptide conjugates listed in 
table 19. HEK293 cells over-expressing the CRHR1 were incubated with 250 nM of the AST
1-11 
conjugates bearing multiple amino acids substitutions, increasing concentrations of the CRHR1-TMD 
specific peptide transtressin were then added and the cAMP production determined. 
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C-term. = carrier 2 
R = -NH2 
(a) 
R = -Ac 
(b) 
Subst. EC50 (nM)
 (c) 
Emin (%)
 
EC50 (nM) 
(c) 
Emin (%) 
  DMSO - - 0.124±0.004 -3.4 0.358±0.014 2.2 
2
5
0
n
M
 
 
AST - - 1.85±0.18 12.2 4.19±0.20 15.2 
 
93 AST1-11 0 0.427±0.001 0.9 1.19±0.03 4.2 
 
107 R-[Cha2tBuAla3]AST1-11 2 0.146±0.003 46.2 0.595±0.023 8.5 
 
108 R-[Cha2Aib4]AST1-11 2 0.277±0.016 26.1 0.721±0.043 25.1 
 109 R-[tBuAla3Aib4]AST1-11 2 0.427±0.029 37.3 1.03±0.12 22.8 
 110 R-[Cha2tBuAla3Aib4]AST1-11 3 0.278±0.005 12.0 0.609±0.025 2.2 
 
111 R-[Cha2Aib4tBuAla8]AST1-11 3 0.180±0.128 62.9 0.589±0.102 27.1 
 
112 R-[D-Pal1Cha2tBuAla3Aib4]AST1-11 4 n.d. >80 1.72±0.51 78.2 
 
113 R-[Cha2tBuAla3,8Aib4]AST1-11 4 0.235±0.011 7.4 0.590±0.023 6.3 
 
114 R-[D-pBrPhe1Cha2,10Aib4tBuAla8]AST1-11 5 0.320±0.018 49.8 0.426±0.068 23.6 
 115 R-[Cha2,10tBuAla3,8Aib4]AST1-11 5 0.257±0.009 7.2 0.700±0.015 6.5 
Table 19. Inhibition of CRHR1 by purified AST
1-11 multisubstituted peptide conjugates in a stable 
CRHR1 overexpressing cell line. 
(a) N-terminally “free amine” conjugates. (b) N-terminally acetylated 
conjugates. (c) EC50 of transtressin. 
Astressin and the AST1-11 conjugate 93 inhibited transtressin; however none of the 
multisubstituted conjugates showed improved inhibitory efficacies. Surprisingly, several 
multisubstituted conjugates showed substantial stimulatory effects as indicated by the Emin values 
obtained in the competition assay (Figure 45, 46 and Table 19). Overall, the N-terminally acetylated 
conjugates produced weaker stimulations to the N-terminally “free” ones. The conjugates 112a and 
112b were the most potent at 250 nM, suggesting that the D-Phe1D-Pal substitution greatly 
contribute to CRHR1 stimulation (compare 112a/b with 110a/b). Interestingly, this substitution alone 
did not further improve the potency of conjugates in the UCN4-15 context (Table 13). The Emin values 
for other conjugates suggested partial agonism at 250 nM (e.g., 107a, 111a, 114a and 108b). 
Although the expected enhanced CRHR1 inhibition was not observed, it seems that combining the 
amino acid substitutions identified in the positional screening greatly improve the stimulatory 
potency of the AST1-11 template. Encouraged by these results, we decided to test the 
multisubstituted C-terminally propargylated AST1-11 peptides directly for CRHR1 stimulation 
(Figure 47 and Table 20). 
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Figure 47. Stimulation of CRHR1 by multisubstituted
 C-terminally propargylated AST1-11 peptides. 
a) N-terminally free amine peptides. b) N-terminally acetylated peptides. 
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 C-term. = propargyl 
R = -NH2 
(a)
 R = -Ac 
(b)
 
Subst. EC50 (µM) Emax (%) EC50 (µM) Emax (%) 
 
116 R-AST1-11 0 n.a. n.a. n.a. n.a. 
 
117 R-[Cha2tBuAla3]AST1-11 2 4.59±0.90 97±6 7.55±2.59 31±2 
 
118 R-[Cha2Aib4]AST1-11 2 8.27±0.72 98±3 50.45±16.38 108±17 
 
119 R-[tBuAla3Aib4]AST1-11 2 18.24±0.98 82±2 1576±8097 676±2830 
 
120 R-[Cha2tBuAla3Aib4]AST1-11 3 11.60±776 37±2 6.78±1.07 57±3 
 
121 R-[Cha2Aib4tBuAla8]AST1-11 3 11.56±4.26 104±12 32.81±22034 76±3 
 
122 R-[D-Pal1Cha2tBuAla3Aib4]AST1-11 4 1.04±0.02 99±1 61.4±14.6 123±14 
 
123 R-[Cha2tBuAla3,8Aib4]AST1-11 4 18.08±2.12 75±4 9.31±0.80 73±3 
 
125 R-[Cha2,10tBuAla3,8Aib4]AST1-11 5 36.75±84.41 73±54 47.1±11.9 105±14 
Table 20. Stimulation of CRHR1 by multisubstituted
 C-terminally propargylated AST1-11 peptides. 
Gratifyingly, the combination of two mutations in conjugates 117, 118 and 119 turned the 
inactive AST1-11 untethered sequence into agonists, potent in the low micromolar range. The 
N-terminally “free” untethered AST1-11 peptides were in general more potent than the same 
N-terminally acetylated sequences, suggesting that the N-terminal primary amine moiety might 
contribute with its positive charge to the binding to the receptor J-domain. The triple mutation in 
conjugates 120 and 121 did not further increase potency. The D-Phe1D-Pal-including tetrasubstituted 
peptide 122a, however, showed a potency of 1.04 ± 0.02 µM, confirming that the pyridyl side chain 
greatly improve the potency of the AST1-11 peptide for CRHR1 stimulation. From a structural point of 
view, it seems that the CRHR1 stimulation potency of AST
1-11 untethered peptides was largely 
achieved by fine-tuning the hydrophobic interactions through incorporation of unnatural amino acid 
side chains (e.g., Cha, tBuAla). This is in line with the UCN4-15 sequence optimization; in particular the 
Leu3tBuAla substitution (Leu13tBuAla in the UCN4-15 screening) was already identified as enhancing 
the stimulation of CRHR1. The high potency of the untethered peptide 122a is surprising because the 
starting AST1-11 motif lacks the N-terminal amino acids which were shown as crucial for the CRHR1 
activation. This N-terminally “truncated” peptide agonist may provide new insights into the 
activation mechanism of CRHR1 and serve as a starting point for further SAR investigations. 
Hereby, we have shown that astressin is in fact a competitive partial agonist and that 
optimization of the astressin-derived AST1-11 template leads to potentially new peptide agonists. 
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Given that the AST1-11 templates functionally compete with transtressin, we believe that the AST1-5 
motif (corresponding to UCN11-15) primarily interact with the juxtamembrane domain of CRHR1. The 
role of the AST6-11 segment for the potency remains to be determined. In general, the mechanism of 
action of AST1-11-derived peptide agonists requires further pharmacological characterization such as 
competition assays against known antagonists (e.g., CRHR1-ECD1 specific peptide 1 and DMP696) or 
using cells lines expressing receptor mutants (e.g., ΔECD1-CRHR1). 
3.3.7 Summary of the astressin biomimetic screening 
 
Figure 48. Astressin biomimetic screening overview: sequence optimization of a class B GPCR 
synthetic peptide antagonist. 
The conjugation of a high-affinity carrier with peptide fragments derived from a synthetic peptide 
antagonist results in a dramatic enhancement in activity. This allows the testing of otherwise inactive 
peptides for modulation of the CRHR1 activity in various assay setups. By applying the biomimetic 
screening methodology to the synthetic peptide antagonist astressin, we discovered N-terminally 
shortened peptide agonists with surprising potencies (Figure 48). Although the approach was first 
designed to identify the structural features responsible for astressin antagonism, the AST1-11 amino 
acid positional screening led to the optimization of single positions for CRHR1 stimulation and several 
improved agonists were discovered. This indicates that peptide binding to the TMD seems to be 
much easier in an activated CRHR1 conformation. Importantly, the AST
1-11-derived untethered 
agonists lack the N-terminal residues which were previously thought as essential for CRHR1 
activation, suggesting a novel mechanism of action for these peptides. Hereby, we also show that 
the biomimetic screening approach can be easily applied to endogenous and synthetic peptide 
class B GPCR ligands, agonists and antagonists. 
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The potencies of the untethered AST1-11-derived agonists reach the low micromolar range. These 
11-mer ligands have a great potential for further activity optimization. In particular, it is obvious that 
the synthesis of an extended C-terminally amidated peptide library may lead to new potent ligands; 
especially by introducing substitutions identified as potency enhancing in the stimulation screening. 
Interestingly, the AST1-11-derived untethered agonists lack the N-terminal amino acid residues 
previously identified as “crucial” for CRHR1 stimulation. This suggests that AST
1-11-derived agonists 
activate CRHR1 through a different mechanism of action than transtressin. The pharmacology of 
these novel agonists remain to be characterized and may provide a deeper insight into the 
mechanism of activation of class B GPCRs. 
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3.4 Synthesis and characterization of nonpeptide CRHR1 
antagonists 
In recent years, a number of non-peptidergic CRHR1 antagonists have been identified and 
characterized. In general, these antagonists exhibit nanomolar affinities for CRHR1 with > 1000-fold 
selectivity for CRHR1 over CRHR2. They are also effective in reducing anxiety-like behaviors in several 
preclinical animal models (Li et al. 2005). However, the efficacy of non-peptidergic CRHR1 
antagonists as drugs for the treatment of psychiatric disorders remains to be demonstrated in 
double-blind clinical trials (see Introduction). Among the reported non-peptidergic CRHR1 antagonist, 
DMP696 [4-(1,3-dimethoxyprop-2-ylamine)-2,7-dimethyl-8-(2,4-dichlorophenyl)-pyrazolo-[1,5-a]-
1,3,5-triazine] was designed as a drug development candidate for the treatment of anxiety and 
depression (Figure 8). DMP696 was synthesized following an initial lead compound with 5.7 μM 
binding affinity at DuPont (Gilligan et al. 2009a; He et al. 2000; Li et al. 2005). Importantly, DMP696 
was reported to have reached clinical trials but its status is currently not known. Structurally, the 
bicyclic pyrazolo-[1,5-a]-triazine core of DMP696 is found in several highly potent CRHR1 ligands 
(e.g., pexacerfont); the aliphatic “top” and aryl “bottom” groups follow the well known 
pharmacophore model of non-peptidergic CRHR1 antagonists (see Introduction). Being a well 
described CRHR1-TMD specific antagonist, DMP696 was used successfully for the in vitro 
pharmacological characterization of transtressin (see Section 3.2.4).  
 
Figure 49. Synthesis of substituted pyrazolo-[1,5-a]-triazines as nonpeptide CRHR1 antagonists. 
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DMP696 is not commercially available; and thus had to be synthesized on our own. For this 
purpose, an efficient and convergent synthetic route for the synthesis of pyrazolo-triazine CRHR1 
antagonists was established (Figure 49). Ethyl acetamidate free base was condensed with 3-amino-
methylpyrazole to give 126 as an acetic acid salt. Ring closure to the pyrazolo-[1,5-a]-triazine scaffold 
of 127 was achieved with diethylcarbonate in strong basic conditions. Finally, the compound 127 
was chlorinated with phosphorous oxylchloride to give the activated key intermediate 128.  
The incorporation of aliphatic top-groups was performed by simple condensation of free amines 
on the intermediate 128. After regioselective iodination at position 8 with N-iodosuccinimide (NIS), 
the bottom aryl group is easily introduced by palladium-catalyzed Suzuki cross-coupling; affording 
the desired non-peptidergic CRHR1 antagonist 131. Our synthetic route is simple, advantageous and 
convergent compared to the reported synthesis of DMP696: the activated intermediate can be 
quickly derivatized with a wide choice of commercially available amines and boronic acids. To 
validate our synthetic route, we synthesized DMP696 (Figure 50, 131a) as well as several closely 
related pyrazolo-[1,5-a]-triazines, such as compounds 131b and 131c which combine top- and 
bottom-groups from DMP696 and DMP904 (Li et al. 2005). 
 
Figure 50. Structure of non-peptidergic pyrazolo-[1,5-a]-triazines CRHR1 antagonists synthesized in 
this study. Compound 131a corresponds to DMP696 itself. Compound 131b associates the top- and 
bottom-groups of DMP904 to the core of DMP696. Compound 131c associates the top-group of 
DMP904 to DMP696. 
The potencies of DMP696 analogs 131a, 131b and 131c were tested in a cAMP competition assay 
against the CRHR1-TMD specific agonist transtressin (Figure 51 and Table 21). In this assay, the 
CRHR1 overexpressing HEK293 cells were first incubated with increasing concentrations of the 
synthesized non-peptidergic CRHR1 antagonists as well as DMP696 itself (generous gift from Bristol-
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Myers Squibb). A fixed concentration of transtressin (5 nM) was then added and the resulting cAMP 
stimulation determined. Gratifyingly, 131a (our “in house” synthesized DMP696) and DMP696 
similarly inhibited transtressin, thus validating our synthesis of CRHR1 antagonists. In vitro, the 
analogs 131b and 131c were also surprisingly potent. The synthesis of DMP696 (131a) by Suzuki 
cross-coupling was then scaled up and the latter synthesized on a one gram scale.  
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Figure 51. cAMP inhibition of CRHR1 by pyrazolo-[1,5-a]-triazine CRHR1 antagonists. HEK293 cells 
overexpressing the CRHR1 were first incubated with increasing concentrations of compounds 131a, 
131b, 131c and DMP696 (Bristol-Myers Squibb). Transtressin (5 nM) was then added and the cAMP 
production was determined. 
 
Transtressin 5 nM
 
 EC50 (nM) Emin Emax 
 
131a 35.7±7.3 -3±3 65±4 
 
DMP696 (BMS) 37.9±10.5 -4±4 56±4 
 
131b 53.4±11.4 -4±4 66±4 
 
131c 19.1±12.0 -3±3 59±4 
Table 21. Characterization of nonpeptide pyrazolo-[1,5-a]-triazine CRHR1 antagonists. 
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Our “in house” synthesized DMP696 was used in cell-based assays, in particular in cAMP 
competition assays addressing the CRHR1-TMD specificity of peptide ligands. In collaboration with 
the groups of Mathias Schmidt and Mayumi Kimura at the Max-Planck-Institute for Psychiatry 
(Munich), 131a was administered to mice for in vivo behavioral and physiological experiments. The 
synthesis of substituted pyrazolo-[1,5-a]-triazines described herein opens the doors for the further 
synthesis and characterization of CRHR1 antagonists with improved potencies and pharmacokinetic 
properties.  
CONCLUSION 
117 
4 Conclusion 
A rapid approach to chemically probe the interaction domain of class B GPCRs was developed. 
The conjugation of a high-affinity carrier resulted in a dramatic enhancement in the activity of 
peptide ligands and allowed the initial testing of peptides whose activity would otherwise have been 
too weak to be detectable. The synthesis and coupling of short length peptides to reconstitute a fully 
functional CRHR1 modulator has several advantages compared to the classical synthesis of whole, 
full length peptide ligands. For example, it is quicker with higher product purities. Importantly, the 
fragment conjugation approach obviated the need for HPLC purification of the initial test peptides, 
thereby enabling a substantially higher screening throughput. Thanks to the exquisite receptor 
specificity of the conjugates imparted by the carrier segment, the crude peptide conjugates were 
compatible with functional assays in living cells. The method produces peptide conjugates which 
mimic the two-domain model of activation for class B GPCRs, thus allowing to rapidly address the 
ligand-receptor interface (Devigny et al. 2011). 
By applying this methodology to the class B GPCR CRHR1, we discovered highly potent agonists 
that are specific for the activation domain of this receptor. For example, the activation mechanism 
of transtressin, a low nanomolar agonist, is almost independent of the extracellular domain and 
resembles the signaling mechanism of canonical class A GPCRs (Devigny et al. 2011). Similarly, by 
applying this methodology to the synthetic antagonist astressin, we discovered N-terminally 
shortened and surprisingly potent agonists. We assume that small peptide agonists such as 
transtressin bind at the endogenous hormone orthosteric site and derive their stimulatory activity 
from optimized hydrophobic interactions and conformation. The structural features which lead to 
CRHR1 antagonism, however, remain to be characterized. CRHR1 domain-specific peptides such as 
transtressin are crucial for the identification of CRHR1-TMD specific inhibitors. 
The mechanism of action and specific amino acid interactions between peptide agonists and 
receptor require to be further characterized (e.g., by CRHR1 mutagenesis studies). The ability of 
peptide conjugates to mimic endogenous hormones and their potential for in vivo CRHR1 targeting 
suggests that fluorescently-tagged conjugates may be successfully used for CRHR1 in vitro and in vivo 
imaging. Given the high mechanistic and structural homology within the class B GPCR family (Hoare 
2005; Parthier et al. 2009), we expect the biomimetic screening approach to be applicable to many 
class B GPCRs. 
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5 Material and methods 
5.1 Chemical methods 
5.1.1 Nuclear Magnetic Resonance 
If not specified otherwise, 1H- and 13C-NMR spectra were recorded at the Department of 
Chemistry and Pharmacy at the Ludwig Maximilian University (Munich) on a Bruker AC300, a Bruker 
XL400 or a Bruker AMX600 at room temperature. Chemicals shifts are reported in parts per million 
referenced with respect to residual solvent (1H: CDCl3 = 7.26 ppm, 
13C: CDCl3 = 77.16 ± 0.06 ppm). 
The coupling constants (J) are given in Hertz (Hz) and the peak multiplicity are abbreviated as such: 
singlet s, doublet d, triplet t, quartet q and multiplet m. 
5.1.2 Mass Spectrometry 
ESI mass spectra (m/z) were recorded on a Thermo Finnigan LCQ DECA XP Plus mass 
spectrometer. C-terminal propargylated and amidated peptides were analyzed by MALDI-TOF on 
Bruker Daltonics Ultraflex I Maldi-TOF/TOF. High resolution mass spectroscopy was carried out at 
the Max Planck Institute for Biochemistry (Munich), Microchemistry Core Facility. 
5.1.3 Liquid chromatography-mass spectrometry 
Liquid chromatography-mass spectrometry (LC-MS) was performed using a Beckman System Gold 
126 Analytical Solvent Module, a Beckman 166 Detector Module, a Beckman 508 Autosampler 
Module with a 50 µL sampling loop, a YMC 100 x 4.6mm analytical column (YMC, Germany), and a 
Thermo Finnigan LCQ DECA XP Plus mass spectrometer. Measurements were performed at a flow 
rate of 1 mL/min using buffer A: 0.1 % formic acid in water/acetonitrile (95/5, v/v) and buffer B: 
0.1 % formic acid in acetonitrile/water (95/5, v/v). HPLC system was interfaced by the 32-Karat 
software.  
5.1.4 High-performance liquid chromatography 
5.1.4.1 Analytical and semi-preparative high-performance liquid chromatography 
Analytical and semi-preparative reverse phase HPLC spectra were performed using a Beckman 
System Gold 125S Analytical Solvent Module, a Beckman 168 Diode Array Detector Module, a Hitachi 
F-1080 Fluorescence Detector Module, a Beckman 508 Autosampler Module with a 50 μL sampling 
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loop, and a Jupiter 4 μm Proteo 90 Å 250 x 4.6 mm analytical column (Phenomenex, Germany) at a 
flow rate of 1 mL/min or a Jupiter Proteo semi-preparative column at a flow rate of 5 mL/min using 
buffer A: 0.1 % TFA in water/acetonitrile (95/5, v/v) and buffer B: 0.1 % TFA in acetonitrile/water 
(95/5, v/v).  
5.1.4.2 Preparative high-performance liquid chromatography 
Reverse phase preparative HPLC was performed with a Beckman System Gold 126NMP 
Preparative Solvent Module, a Beckman 166 Detector Module, a Beckman SC-100 fraction collector 
and a Jupiter column (Phenomenex, Germany) at a flow rate of 25 mL/min using buffer A: 0.1 % TFA 
in water/acetonitrile (95/5, v/v) and buffer B: 0.1 % TFA in acetonitrile/water (95/5, v/v). 
HPLC systems were interfaced by the 32-Karat software.  
5.1.5 Flash chromatography 
Chromatographic separations were performed either manually or with an Interchim Puriflash 430 
automatic flash chromatography system. Silica gel 60 (Merck 70-230 mesh) was used for manual 
column chromatography. Puriflash columns 50 Silica 50 µM (10 g, 25 g, and 40 g) were used for 
automated chromatography. 
5.1.6 Thin layer chromatography 
Thin layer chromatography (TLC) was performed using Merck-preprared aluminium plates (Silica 60 
F254, 0.25 mm). The substances were detected with UV-light (λ = 254/366 nm). Thin layers plates 
were also stained with the following solutions: 
 Hanessian’s: 5 g CeSO4, 25 g NH4MO7O24·4 H2O, 450 mL H2O, 50 mL H2SO4.   
 Potassium permanganate: 1.5 g KMnO4, 10 g K2CO3, 1.25 mL 10 % NaOH in 200 mL H2O. 
The TLC plates were shortly dipped in the staining solution and heated until visualization. 
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5.1.7 Chemicals 
The chemicals were purchased from the companies Acros, Alfa Aesar, Bachem, Fluka, Iris Biotech, 
Novabiochem, PolyPeptide Group, Sigma-Aldrich and VWR with the mentioned purities. The 
following chemicals were used without further purification. 
Substance CAS-Number Supplier Purity 
Acetic acid 64-19-7 Roth 100% 
Acetic anhydride 108-24-7 Roth > 99.0 % 
3-Amino-5-methylpyrazole 31230-17-8 Sigma-Aldrich 97.0 % 
(+)-Ascorbic acid sodium salt 134-03-2 Roth > 99.0 % 
Bromoacetic acid 79-08-3 Alfa Aesar > 98.0 % 
tert-Butyl bromoacetate 5292-43-3 Alfa Aesar > 98.0 % 
4-Carboxybenzaldehyde 619-66-9 Sigma-Aldrich > 99.0 % 
p-Chloranil 118-75-2 Merck > 98.0 % 
Chloroform D1 865-49-6 Roth 99.8 % 
6-Chloronicotinic acid 5326-23-8 Acros 99.0 % 
4-Chloro-7-nitrobenzofurazane 10199-89-0 Fluka > 99.0 % 
Chromium(VI) oxide 1333-82-0 Sigma-Aldrich > 99.0 % 
Copper(II) sulfate pentahydrate 7758-99-8 Sigma-Aldrich 99.999 % 
1,8-Diazabicyclo[5.4.0]undec-7-ene 6674-22-2 Fluka > 99.0 % 
2,4-Dichlorobenzeneboronic acid 68716-47-2 Chempur > 99.0 % 
Diethyl carbonate 105-58-8 Sigma-Adrich > 99.0 % 
Diethylene glycol 111-46-6 Merck > 99.0 % 
N,N-Diisopropylethylamine 7087-68-5 Merck > 98.0 % 
Di-tert-butyl dicarbonate 24424-99-5 Fluka > 98.0 % 
Ethyl acetamidate hydrochloride 2208-07-3 Sigma-Aldrich > 97.0 % 
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Ethylene glycol 107-21-1 Sigma-Aldrich > 99.0 % 
Fmoc-chloride 28920-43-6 Bachem > 98.0 % 
FMPB-linker 26628-22-8 Iris Biotech > 98.0 % 
HATU 148893-10-1 Novabiochem > 98.0 % 
HBTU 94790-37-1 Novabiochem > 98.0 % 
1-Hydroxybenzotriazole hydrate 123333-53-9 Fluka > 99.0 % 
Hydrazine monohydrate 7803-57-8 Sigma-Aldrich 98.0 % 
2-Hydrazinopyridine 4930-98-7 Sigma-Aldrich 97.0 % 
Hydrochloric acid 7647-01-0 Roth 37 % 
Iodomethane 74-88-4 Merck > 99.0 % 
N-Iodosuccinimide 516-12-1 Sigma-Aldrich 95.0 % 
Magnesium sulfate 7487-88-9 Roth > 99.0 % 
4-Methoxy-2-methylbenzene boronic 
acid 208399-66-0 Alfa Aesar 98.0 % 
4-Methylmorpholine 109-02-4 Sigma-Aldrich > 99.5 % 
Ninhydrin 485-47-2 Roth > 99.0 % 
4-Nitrobenzaldehyde 555-16-8 Fluka > 99.0 % 
Pentaethylene glycol 4792-15-8 Alfa Aesar > 98.0 % 
3-Pentylamine 616-24-0 Sigma-Aldrich 97.0 % 
Phenol 108-95-2 Merck > 99.0 % 
Phosphorous oxylchloride 10025-87-3 Sigma-Aldrich > 99.0 % 
Potassium carbonate 584-08-7 Roth > 99.0 % 
Potassium hydroxide 1310-58-3 Merck > 85.0 % 
Potassium iodide 7681-11-0 Roth > 99.0 % 
Potassium permanganate 7722-64-7 Merck > 99.0 % 
Potassium tert-butylate 865-47-4 Merck > 98.0 % 
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Propargylamine 2450-71-7 Sigma-Aldrich 98.0 % 
PyBOP 128625-52-5 Novabiochem > 97.0 % 
Seesand  Roth  
Serinol 534-03-2 Sigma-Aldrich > 98.0 % 
Silver(I) oxide 7758-99-8 Merck > 98.0 % 
Sodium 7440-23-5 Sigma-Aldrich > 99.0 % 
Sodium azide 26628-22-8 Merck > 99.0 % 
Sodium chloride 7647-14-5 Merck > 99.5 % 
Sodium cyanoborohydride 25895-60-7 Fluka > 95.0 % 
Sodium diethyldithiocarbamate 
trihydrate 20624-25-3 Fluka > 99.0 % 
Sodium hydride 7646-69-7 Sigma-Aldrich 95.0 % 
Sodium hydrogen carbonate 144-55-8 Roth > 99.0 % 
Sodium hydroxide 1310-73-2 VWR > 99.0 % 
Sulfuric acid 7664-93-9 Roth > 99.5 % 
Tetraethylene glycol 112-60-7 Alfa Aesar > 99.0 % 
Tetrakis(triphenylphosphine)palladium(0) 14221-01-3 Acros 99.0 % 
Toluene sulfonyl chloride 98-59-9 Fluka > 99.0 % 
Triethylene glycol 112-27-6 Merck > 99.0 % 
Trifluoroacetic acid 76-05-1 Roth > 99.9 % 
2,2,2-Trifluoroethanol 75-89-8 Fluka > 99.0 % 
Triisopropyl silane 6485-79-6 Sigma-Aldrich 99.0 % 
Tris[(1-benzyl-1H-1,2,3-triazol-4-
yl)methyl]amine 510758-28-8 Sigma-Aldrich > 97.0 % 
Table 22. Chemicals. 
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Substance CAS-Number Supplier Purity 
Fmoc-Aib-OH 94744-50-0 Novabiochem > 98.0 % 
Fmoc-Aic-OH 135944-07-9 NeoMPS > 98.0 % 
Fmoc-Ala-OH 35661-39-3 Novabiochem > 98.0 % 
Fmoc-D-Ala-OH 79990-15-1 Novabiochem > 98.0 % 
Fmoc-tBu-Ala-OH 139551-74-9 NeoMPS > 98.0 % 
Fmoc-1-amino-cyclohexane carboxylic 
acid 162648-54-6 NeoMPS > 98.0 % 
Fmoc-1-amino-cyclopentane carboxylic 
acid 117322-30-2 NeoMPS > 98.0 % 
Fmoc-Arg(Pbf)-OH 154445-77-9 Novabiochem > 98.0 % 
Fmoc-D-Arg(Pbf)-OH 187618-60-6 Novabiochem > 98.0 % 
Fmoc-Asn(Trt)-OH 132388-59-1 Novabiochem > 98.0 % 
Fmoc-Asp(OtBu)-OH 71989-14-5 Novabiochem > 98.0 % 
Fmoc-D-Asp(OtBu)-OH 112883-39-3 Bachem > 98.0 % 
Fmoc-Cha-OH 135673-97-1 Novabiochem > 98.0 % 
Fmoc-D-Cha-OH 144701-25-7 NeoMPS >99.0 % 
Fmoc-Chg-OH 161321-36-4 Bachem > 98.0 % 
Fmoc-Cit-OH 133174-15-9 Fluka > 98.0 % 
Fmoc-Dab(Boc)-OH 125238-99-5 NeoMPS > 98.0 % 
Fmoc-Dap(Boc)-OH 162558-25-0 NeoMPS > 98.0 % 
Fmoc-Gln(Trt)-OH 132327-8-1 Novabiochem > 98.0 % 
Fmoc-Glu(OAll)-OH 133464-46-7 Bachem > 98.0 % 
Fmoc-Glu(OtBu)-OH 71989-18-9 Novabiochem > 98.0 % 
Fmoc-Gly-OH 29022-11-5 Novabiochem > 98.0 % 
Fmoc-tBu-Gly-OH 132684-60-7 NeoMPS > 98.0 % 
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Fmoc-His(Trt)-OH 109425-51-6 Novabiochem > 98.0 % 
Fmoc-D-His(Trt)-OH 135610-90-1 Bachem > 98.0 % 
Fmoc-Ile-OH 71989-23-6 Novabiochem > 98.0 % 
Fmoc-D-Ile-OH 143688-83-9 Fluka > 98.0 % 
Fmoc-Leu-OH 35661-60-0 Novabiochem > 98.0 % 
Fmoc-D-Leu-OH 114360-54-2 Fluka > 98.0 % 
Fmoc-α-Me-Leu-OH 312624-65-0 Bachem > 98.0 % 
Fmoc-Lys(Aloc)-OH 146982-27-6 Bachem > 98.0 % 
Fmoc-Lys(Boc)-OH 71989-26-9 Novabiochem > 98.0 % 
Fmoc-Lys(ivDde)-OH 204777-78-6 Novabiochem > 96.0 % 
Fmoc-D-Nal(1)-OH 138774-93-3 NeoMPS > 98.0 % 
Fmoc-D-Nal(2)-OH 138774-94-4 NeoMPS > 98.0 % 
Fmoc-Nle-OH 77284-32-3 Novabiochem > 98.0 % 
Fmoc-Nva-OH 135112-28-6 NeoMPS > 98.0 % 
Fmoc-Orn(Boc)-OH 109425-55-0 Fluka > 98.0 % 
Fmoc-D-3-Pal-OH 142994-45-4 NeoMPS > 98.0 % 
Fmoc-Phe-OH 35661-40-6 Novabiochem > 98.0 % 
Fmoc-4-bromo-D-Phe-OH 198545-76-5 Bachem > 98.0 % 
Fmoc-4-nitro-D-Phe-OH 177966-63-1 NeoMPS > 98.0 % 
Fmoc-Phg-OH 102410-65-1 Fluka > 98.0 % 
Fmoc-D-Phe-OH 86123-10-6 Novabiochem > 98.0 % 
Fmoc-α-Me-D-Phe-OH 152436-04-9 Bachem > 98.0 % 
Fmoc-Pro-OH 71989-31-6 Novabiochem > 98.0 % 
Fmoc-Ser(tBu)-OH 71989-33-8 Novabiochem > 98.0 % 
Fmoc-D-Ser(tBu)-OH 128107-47-1 Novabiochem > 98.0 % 
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Fmoc-homoSer(Trt)-OH 111061-55-3 Fluka > 98.0 % 
Fmoc-Thr(tBu)-OH 71989-35-0 Novabiochem > 98.0 % 
Fmoc-D-Thr(tBu)-OH 138797-71-4 Fluka > 98.0 % 
Fmoc-allo-Thr(tBu)-OH 201481-37-0 Bachem > 98.0 % 
Fmoc-threo-β-phenylserine 487060-72-0 NeoMPS > 97.0 % 
Fmoc-Trp(Boc)-OH 143824-78-6 Novabiochem > 98.0 % 
Fmoc-D-Trp(Boc)-OH 163619-04-3 NeoMPS > 98.0 % 
Fmoc-Tyr(tBu)-OH 71989-38-3 Novabiochem > 98.0 % 
Fmoc-D-Tyr(tBu)-OH 118488-18-9 Novabiochem > 98.0 % 
Fmoc-Val-OH 68858-20-8 NeoMPS > 98.0 % 
Fmoc-D-Val-OH 84624-17-9 NeoMPS > 98.0 % 
Rink amide MBHA resin 431041-83-7 Novabiochem  
Tentagel™ S-NH2  Sigma-Aldrich  
Table 23. Resins and building blocks used for the solid phase synthesis of peptides. 
5.1.8 Solvents 
Solvents were purchased from the companies Roth and Sigma-Aldrich in ROTISOLV®, 
ROTIPURAN®, ROTIDRY® or HPLC Gradient Grade quality. The solvents were used without further 
purification. 
Solvent CAS number Supplier Quality 
Acetone 67-64-1 Roth ROTIPURAN® > 99.8 % 
Acetonitrile 75-05-8 Roth ROTISOLV® > 99.9 % 
Acetonitrile 75-05-8 Roth ROTIPURAN® > 99.5 % 
tert-Butanol 75-65-0 Roth > 99.5 % 
Cyclohexane 110-82-7 Roth ROTIPURAN > 99.9 % 
Chloroform 67-66-3 Roth ROTIPURAN > 99 % 
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Chloroform 67-66-3 Sigma-Aldrich Anhydrous > 99 % 
Dichloromethane 75-09-2 Roth ROTIDRY ＞99.8% 
Diethyl ether 60-29-7 Roth ROTISOLV® > 99.8 % 
1,4-Dioxane 123-91-1 Sigma-Aldrich Anhydrous 99.8 % 
N,N-Dimethylformamide 68-12-2 Roth Peptide synthesis grade > 99.8 % 
N,N-Dimethylformamide 68-12-2 Roth Synthesis grade > 99.5 % 
Ethanol 64-17-5 Roth ROTIPURAN® > 99.8 % 
Ethyl acetate 141-78-6 Roth ROTISOLV® > 99.9 % 
n-Hexane 110-54-3 Roth ROTIPURAN® > 99 % 
Methanol 67-56-1 Roth ROTISOLV® > 99.9 % 
Methanol 67-56-1 Roth ROTIPURAN® > 99.9 % 
N-methyl-2-pyrrolidone 872-50-4 Roth Peptide synthesis grade > 99.8 % 
Tetrahydrofuran 109-99-9 Roth ROTIDRY® > 99.5 % 
Toluene 108-88-3 Roth ROTIDRY® > 99.5 % 
Water 7732-18-5 On tap  
Table 24. Solvents. 
5.1.9 Others materials 
Polypropylene syringe reactors for Solid Phase Peptide Synthesis were purchased from 
Multisyntech GmbH (Germany). The Flexchem® Synthesis System for combinatorial peptide 
synthesis was purchased from SciGene (CA, USA).  
MATERIAL & METHODS 
128 
5.2 Synthetic methods 
5.2.1 Synthesis of azide-functionalized spacers 
General procedure for the synthesis of 2-hydroxyethyl tosylates 4, 39 and 40: 
The compounds were synthesized as published (Bouzide and Sauve 2002). 
To a stirred solution of ethylene glycol (10 mmol) in methylene chloride (50 mL) were added silver 
oxide (1.5 eq., 3.48 g, 15 mmol), potassium iodide (0.2 eq., 332 mg, 2 mmol) and toluene sulfonyl 
chloride (1.1 eq., 2.1 g, 11 mmol). The mixture was stirred at room temperature for 1 hr and then 
filtered over a celite pad. The filtrate was concentrated and purified by flash chromatography using 
ethyl acetate/hexane (50/50, v/v). 
 2-[2-(2-hydroxyethoxy)ethoxy]ethyl tosylate 4:  
 
A colorless oil was obtained (2.4 g, 77 %). 
1H-NMR (300 MHz, CDCl3): δ = 7.80 (d, J = 8 Hz, 2H), 7.34 (d, J = 8 Hz, 2H), 4.17 (m, 2H), 3.71 (m, 
4H), 3.61 (s, 4H), 3.57 (m, 2H), 2.63 (s, 1H), 2.44 (s, 3H) ppm. 13C-NMR (75 MHz, CDCl3): δ = 
145.19, 133.33, 130.17, 128.31, 72.74, 71.14, 70.66, 69.49, 69.07, 62.11, 21.98 ppm. 
MS (ESI) calc. for [C13H20O6S + H]
+.: 305.10; found: 305.31. 
TLC (AcOEt/Hexane, 1/1, v/v): Rf = 0.10. 
 2-[2-[2-(2-Hydroxyethoxy)ethoxy]ethoxy]ethyl tosylate 39: 
 
A colorless oil was obtained (1.9 g, 53 %). 
1H-NMR (300 MHz, CDCl3): δ = 7.79 (d, J = 8 Hz, 2H), 7.34 (d, J = 8 Hz, 2H), 4.16 (m, 2H), 3.57 - 
3.72 (m, 15H), 2.44 (s, 3H) ppm. 13C-NMR (75 MHz, CDCl3): δ = 145.12, 133.34, 130.14, 128.29, 
72.79, 71.07, 70.98, 70.80, 70.66, 69.56, 69.04, 62.06, 21.96 ppm. 
MS (ESI) calc. for [C15H24O7S + Na]
+: 371.11; found: 370.79. 
TLC (AcOEt): Rf = 0.30. 
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 Pentaethylene glycol monotosylate 40: 
 
A colorless oil was obtained (2.1 g, 54 %). 
1H-NMR (300 MHz, CDCl3): δ = 7.79 (d, J = 8 Hz, 2H), 7.33 (d, J = 8 Hz, 2H), 4.15 (m, 2H), 3.58 - 
3.72 (m, 19H), 2.44 (s, 3H) ppm. 13C-NMR (75MHz, CDCl3): δ = 145.10, 135.37, 130.14, 128.30, 
72.82, 71.07, 70.93, 70.91, 70.87, 70.84, 70.66, 69.57, 69.01, 62.06, 21.96 ppm. 
MS (ESI) calc. for [C17H28O8S + Na]
+: 415.14; found: 415.63. 
TLC (AcOEt): Rf = 0.20. 
General procedure for the synthesis of azides 5, 41 and 42: 
To a stirred solution of the tosylates 4,39 or 40 (5 mmol) in dimethylformamide (20 mL) sodium 
azide (2 eq., 10 mmol) was added. The mixture was stirred for 16 hrs at room temperature. 
Dichloromethane (50 mL) was added and the mixture was washed with brine (4 x 100 mL). The 
organic phase was dried over magnesium sulfate, filtered, and concentrated under reduced 
pressure. The residue was purified by flash chromatography using ethyl acetate/hexane (50/50, v/v). 
 2-[2-(2-azidoethoxy)ethoxy]ethanol 5: 
 
A colorless oil was obtained (0.73 g, 83 %). 
1H-NMR (300 MHz, CDCl3):  = 3.46 - 3.78 (m, 11 H), 3.27 - 3.46 (m, 2 H), 2.74 (br. s, 1 H) ppm. 
13C-NMR (75 MHz, CDCl3):  = 72.4, 70.5, 70.2, 69.8, 61.5, 50.5 ppm. 
MS (ESI) calc. for [C6H13N3O3 + Na]
+: 198.09; found: 198.13. 
TLC (AcOEt/Hexane, 1/1, v/v): Rf = 0.37. 
 2-[2-[2-(2-Azidoethoxy)ethoxy]ethoxy]ethanol 41: 
 
A colorless oil was obtained (0.69 g, 63 %). 
1H-NMR (300 MHz, CDCl3): δ = 3.68 – 3.72 (m, 2H), 3.64 – 3.67 (m, 10H), 3.58 – 3.61 (m, 2H), 3.38 
(t, J = 5 Hz, 2H), 2.59 (br. s, 1H) ppm. 13C-NMR (75 MHz, CDCl3): δ = 72.58, 70.80, 70.76, 70.69, 
70.45, 70.14, 61.82, 50.77 ppm. 
MS (ESI) calc. for [C8H17N3O4 + Na]
+: 242.11; found: 242.64. 
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TLC (AcOEt): Rf = 0.25. 
 14-Azido-3,6,9,12-tetraoxatetradecan-1-ol 42: 
 
A colorless oil was obtained (0.93 g, 71 %). 
1H-NMR (300 MHz, CDCl3): δ = 3.67 – 3.75 (br. m, 3H), 3.65 – 3.67 (m, 13H), 3.59 .- 3.62 (m, 2H), 
3.38 (t, J = 10 Hz, 2H), 2.61 (br. s, 1H) ppm. 13C-NMR (75 MHz, CDCl3): δ = 72.65, 70.83, 70.78, 
70.76, 70.74, 70.71, 70.48, 70.15, 61.89, 50.82 ppm. 
MS (ESI) calc. for [C10H21N3O5 + Na]
+: 286.14; found: 286.18. 
TLC (AcOEt): Rf = 0.20. 
General procedure for the synthesis of tert-butyl acetates 6, 36, 43 and 44: 
To a stirred solution of the azides 5, 41 or 42 (4 mmol) in tert-butanol (30 mL), potassium tert-
butoxide (1.5 eq., 6 mmol) was added. The mixture was stirred at 30 °C for 15 min and tert-butyl 
bromoacetate (2 eq., 8 mmol) was added. The mixture was stirred at 30 °C for 16 hrs and then the 
solvent was evaporated under reduced pressure. The crude product was dissolved in 
dichloromethane (30 mL) and washed with brine (3 x 30 mL). The organic phase was dried over 
magnesium sulfate, filtered, and evaporated under reduced pressure. The crude product was 
purified by flash chromatography using ethyl acetate/hexane (50/50, v/v).  
 Tert-butyl-2-[2-(2-(2-azidoethoxy)ethoxy)ethoxy]acetate 6:  
 
A colorless oil was obtained (0.76 g, 2.6 mmol, 66 %). 
1H-NMR (300 MHz, CDCl3):  = 4.02 (s, 2 H), 3.62 – 3.72 (m, 10H), 3.38 (t, J = 5 Hz, 2H), 1.47 (s, 
9H) ppm. 13C-NMR (75 MHz, CDCl3):  = 169.64, 81.55, 70.74, 70.69, 70.66, 70.03, 69.06, 50.70, 
28.11 ppm.  
MS (ESI) calc. for [C12H23N3O5 + Na]
+: 312.15; found: 312.07. 
TLC (AcOEt/Hexane, 1/2, v/v): Rf = 0.39. 
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 Tert-butyl-2-(2-azidoethoxy)acetate 36: 
 
A colorless oil was obtained (0.40 g, 2.0 mmol, 49 %). 
1H-NMR (300 MHz, CDCl3):  = 4.02 (s, 2H), 3.72 (t, J = 5 Hz, 2H), 3.44 (t, J = 5 Hz, 2H), 1.48 (s, 9H) 
ppm. 13C-NMR (75 MHz, CDCl3):  = 169.43, 81.99, 70.29, 69.12, 50.97, 28.24 ppm. 
MS (ESI) calc. for [C8H15N3O3 + Na]
+: 224.10; found: 224.10. 
TLC (AcOEt/Hexane, 1/9, v/v): Rf = 0.25. 
 Tert-butyl-2-[2-[2-[2-(2-azidoethoxy)ethoxy]ethoxy]ethoxy]acetate 43: 
 
A colorless oil was obtained (1.31 g, 3.9 mmol, 98 %). 
1H-NMR (300 MHz, CDCl3):  = 4.01 (s, 2H), 3.68 – 3.72 (m, 4H), 3.65 – 3.67 (m, 10H), 3.38 (t, J = 5 
Hz, 2H), 1.47 (s, 9H) ppm. 13C-NMR (75 MHz, CDCl3):  = 169.79, 81.65, 70.87, 70.84, 70.80, 
70.79, 70.77, 70.74, 70.17, 69.20, 50.85, 28.26 ppm. 
MS (ESI) calc. for [C14H27N3O6 + Na]
+: 356.18; found: 356.14. 
TLC (AcOEt/Hexane, 1/1, v/v): Rf = 0.31. 
 Tert-butyl-2-[2-[2-[2-[2-(2-azidoethoxy)ethoxy]ethoxy]ethoxy]ethoxy]acetate 44: 
 
A colorless oil was obtained (0.64 g, 1.7 mmol, 43 %). 
1H-NMR (300 MHz, CDCl3):  = 4.01 (s, 2H), 3.65 – 3.71 (m, 17H), 3.38 (t, J = 5 Hz, 2H), 1.47 (s, 9H) 
ppm. 13C-NMR (75 MHz, CDCl3):  = 169.79, 81.65, 70.87, 70.84, 70.80, 70.79, 70.77, 70.74, 
70.17, 69.20, 50.85, 28.26 ppm. 
MS (ESI) calc. for [C16H31N3O7 + Na]
+: 400.21; found: 400.18. 
TLC (AcOEt/Hexane, 1/1, v/v): Rf = 0.27. 
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General procedure for the synthesis of azidoacetic acids 7, 37, 45 and 46: 
The tert-butyl acetates 6, 36, 43 or 44 (2.4 mmol) were dissolved in dichloromethane/trifluoroacetic 
acid (50/50, v/v) and the mixture was stirred at room temperature for 30 min. The solvent was 
evaporated under reduced pressure and the residue was dissolved in water (40 mL). The pH was 
adjusted to pH = 10 by addition of an aqueous sodium hydroxide solution (1 M). The solution was 
washed with diethylether (3 x 40 mL) and the pH was adjusted to 2 by addition of an aqueous 
hydrochloric acid solution (3 M). The aqueous layer was extracted with ethyl acetate (5 x 50 mL). The 
combined extracts were dried over magnesium sulfate, filtered, and evaporated under reduced 
pressure. The obtained products were used without further purification. Eventually, the crude was 
purified by flash chromatography using dichloromethane/methanol/acetic acid (90/8/2, v/v/v). 
 2-[2-(2-(2-azidoethoxy)ethoxy)ethoxy]acetic acid 7: 
 
A yellowish oil was obtained (g, mmol, %). 
1H-NMR (300 MHz, CDCl3): δ = 6.33 (br. S, 1H), 4.16 (s, 2H), 3.79-3.74 (m, 2H), 3.73-3.66 (m, 8H), 
3.40 (t, J = 4.8 Hz, 2H) ppm. 13C-NMR (75 MHz, CDCl3): δ = 172.35, 71.62, 70.84, 70.58, 70.32, 
70.21, 68.96, 50.83 ppm. 
MS (ESI) calc. for C8H15N3O5 neg.: 232.21; found: 232.20. 
TLC (Dichloromethane/Methanol/Acetic acid, 90/8/2, v/v/v): Rf= 0.25. 
 2-(2-azidoethoxy)acetic acid 37: 
 
A yellowish oil was obtained (g, mmol, %). 
1H-NMR (300 MHz, CDCl3): δ = 9.31 (br. s, 1H), 4.20 (s, 2H), 3.75 (t, J = 5 Hz, 2H), 3.46 (t, J = 5 Hz, 
2H) ppm. 13C-NMR (75 MHz, CDCl3): δ = 175.26, 70.55, 68.11, 50.80 ppm. 
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 2-[2-[2-[2-(2-azidoethoxy)ethoxy]ethoxy]ethoxy]-acetic acid 45: 
 
A yellowish oil was obtained (g, mmol, %). 
1H-NMR (400 MHz, CDCl3): δ = 10.08 (br. s, 1H), 4.11 (s, 2H), 3.68 – 3.71 (m, 2H), 3.60 – 3.65 (m, 
12H), 3.33 (t, J = 5 Hz, 2H) ppm. 13C-NMR (100 MHz, CDCl3): δ = 173.39, 71.13, 70.58, 70.53, 
70.48, 70.41, 70.30, 69.94, 68.51, 50.57 ppm. 
MS (ESI) calc. for [C10H19N3O6 + Na]
+: 300.12; found: 300.31. 
 2-[2-[2-[2-[2-(2-azidoethoxy)ethoxy]ethoxy]ethoxy]ethoxy]-acetic acid 46: 
 
A yellowish oil was obtained (g, mmol, %). 
1H-NMR (400 MHz, CDCl3): δ = 8.91 (br. s, 1H), 4.11 (s, 2H), 3.67 – 3.70 (m, 2H), 3.60 – 3.65 (m, 
16H), 3.35 (t, J = 5 Hz, 2H) ppm. 13C-NMR (100 MHz, CDCl3): δ = 173.04, 78.89, 70.53, 70.46, 
70.44, 70.43, 70.30, 70.26, 70.21, 69.93, 68.66, 50.58 ppm. 
MS (ESI) calc. for [C12H23N3O7 + Na]
+: 344.14; found: 344.34. 
Synthesis of 2-azidoacetic acid 34: 
 
The compound was synthesized as published (Parkhouse et al. 2008). 
Sodium azide (2 eq., 0.98 g, 15 mmol) was dissolved in water (10 mL) and cooled on an ice bath. 
Bromoacetic acid (1.04 g, 7.5 mmol) was added to the mixture and was stirred at 5 °C for 2 hrs. The 
mixture was allowed to warm to room temperature and further stirred for 24 hrs. The mixture was 
acidified to pH = 5 with an aqueous hydrochloric acid solution (1 M), and extracted with diethylether 
(3 x 30 mL). The ethereal extract was dried and evaporated to dryness to give 2-azidoacetic acid as 
pale yellow oil (0.26 g, 32 %).  
1H-NMR (300 MHz, CDCl3): δ = 11.28 (br. s, 1H), 3.97 (s, 2H) ppm. 
13C-NMR (75 MHz, CDCl3): δ = 
174.56, 50.08 ppm. 
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Synthesis of 2-azidoethanol 35: 
 
The compound was synthesized as published (Cheng et al. 2005). 
2-Chloroethanol (16.1 mL, 200 mmol) was added to a solution of sodium azide (1.23 eq., 16.0 g, 246 
mmol) and sodium hydroxide (0.1 eq., 0.8 g, 20 mmol) in water (60 mL). The mixture was stirred at 
room temperature for 3 days, and sodium sulfate was added (19 g). After 10 min, the mixture was 
extracted with dichloromethane (3 x 37 mL). The combined organic phases were dried over 
magnesium sulfate, filtered and evaporated. The residue was distilled to give 2-azidoethanol as 
colourless oil (16.4 g, 94 %). 
1H-NMR (300 MHz, CDCl3): δ = 3.75 (t, J = 10 Hz, 2H), 3.41 (t, J = 10 Hz, 2H), 2.52 (s, 1H) ppm. 
13C-
NMR (75 MHz, CDCl3): δ = 61.48, 53.58 ppm. 
Synthesis of 2-[2-(2-azidoethoxy)ethoxy]-acetic acid 38: 
 
To a stirred solution of 2-[2-(2-azidoethoxy)ethoxy]ethanol 5 (6 mmol) in acetone (6 mL), cooled to 
5 °C, an aqueous solution of chromium oxide (3 eq., 1.8 g, 18 mmol) in hydrochloric acid (10 N, 22.5 
mL) was added slowly at such a rate that the internal temperature was maintained between 5 and 
15 °C. After the addition was complete, the reaction mixture was stirred at 5 °C for 1.5 hr and then at 
room temperature for 1 hr. After concentration under reduced pressure, the residue was dissolved 
in water (10 mL) and extracted with diethylether (6 x 20 mL). The combined extracts were washed 
with water (3 x 20 mL), dried over magnesium sulfate and concentrated. The crude was purified by 
flash chromatography using dichloromethane/methanol/acetic acid (90/8/2, v/v/v). 
A yellowish oil was obtained (g, mmol, %). 
1H-NMR (300 MHz, CDCl3): δ = 10.24 (br. s, 1H), 4.17 (s, 2H), 3.63 – 3.74 (m, 6H), 3.41 (t, J = 5 Hz, 
2H) ppm. 13C-NMR (75 MHz, CDCl3): δ = 174.80, 71.03, 70.47, 70.33, 69.99, 68.29, 67.96, 50.57 ppm. 
MS (ESI) calc. for [C6H11N3O4 + Na]
+: 212.06; found: 212.31. 
TLC (Dichloromethane/Methanol/Acetic acid, 90/8/2, v/v/v): Rf= 0.32. 
 
MATERIAL & METHODS 
135 
5.2.2 Synthesis of HNA and SFB modification reagents 
Synthesis of 6-hydrazinopyridine-3-carboxylic acid 132: 
 
The compound was synthesized as published (Abrams et al. 1990). 
6-Chloronicotinic acid (1.70 g, 10.8 mmol) was added to 80 % hydrazine monohydrate (large excess) 
and stirred at 100 °C in an oil bath for 4 hrs. The mixture was cooled to room temperature and 
concentrated to dryness to give a brown solid. The solid was dissolved in water (30 mL) and the pH 
was adjusted to 5.5 by addition of an aqueous hydrochloric acid solution (2 M). A yellow precipitate 
was formed and isolated by filtration. The precipitate was washed with a cold mixture of ethanol and 
diethylether (95/5, v/v). The precipitate was dried under vacuum and used without further 
purification (1.33 g, 81 %). 
1H-NMR (300 MHz, DMSO-d6): δ = 8.52 (s, 1H), 8.30 (br. s, 1H), 7.86 (d, J = 9 Hz, 1H), 6.71 (s, 1H) 
ppm. 13C-NMR (75 MHz, DMSO-d6): δ = 166.74, 163.47, 150.60, 137.62, 114.48, 104.91 ppm. 
MS (ESI) calc. for [C6H7N3O2 + H]
+: 154.05; found: 153.23. 
Synthesis of 6-Boc-hydrazinopyridine-3-carboxylic acid 9 (HNA): 
 
The compound was synthesized as published (Abrams et al. 1990). 
To a solution of 6-hydrazinopyridine-3-carboxylic acid 132 (0.35 g, 2.5 mmol) and triethylamine (1.2 
eq., 3.0 mmol) in dimethylformamide (3 mL) was added di-tert-butyl dicarbonate (1 eq., 0.53 g). The 
reaction mixture was stirred for 16 hrs. The reaction mixture was concentrated to dryness under 
reduced pressure to give a brown solid. The residue was triturated in cold ethyl acetate (10 mL), and 
then filtered to give the desired product as a light yellow solid, which was used without further 
purification (0.31 g, 53 %). 
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1H-NMR (300 MHz, DMSO-d6): δ = 12.57 (br. s, 1H), 8.97 (br. s, 1H), 8.89 (s, 1H), 8.58 (s, 1H), 7.97 (d, 
J = 9 Hz, 1H), 6.54 (d, J = 9 Hz, 1H), 1.42 (s, 9H) ppm. 13C-NMR (75 MHz, DMSO-d6): δ = 166.48, 
155.67, 150.43, 138.38, 116.62, 79.26, 28.07 ppm. 
MS (ESI) calc. for [C11H15N3O4 + H]
+: 254.11; found: 254.14. 
Synthesis of p-formylbenzoic acid N-hydroxysuccinimide ester 24 (SFB): 
 
A stirred solution of carboxybenzaldehyde (0.40 g, 2.7 mmol), N-hydroxysuccinimide (1.5 eq., 0.46 g, 
4.0 mmol) and diisopropylethylamine (2.2 eq., 6.0 mmol) in dry tetrahydrofuran (50 mL) was cooled 
to 0°C. N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide (1.1 eq., 3. mmol) was added. The solution 
was stirred at 0 °C for 30 min and then allowed to warm at room temperature. The reaction was 
further stirred for 2 hrs, then concentrated under reduced pressure, and finally purified by flash 
chromatography. 
1H-NMR (300 MHz, CDCl3): δ = 9.74 (s, 1H), 8.16 (d, J = 7 Hz, 2H), 7.92 (d, J = 7 Hz, 2H), 3.53 (s, 4H) 
ppm. 13C-NMR (75 MHz, CDCl3): δ = 191.27, 169.05, 161.20, 141.51, 131.34, 129.87, 25.84 ppm. 
TLC (AcOEt) Rf= 0.54. 
Synthesis of 4-[[2-(2-pyridinyl)hydrazinylidene]methyl]-benzoic acid 133: 
 
Carboxybenzaldehyde (3 mmol) was dissolved in a mixture of “conjugation buffer” (100 mM acetate, 
pH 5.0) and DMF (50/50, v/v) (5 mL). 2-Hydrazinopyridine (1 eq., 3 mmol) was added portionwise 
under vigorous stirring. The mixture was stirred for 16 hrs and the mixture was filtered. The 
precipitate was washed with cold diethylether (3 x 20 mL) and dried under vacuum to afford 
compound 133 as a light brown solid (0.72 g, 100 %).  
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1H-NMR (300 MHz, DMSO-d6): δ = 8.20 (s, 1H), 8.17 (d, J = 6 Hz, 1H), 8.01 (br. s, 1H), 7.98 (br. s, 1H), 
7.94 (br. s, 1H), 7.91, (br. s, 1H), 7.28 (d, J = 9 Hz, 1H), 6.99 (t, J = 6 Hz, 1H) ppm. 13C-NMR (75 MHz, 
DMSO-d6): δ = 166.95, 158.79, 158.46, 158.14, 157.81, 138.39, 131.28, 129.68, 126.95, 118.22, 
115,33 ppm. 
MS (ESI) calc. for [C13H11N3O2 + H]
+: 242.09; found: 242.10. 
5.2.3 Solid phase synthesis of peptides 
5.2.3.1 Standard SPPS procedure 
 
Figure 52: The coupling-wash-deprotection-wash cycle in SPPS. N-protected amino acid residues 
are coupled sequentially on a functionalized resin. Cleavage from the solid support releases the fully 
unprotected peptide.  
A functionalized resin was weighted in a polypropylene syringe reactor. It was swelled for 1 hr in 
dried DCM (1 mL/100 mg resin), then filtered and washed with DMF (4 x 1 mL/100 mg resin). The 
resin was treated with 20 % 4-methylpiperidine in DMF (1 mL/100 mg resin) for 20 min, then filtered 
and washed with DMF (4 x 1 mL/100 mg resin). To the resin was added a solution of Fmoc-AA-OH (4 
eq.), HATU (3.8 eq.) or HBTU (3.8 eq.)/HOBt (3.8 eq.) and DIEA (8 eq.) in DMF (1 mL/100 mg resin) or 
DMF/NMP (50/50, v/v) (1 mL/100 mg resin) respectively. HATU was used for N-Fmoc amino acid 
residue coupling to secondary amino acid residues. Unless otherwise mentioned, HBTU/HOBt was 
systematically used as coupling reagent. After the mixture was shaken for 2 hrs, the resin was 
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filtered and washed with DMF (1 mL/100 mg resin). The resin was treated with acetic anhydride (8 
eq.) and DIEA (8 eq.) in DMF (1 mL/100 mg resin) for 15 min. The resin was filtered and washed with 
DMF (1 mL/100 mg resin). The above operation cycle was repeated with the desired N-Fmoc 
protected amino acid residues. After coupling of the final amino acid, the resin was treated with 
20 % 4-methylpiperidine in DMF (1 mL/100 mg resin) for 20 min. The resin was filtered and washed 
with DMF (4 x 1 mL/100 mg resin). The resin was then either left as a free terminal amine or treated 
with acetic anhydride (8 eq.) and DIEA (8 eq.) in DMF (1 mL/100 mg resin) for 15 min. The resin was 
filtered and washed with DMF (4 x 1 mL/100 mg resin), methanol (4 x 1 mL/100 mg resin), 
chloroform (1 mL/100 mg resin) and diethylether (4 x 1 mL/100 mg resin), and then dried under 
vacuum. The resin was transferred into a round bottom flask and TFA/water/TIS (95/2.5/2.5, v/v/v) 
(1 mL/100 mg resin) was added. After the mixture was shaken for 2 hrs, the resin was filtered and 
washed with TFA/water/TIS (95/2.5/2.5) (0.5 mL/100 mg resin). The filtrate and washings were 
combined, and then concentrated to approximately 1 mL with a light air stream. To the solution was 
added cold diethylether (20 mL/100 mg resin), the mixture was then shaken and centrifugated. After 
removal of supernatant by decantation, the precipitate was washed again with diethylether, and 
then dried. Typically, the dried precipitate was dissolved in acetonitrile/water/trifluoroacetic acid 
(1/1/1, v/v/v) and analyzed by reverse phase HPLC. The peptides were purified by preparative HPLC 
where indicated. 
5.2.3.2 Synthesis of CRHR1-ECD1 specific high-affinity peptide probes 
Rink amide resin (0.45 mmol/g, 100-200 mesh) (0.25 g, 0.113 mmol) was treated with 20 % 4-
methylpiperidine in DMF (2.5 mL) for 20 min. The resin was filtered and washed with DMF (4 x 2.5 
mL). To the resin was added a solution of Fmoc-Ile-OH (4 eq., 0.45 mmol), HBTU (3.8 eq., 
0.43 mmol), HOBt (3.8 eq., 0.43 mmol) and DIEA (8 eq., 0.9 mmol) in DMF/NMP (50/50, v/v) (2.5 
mL). The mixture was shaken for 2 hrs, then the resin was filtered and washed with DMF (4 x 2.5 
mL). The resin was treated with acetic anhydride (8 eq., 0.9 mmol) and DIEA (8 eq., 0.9 mmol) in 
DMF/NMP (50/50, v/v) (2.5 mL). The above operation cycle was repeated with the following N-Fmoc 
protected amino acid residues: Fmoc-Ile-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Cha-OH, Fmoc-Leu-OH, 
Fmoc-Lys(Boc)-OH or Fmoc-Lys(ivDde)-OH (for the synthesis of fluorescently tagged peptides), Fmoc-
Arg(Pbf)-OH, Fmoc-Lys(aloc)-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Ala-OH, Fmoc-Glu(OAll)-OH and Fmoc-
Gln(Trt)-OH. After the final amino acid coupling, the resin was filtered and washed with DMF (4 x 2.5 
mL), methanol (2 x 2.5 mL), chloroform (4 x 2.5 mL) and diethylether (2.5 mL), then dried under 
vacuum. The resin was transferred into a round bottom flask (25 mL) and swelled in a solution of 
chloroform (9.5 mL), acetic acid (0.5 mL) and NMM (0.25 mL). After argon gas was bubbled through 
the mixture for 15 min, (Ph3P)4Pd (3 eq., 0.34 mmol) was added. After the mixture was shaken for 16 
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hrs, the resin was filtered and washed with chloroform (3 x 2.5 mL), DMF (3 x 2.5 mL), 0.5% DIEA in 
DMF (3 x 2.5 mL), 0.02M EtNCS2Na in DMF (3 x 2.5 mL) and DMF (5 x 2.5 mL). To the resin was added 
a solution of PyBop (3 eq., 0.34 mmol), HOBt (3 eq., 0.34 mmol) and DIEA (9 eq., 0.45 mmol) in 
DMF/NMP (50/50, v/v) (7.5 mL). After the mixture was shaken for 16 hrs, the resin was filtered and 
washed with DMF (4 x 2.5 mL). The resin was treated with 20 % 4-methylpiperidine in DMF (2.5 mL) 
for 20 min. The resin was filtered and washed with DMF (4 x 2.5 mL). To the resin was added a 
solution of azide-functionalized ethylene glycol spacer 7, 34, 37, 38, 45, 46 or HNA 9 (4 eq., 0.45 
mmol), HBTU (3.8 eq., 0.43 mmol), HOBt (3.8 eq., 0.43 mmol) and DIEA (8 eq., 0.9 mmol) in 
DMF/NMP (50/50, v/v) (2.5 mL). Thereafter, the mixture was shaken for 2 hrs, and the resin was 
filtered and washed with DMF (4 x 2.5 mL). For the synthesis of fluorescently tagged peptides 2, 27, 
28, 29, 30 and 31, the resin was treated with 3 % hydrazine in DMF (10 x 2.5 mL) for 5 min. The resin 
was filtered and washed with DMF (5 x 2.5 mL). To the resin was added a solution of 4-chloro-7-
nitrobenzofurazan (4 eq., 0.45 mmol) and DIEA (8 eq., 0.9 mmol) in DMF/NMP (50/50, v/v) (2.5 mL). 
After the mixture was shaken for 16 hrs, the 4-chloro-7-nitrobenzofurazan coupling was repeated. 
The mixture was shaken for 2 hrs, the resin was filtered and washed with DMF (4 x 2.5 mL), 
methanol (2 x 2.5 mL), chloroform (4 x 2.5 mL) and diethylether (2.5 mL), then dried under vacuum. 
The resin was transferred into a round bottom flask (10 mL) and TFA/water/TIS (95/2.5/2.5, v/v/v) (4 
mL) was added. After the mixture was shaken for 1 hr, the resin was filtered and washed with 
TFA/water/TIS (95/2.5/2.5, v/v/v) (2 x 1 mL). The filtrate and washings were combined and 
concentrated down to 2 mL using a light air stream. To the solution was added cold diethylether (35 
mL), and the mixture was shaken and centrifugated. After removal of supernatant by decantation, 
the precipitate was washed with cold diethylether, and then dried under vacuum. The precipitate 
was dissolved in acetonitrile/water (50/50, v/v), then purified by preparative HPLC according to the 
following procedure: a solution of the crude peptidic carrier in acetonitrile/water (50/50, v/v) (1.5 
mL) was loaded onto the column (Jupiter 10μm Proteo 90Å 250 x 21.2 mm) at a flow of 25 mL/min. 
The mobile phase was held at 60 % in buffer A (buffer A: 0.1 % TFA in water/acetonitrile, 95/5, v/v; 
buffer B: 0.1 % TFA in acetonitrile/water, 95/5, v/v) for 3 min, then the gradient was started at 40 % 
B in A to 60 % B in A in 15 min. The peptide containing fractions were combined and lyophilized to 
give pure the desired peptide carrier. 
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Peptide sequence R = 
Mass calc. 
[M+H]
+
 
Mass calc. 
[M+2H]
2+
 
Mass found 
[M+2H]
2+
 
Purity 
(%) 
Yield 
(%) 
1 R-EAEKNRKLXDII-NH2 Ac- 1504.88 752.94 753.53 97 17 
2 R-QEAEKNRKLXDII-NH2 N3-TEG 1969.02 985.01 996.33 99 8 
3 R-QEAEKNRKLXDII-NH2 HNA 1725.97 863.49 864.00 95 12 
27 R-QEAEKNRKLXDII-NH2 N3- 1836.94 918.97 930.31
(a)
 92 10 
28 R-QEAEKNRKLXDII-NH2 N3-MEG 1880.97 940.99 952.36 96 5 
29 R-QEAEKNRKLXDII-NH2 N3-DEG 1924.99 963.00 974.47 96 5 
30 R-QEAEKNRKLXDII-NH2 N3-PEG
4
 2013.04 1007.02 1018.40 95 8 
31 R-QEAEKNRKLXDII-NH2 N3-PEG
5
 2057.07 1029.04 1040.39 99 11 
Table 25. Characterization of purified CRHR1-ECD1 high-affinity peptide probes. 
(a) Mass found 
corresponds to [M + H + Na]2+. EAEK = lactam bridge; K = NBD-tagged lysine. 
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5.2.3.3 Synthesis of BAL solid support 
Synthesis of 4-(3-methoxy-4-([(9H-fluoren-9-ylmethoxycarbonyl)(prop-2-ynyl)-
amino]methyl)(1)phenoxy) butanoic Acid 21:  
 
To a stirred solution of 4-(4‘-formyl-3‘-methoxyphenoxy) butanoic acid (Iris Biotech, Germany) (1.2 g, 
5 mmol) in anhydrous methanol (75 mL) and under argon atmosphere were added propargylamine 
(1.5 eq., 7.5 mmol), acetic acid (1.5 eq., 7.5 mmol) and sodium cyanoborohydride (1.2 eq., 6 mmol). 
The mixture was stirred for 90 min followed by evaporation of the solvents under reduced pressure. 
The crude product was dissolved in 1,4-dioxane/acetonitrile/water (1/1/1, v/v/v) (15 mL), and then 
cooled down to 0 °C in an ice bath. Sodium hydrogen carbonate (3 eq., 15 mmol) was added and the 
mixture was stirred for 5 min. To the mixture was added dropwise a solution of 9-fluorenylmethyl 
chloroformate (2 eq., 10 mmol) in 1,4-dioxane (10 mL). The mixture was stirred for 16 hrs at room 
temperature. The organic phase was evaporated under reduced pressure and the aqueous phase 
was acidified to pH = 2 using an aqueous hydrochloric acid solution (5 %). The aqueous phase was 
extracted with ethyl acetate (4 x 100 mL). The combined organic phases were dried over magnesium 
sulfate, filtered and concentrated under reduced pressure. The crude product was purified by flash 
chromatography using ethyl acetate/hexanes (50/50, v/v). A white solid was obtained (1.9 g, 
3.9 mmol, 77 %).  
1H-NMR (400 MHz, CDCl3): δ = 7.75 (d, J = 8 Hz, 2H), 7.58 (br. s., 2H), 7.38 (t, J = 7 Hz, 2H), 7.28 (t, J = 
7 Hz, 2H), 6.46 (d, J = 2 Hz, 1H), 6.40 (br. s., 1H), 4.54 (br. s., 2H), 4.49 (d, J = 6 Hz, 2H), 4.27 (br. s., 
1H), 4.08 (br. s., 2H), 4.03 (t, J = 6 Hz, 2H), 3.80 (s, 3H), 2.59 (t, J = 7 Hz, 2H), 2.19 (m, 1H), 2.13 (m, 
2H) ppm. 13C-NMR (100 MHz, CDCl3): δ = 178.0, 159.9, 144.3, 141.6, 127.8, 127.2, 125.3, 125.3, 
120.1, 118.0, 105.3, 99.3, 79.8, 71.5, 68.0, 67.0, 55.6, 47.6, 44.9, 36.3, 30.5, 24.7 ppm. 
MS (ESI) calc. for [C30H29NO6 + Na]
+: 522.19; found: 522.13. 
TLC (AcOEt): Rf = 0.22.  
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Synthesis of solid support 22: 
TentagelTM S-NH2 resin (0.45 mmol/g, 150-200 μm, Sigma-Aldrich, Germany) (1.0 g, 0.45 mmol) was 
swollen in dichloromethane (10 mL) for 1 hr. The resin was filtered and washed with DMF (4 x 10 
mL). To the resin was added a solution of modified FMPB linker 21 (4 eq., 1.8 mmol), HATU (4 eq., 
1.8 mmol) and DIEA (8 eq., 3.6 mmol) in DMF (10 mL). After that the mixture was shaken for 4 hrs, 
the resin was filtered and washed with DMF (4 x 10 mL), methanol (2 x 10 mL), chloroform (4 x 10 
mL) and diethylether (10 mL), then dried under vacuum. Final loading (0.38 mmol/g) of the resin was 
calculated according to the UV-Fmoc test. 
5.2.3.4 Synthesis of C-terminally propargylated peptides 
BAL resin 22 (0.38 mmol/g) (100 mg, 38 μmol) was swollen in dichloromethane (1 mL) for 1 hr. The 
resin was filtered and washed with DMF (4 x 1 mL). The resin was treated with 20 % 4-
methylpiperidine in DMF (1 mL) for 20 min. The resin was filtered and the previous treatment was 
repeated. The resin was filtered and washed with DMF (5 x 1 mL). To the resin was added a solution 
of Fmoc-AA-OH (4 eq., 152 μmol), HATU (3.8 eq., 144 μmol) and DIEA (8 eq., 304 μmol) in DMF (1 
mL). After the mixture was shaken for 4 hrs, the resin was filtered and the coupling step was 
repeated. After the mixture was shaken for 2 hrs, the resin was filtered and washed with DMF (4 x 1 
mL). The resin was treated with acetic anhydride (8 eq., 304 μmol) and DIEA (8 eq., 304 μmol) in 
DMF/NMP (50/50, v/v) (1 mL) for 15 min. The resin was filtered and washed with DMF (4 x 1 mL). 
The resin was treated with 20 % 4-methylpiperidine in DMF (1 mL) for 20 min. The resin was filtered 
and washed with DMF (5 x 1 mL). To the resin was added a solution of Fmoc-AA-OH (4 eq., 
152 μmol), HBTU (3.8 eq., 144 μmol), HOBt (3.8 eq., 144 μmol) and DIEA (8 eq., 304 μmol). After the 
mixture was shaken for 2 hrs, the resin was filtered and washed with DMF (4 x 1 mL). The resin was 
treated with acetic anhydride (8 eq., 304 μmol) and DIEA (8 eq., 304 μmol) in DMF/NMP (50/50, v/v) 
(1 mL) for 15 min. The resin was filtered and washed with DMF (4 x 1 mL). The above operation cycle 
was repeated with the desired N-Fmoc protected amino acid residues. After coupling of the final 
amino acid, the resin was treated with 20 % 4-methylpiperidine in DMF (1 mL) for 20 min. The resin 
was filtered and washed with DMF (5 x 1mL). The resin was treated with acetic anhydride (8 eq., 304 
μmol) and DIEA (8 eq., 304 μmol) in DMF/NMP (50/50, v/v) (1mL) for 15 min. The resin was filtered 
and washed with DMF (4 x 1 mL), methanol (2 x 1 mL), chloroform (4 x 1 mL) and ether (1 mL), then 
dried under vacuum. The resin was transferred into a round bottom flask (5 mL) and TFA/water/TIS 
(95/2.5/2.5, v/v/v) (1.5 mL) was added. After the mixture was shaken for 1 hr, the resin was filtered 
and washed with TFA/water/TIS (95/2.5/2.5, v/v/v) (0.5 mL). The filtrate and washings were 
combined, and then concentrated to approximately 1 mL with a light air stream. To the solution was 
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added cold ether (20 mL), and the mixture was shaken and centrifugated. After removal of the 
supernatant by decantation, the precipitate was washed with diethylether, and then dried. The 
precipitate was dissolved in acetonitrile/water (1/1, v/v) and used directly for conjugation. 
 
R = propargyl 
Mass calc. 
[M+H]
+
 
Mass found 
[M+H]
+
 
Purity 
(%) 
Yield 
(%) Peptide sequence 
15 Ac-UCN1-15-R Ac-DNPSLSIDLTFHLLR-R 1819.96 1819.93 92 12 
 Ac-UCN1-14-R Ac-DNPSLSIDLTFHLL-R 1663.86 1663.91 96 34 
 Ac-UCN2-15-R Ac-NPSLSIDLTFHLLR-R 1704.94 1704.90 92 45 
 Ac-UCN3-15-R Ac-PSLSIDLTFHLLR-R 1590.89 1590.94 97 9 
 Ac-UCN4-15-R Ac-SLSIDLTFHLLR-R 1493.84 1493.77 94 71 
 Ac-UCN5-15-R Ac-LSIDLTFHLLR-R 1406.81 1406.75 96 71 
 Ac-UCN6-15-R Ac-SIDLTFHLLR-R 1293.72 1293.72 95 80 
 Ac-[Thr
4Cha5]UCN4-15-R 1547.89 1548.04 97 65 
 Ac-[Thr
4Cha5D-Phe11]UCN4-15-R 1547.89 1548.10 97 68 
 Ac-[Thr
4Cha5,13D-Phe11]UCN4-15-R 1587.92 1588.07 98 67 
 Ac-[Thr
4Cha5,13Chg7D-Phe11]UCN4-15-R 1613.93 1614.07 100 42 
 Ac-[Thr
4Cha5,13Chg7tBuAla9D-Phe11]UCN4-15-R 1627.95 1628.11 98 46 
 Ac-[D-Phe
11]UCN4-15-R 1493.84 1493.90 92 43 
 Ac-[D-Nal(1)11]UCN4-15-R 1543.86 1543.93 71 45 
 Ac-[D-Nal(2)11]UCN4-15-R 1543.86 1543.91 70 53 
 Ac-[D-Pal11]UCN4-15-R 1494.84 1494.89 88 75 
 Ac-[D-pNO2-Phe
11]UCN4-15-R 1538.83 1538.86 92 25 
 Ac-[Ach11]UCN4-15-R 1471.86 1472.00 69 27 
 Ac-[Acp11]UCN4-15-R 1457.84 1457.88 88 32 
 Ac-[Aic11]UCN4-15-R 1505.84 1527.81 54 44 
 Ac-[D-Trp11]UCN4-15-R 1532.85 1532.75 92 14 
90 Ac-AST1-14-R Ac-fHLLREVLEBARAE-R 1774.99 887.47
(a)
 95 10 
 Ac-AST1-13-R Ac-fHLLREVLEBARA-R 1645.95 823.90
(a)
 94 77 
 Ac-AST1-12-R Ac-fHLLREVLEBAR-R 1574.91 1547.94 98 48 
 Ac-AST1-11-R Ac-fHLLREVLEBA-R 1418.81 1418.80 98 35 
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 Ac-AST1-10-R Ac-fHLLREVLEB-R 1347.77 1347.75 98 65 
 Ac-AST1-9-R Ac-fHLLREVLE-R 1234.69 624.41
(a)
 92 79 
 Ac-AST1-8-R Ac-fHLLREVL-R 1105.64 1104.71 98 76 
 Ac-AST1-7-R Ac-fHLLREV-R 992.56 992.63 99 86 
 Ac-AST1-6-R Ac-fHLLRE-R 893.49 893.56 98 91 
 Ac-AST1-5-R Ac-fHLLR-R 764.45 764.54 98 90 
 H2N-AST
1-11-R H2N-fHLLREVLEBA-R 1376.80 1376.93 97 42 
 Ac-AST2-11-R Ac-HLLREVLEBA-R 1271.74 1271.82 88 64 
 Ac-[Cha2tBuAla3]AST1-11-R 1448.88 1449.00 75 72 
 Ac-[Cha2Aib4]AST1-11-R 1406.83 1406.85 72 61 
 Ac-[tBuAla3Aib4]AST1-11-R 1404.79 1404.85 65 70 
 Ac-[Cha2tBuAla3Aib4]AST1-11-R 1420.85 1420.91 82 70 
 Ac-[Cha2Aib4tBuAla8]AST1-11-R 1420.85 1420.85 88 55 
 Ac-[D-Pal1Cha2tBuAla3Aib4]AST1-11-R 1421.84 1421.90 94 79 
 Ac-[Cha2tBuAla3,8Aib4]AST1-11-R 1434.86 1435.01 92 9 
 Ac-[D-pBrPhe1Cha2,10Aib4tBuAla8]AST1-11-R 1538.79 1540.78 72 64 
 Ac-[Cha2,10tBuAla3,8Aib4]AST1-11-R 1474.90 1475.06 84 62 
 H2N-[Cha
2tBuAla3]AST1-11-R 1406.87 1406.93 96 79 
 H2N -[Cha
2Aib4]AST1-11-R 1364.82 1364.91 94 73 
 H2N -[tBuAla
3Aib4]AST1-11-R 1362.78 1362.86 97 89 
 H2N -[Cha
2tBuAla3Aib4]AST1-11-R 1378.84 1378.89 91 80 
 H2N -[Cha
2Aib4tBuAla8]AST1-11-R 1378.84 1378.89 98 91 
 H2N -[D-Pal
1Cha2tBuAla3Aib4]AST1-11-R 1379.83 1379.91 98 72 
 H2N -[Cha
2tBuAla3,8Aib4]AST1-11-R 1392.85 1392.96 97 90 
 H2N -[D-pBrPhe
1Cha2,10Aib4tBuAla8]AST1-11-R 1496.78 1498.80 92 79 
 H2N -[Cha
2,10tBuAla3,8Aib4]AST1-11-R 1432.89 1433.00 94 80 
Table 26. Characterization of truncated and substituted analogs of the N-terminally propargylated 
fragments of human urocortin1 and astressin. (a) Mass found corresponds to [M + 2H]2+. 
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5.2.3.5 Flexchem synthesis of the propargylated peptide libraries 
In each vial of a FlexChem® 96 well reactor block (SciGene, CA, USA) was introduced BAL resin 22 
(0.38 mmol/g) (10 mg x 96). The resins were swollen in dichloromethane for 1 hr, then filtered and 
washed with DMF (4 x 1 mL). The resins were treated with 20 % 4-methylpiperidine for 20 min. The 
resins were filtered and washed with DMF (5 x 1 mL). In each well was added a solution of Fmoc-AA-
OH (5 eq., 19 μmol), HATU (4.8 eq., 18 μmol) and DIEA (10 eq., 38 μmol) in DMF (0.5 mL). After that 
the reactor block was shaken for 4 hrs, the resins were filtered and washed with DMF (1 mL x 4). The 
resins were treated with acetic anhydride (10 eq., 38 μmol) and DIEA (10 eq., 38 μmol) in DMF/NMP 
(50/50, v/v) (0.5 mL) for 15 min. The resins were filtered and washed with DMF (4 x 1 mL). The resins 
were treated with 20 % 4-methylpiperidine in DMF (1 mL) for 20 min. The resins were filtered and 
washed with DMF (5 x 1 mL). In each well was added a solution of Fmoc-AA-OH (5 eq., 19 μmol), 
HBTU (4.8 eq., 18 μmol), HOBt (4.8 eq., 18 μmol) and DIEA (10 eq., 38 μmol) in DMF/NMP (50/50, 
v/v) (0.5 mL). After that the reactor block was shaken for 2 hrs, the resins were filtered and washed 
with DMF (4 x 1 mL). The above operation cycle was repeated with the desired N-Fmoc protected 
amino acid residues. After that the final amino acid was coupled, the resins were treated with 20 % 
4-methylpiperidine in DMF (1 mL) for 20 min. The resins were filtered and washed with DMF (5 x 1 
mL). The resins were treated with acetic anhydride (10 eq., 38 μmol) and DIEA (10 eq., 38 μmol) in 
DMF/NMP (50/50, v/v) (0.5 mL) for 15 min. The resins were filtered and washed with DMF (4 x 1 
mL), methanol (2 x 1 mL), chloroform (4 x 1 mL) and diethylether (1 mL), then dried under vacuum. 
In each well was added TFA/water/TIS (95/2.5/2.5, v/v/v) (0.5 mL) and the reactor block was shaken 
for 1 hr. The resins were filtered and filtrates were collected into a 96 x 2 mL well plate. The resins 
were washed with TFA/water/TIS (95/2.5/2.5, v/v/v) (2 x 0.2 mL). The filtrate and washings were 
combined and reduced down to 0.1 mL with a light air stream. In each well was added cold ether (2 
mL), and the mixture was shaken and centrifugated. After removal of supernatant by decantation, 
the precipitates were washed with ether (0.5 mL), and then dried under vacuum. The precipitate 
were dissolved in acetonitrile/water (1/1, v/v) and transferred into reaction tubes (1.5 mL). The 
solvents were evaporated under reduced pressure and the crude residues were dissolved in buffer 
A/B (1/1, v/v) to a final concentration of 1 mM. 
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R = propargyl 
Mass calc. 
[M+H]
+
 
Mass found 
[M+H]
+
 
Purity 
(%) 
 
Peptide Subst. N-terminal Sequence 
Yield 
(%) 
Se
r 
4
 
A1 Ala Ac-ALSIDLTFHLLR- 1477.85 1478.03 53 23 
B1 Aib Ac-(Aib)LSIDLTFHLLR- 1491.86 1492.04 41 10 
C1 D-Ser Ac-(D-Ser)LSIDLTFHLLR- 1493.84 1494.03 30 36 
D1 Thr Ac-TLSIDLTFHLLR- 1507.86 1508.09 38 20 
E1 Glu Ac-ELSIDLTFHLLR- 1535.85 1535.00 61 13 
F1 Lys Ac-KLSIDLTFHLLR- 1534.90 1535.08 61 22 
G1 Dap Ac-(Dap)LSIDLTFHLLR- 1492.86 1493.21 51 32 
H1 h-Ser Ac-(h-Ser)LSIDLTFHLLR- 1507.86 1507.98 32 8 
Le
u
 5
 
A2 Ala Ac-SASIDLTFHLLR- 1451.79 1451.99 83 31 
B2 Aib Ac-S(Aib)SIDLTFHLLR- 1465.81 1465.98 80 8 
C2 D-Leu Ac-S(D-Leu)SIDLTFHLLR- 1493.84 1494.02 41 24 
D2 Ile Ac-SISIDLTFHLLR- 1493.84 1493.94 37 26 
E2 Glu Ac-SESIDLTFHLLR- 1509.80 1509.98 79 24 
F2 Lys Ac-SKSIDLTFHLLR- 1508.85 1508.99 51 21 
G2 Cha Ac-S(Cha)SIDLTFHLLR- 1533.87 1534.05 59 18 
H2 Nleu Ac-S(Nleu)SIDLTFHLLR- 1493.84 1494.03 38 24 
Se
r 
6  
A3 Ala Ac-SLAIDLTFHLLR- 1477.85 1478.02 72 25 
B3 Aib Ac-SL(Aib)IDLTFHLLR- 1491.86 1492.04 55 9 
C3 D-Ser Ac-SL(D-Ser)IDLTFHLLR- 1493.84 1493.96 78 21 
D3 Thr Ac-SLTIDLTFHLLR- 1507.86 1508.09 61 21 
E3 Glu Ac-SLEIDLTFHLLR- 1535.85 1536.04 72 27 
F3 Lys Ac-SLKIDLTFHLLR- 1534.90 1535.07 47 22 
G3 Dap Ac-SL(Dap)IDLTFHLLR- 1492.86 1493.02 39 34 
H3 h-Ser Ac-SL(h-Ser)IDLTFHLLR- 1507.86 1508.03 41 14 
Il
e
 7
 
A4 Ala Ac-SLSADLTFHLLR- 1451.79 1451.93 53 21 
B4 Aib Ac-SLS(Aib)DLTFHLLR- 1465.81 1465.99 67 13 
C4 D-Ile Ac-SLS(D-Ile)DLTFHLLR- 1493.84 1494.10 28 34 
D4 Leu Ac-SLSLDLTFHLLR- 1493.84 1494.01 29 20 
E4 Val Ac-SLSVDLTFHLLR- 1479.82 1480.00 65 25 
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F4 Thr Ac-SLSTDLTFHLLR- 1481.80 1481.94 74 25 
G4 Chg Ac-SLS(Chg)DLTFHLLR- 1519.86 1520.03 70 23 
H4 tBuGly Ac-SLS(tBuGly)DLTFHLLR- 1493.84 1494.03 51 30 
A
sp
 8
 
A5 Ala Ac-SLSIALTFHLLR- 1449.85 1450.15 59 32 
B5 Aib Ac-SLSI(Aib)LTFHLLR- 1463.87 1464.06 84 8 
C5 D-Asp Ac-SLSI(D-Asp)LTFHLLR- 1493.84 1494.01 24 23 
D5 Asn Ac-SLSINLTFHLLR- 1492.86 1493.02 28 24 
E5 Glu Ac-SLSIELTFHLLR- 1507.86 1508.00 31 17 
F5 Thr Ac-SLSITLTFHLLR- 1479.86 1480.19 19 21 
G5 Dab Ac-SLSI(Dab)LTFHLLR- 1478.88 1478.05 39 26 
H5 h-Ser Ac-SLSI(h-Ser)LTFHLLR- 1479.86 1480.00 41 21 
Le
u
 9
 
A6 Ala Ac-SLSIDATFHLLR- 1451.79 1452.05 72 30 
B6 Aib Ac-SLSID(Aib)TFHLLR- 1465.81 1465.99 58 16 
C6 D-Leu Ac-SLSID(D-Leu)TFHLLR- 1493.84 1494.05 42 21 
D6 Ile Ac-SLSIDITFHLLR- 1493.84 1494.16 66 20 
E6 Val Ac-SLSIDVTFHLLR- 1479.82 1480.21 100 21 
F6 Phe Ac-SLSIDFTFHLLR- 1527.82 1527.99 61 38 
G6 Cha Ac-SLSID(Cha)TFHLLR- 1533.87 1534.02 51 24 
H6 tBuAla Ac-SLSID(tBuAla)TFHLLR- 1507.86 1508.03 27 19 
Th
r 
10
 
A7 Ala Ac-SLSIDLAFHLLR- 1463.83 1464.25 71 27 
B7 Aib Ac-SLSIDL(Aib)FHLLR- 1477.85 740.10 50 15 
C7 D-Thr Ac-SLSIDL(D-Thr)FHLLR- 1493.84 1493.98 33 23 
D7 Ser Ac-SLSIDLSFHLLR- 1479.82 1479.99 85 22 
E7 Glu Ac-SLSIDLEFHLLR- 1521.84 1522.00 22 35 
F7 Lys Ac-SLSIDLKFHLLR- 1520.89 1521.06 56 18 
G7 Dap Ac-SLSIDL(Dap)FHLLR- 1478.84 1479.12 79 25 
H7 h-Ser Ac-SLSIDL(h-Ser)FHLLR- 1493.84 1494.05 59 24 
P
h
e
 1
1
 
A8 Ala Ac-SLSIDLTAHLLR- 1417.81 1418.21 81 28 
B8 Aib Ac-SLSIDLT(Aib)HLLR- 1431.82 1432.00 75 10 
C8 D-Phe Ac-SLSIDLT(D-Phe)HLLR- 1493.84 1494.00 50 21 
D8 Tyr Ac-SLSIDLTYHLLR- 1509.84 1510.02 43 37 
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E8 Trp Ac-SLSIDLTWHLLR- 1532.85 1533.01 30 24 
F8 Lys Ac-SLSIDLTKHLLR- 1474.87 1475.06 85 22 
G8 pI-Phe Ac-SLSIDLT(pI-Phe)HLLR- 1619.74 1619.92 46 26 
H8 Phg Ac-SLSIDLT(Phg)HLLR- 1479.82 1480.00 26 22 
H
is
 1
2  
A9 Ala Ac-SLSIDLTFALLR- 1427.82 1427.94 63 26 
B9 Aib Ac-SLSIDLTF(Aib)LLR- 1441.83 1442.03 76 20 
C9 D-His Ac-SLSIDLTF(D-His)LLR- 1493.84 1494.03 31 22 
D9 Arg Ac-SLSIDLTFRLLR- 1512.88 1513.04 67 27 
E9 Glu Ac-SLSIDLTFELLR- 1485.82 1486.00 44 25 
F9 Lys Ac-SLSIDLTFKLLR- 1484.88 1485.03 34 25 
G9 Cha Ac-SLSIDLTF(Cha)LLR- 1509.90 1510.02 43 20 
H9 h-Ser Ac-SLSIDLTF(h-Ser)LLR- 1457.83 1458.00 50 12 
Le
u
 1
3
 
A10 Ala Ac-SLSIDLTFHALR- 1451.79 1452.12 62 27 
B10 Aib Ac-SLSIDLTFH(Aib)LR- 1465.81 1466.06 95 19 
C10 D-Leu Ac-SLSIDLTFH(D-Leu)LR- 1493.84 1494.14 36 23 
D10 Ile Ac-SLSIDLTFHILR- 1493.84 1494.01 38 24 
E10 Val Ac-SLSIDLTFHVLR- 1479.82 1480.00 82 24 
F10 Phe Ac-SLSIDLTFHFLR- 1527.82 1527.97 32 18 
G10 Cha Ac-SLSIDLTFH(Cha)LR- 1533.87 1533.02 38 23 
H10 tBuAla Ac-SLSIDLTFH(tBuAla)LR- 1507.86 1508.06 46 20 
Le
u
 1
4
 
A11 Ala Ac-SLSIDLTFHLAR- 1451.79 1452.12 61 30 
B11 Aib Ac-SLSIDLTFHL(Aib)R- 1465.81 1466.13 46 13 
C11 D-Leu Ac-SLSIDLTFHL(D-Leu)R- 1493.84 1494.16 36 20 
D11 Ile Ac-SLSIDLTFHLIR- 1493.84 1494.13 33 22 
E11 Val Ac-SLSIDLTFHLVR- 1479.82 1480.05 42 20 
F11 Phe Ac-SLSIDLTFHLFR- 1527.82 1528.11 37 35 
G11 Cha Ac-SLSIDLTFHL(Cha)R- 1533.87 1534.02 26 28 
H11 tBuAla Ac-SLSIDLTFHL(tBuAla)R- 1507.86 1508.01 60 23 
A
rg
 1
5  
A12 Ala Ac-SLSIDLTFHLLA- 1408.78 1409.24 75 25 
B12 Aib Ac-SLSIDLTFHLL(Aib)- 1422.79 1422.93 34 20 
C12 D-Arg Ac-SLSIDLTFHLL(D-Arg)- 1493.84 1494.12 44 17 
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D12 Gln Ac-SLSIDLTFHLLQ- 1465.80 1465.97 67 26 
E12 Glu Ac-SLSIDLTFHLLE- 1466.78 1466.97 42 22 
F12 Lys Ac-SLSIDLTFHLLK- 1465.83 1465.98 30 22 
G12 Cit Ac-SLSIDLTFHLL(Cit)- 1494.82 1494.97 69 10 
H12 Orn Ac-SLSIDLTFHLL(Orn)- 1451.82 1451.99 33 12 
Table 27. Characterization of crude single-substituted analogs of the C-terminally propargylated 
fragment of human urocortin14-15. 
 
  
R = propargyl 
Mass calc. 
[M+H]
+
 
Mass found 
[M+H]
+
 
Purity 
(%)
(a)
 
 
Peptide Subst. N-terminal Sequence 
Yield 
(%) 
D
-P
h
e
 1
 
A1 Ala Ac-AHLLREVLEBA-R 1342.78 1343.91 100 71 
B1 Aib Ac-(Aib)HLLREVLEBA-R 1356.79 1357.24 100 82 
C1 Phe Ac-FHLLREVLEBA-R 1418.81 710.73
(a)
 100 84 
D1 D-Tyr Ac-(D-Tyr)HLLREVLEBA-R 1434.80 1435.10 97 76 
E1 D-Trp Ac-(D-Trp)HLLREVLEBA-R 1457.82 1458.08 71 75 
F1 D-His Ac-(D-His)HLLREVLEBA-R 1408.80 1409.29 92 79 
G1 D-3-Pal Ac-(D-Pal)HLLREVLEBA-R 1419.80 1420.95 100 80 
H1 D-pBrPhe Ac-(D-pBrPhe)HLLREVLEBA-R 1496.72 1498.91 96 94 
D
-P
h
e
 1
 
A2 D-pNO2Phe Ac-(D-pNO2Phe)HLLREVLEBA-R 1463.79 1463.93 92 77 
B2 D-Nal(1) Ac-(D-Nal1)HLLREVLEBA-R 1468.82 1469.03 88 75 
C2 D-Nal(2) Ac-(D-Nal2)HLLREVLEBA-R 1468.82 1468.95 87 70 
D2 D-αMePhe Ac-(D-αMePhe)HLLREVLEBA-R 1432.82 1433.95 92 42 
E2 thr-pheSer Ac-(thr-pheSer)HLLREVLEBA-R 1434.80 1435.16 27 58 
F2 Aic Ac-(Aic)HLLREVLEBA-R 1430.81 1431.86 96 64 
G2 Cha Ac-(Cha)HLLREVLEBA-R 1424.86 713.43
(a)
 87 79 
H2 D-Cha Ac-(D-Cha)HLLREVLEBA-R 1424.86 1425.14 92 82 
H
is
 2
 
A3 Ala Ac-fALLREVLEBA-R 1352.79 1352.92 100 83 
B3 Aib Ac-f(Aib)LLREVLEBA-R 1366.80 1366.91 76 51 
C3 D-His Ac-f(D-His)LLREVLEBA-R 1418.81 701.97
(a)
 100 67 
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D3 Glu Ac-fELLREVLEBA-R 1410.79 1410.90 100 49 
E3 Trp Ac-fWLLREVLEBA-R 1467.83 734.76
(a)
 94 75 
F3 Phe Ac-fFLLREVLEBA-R 1428.82 715.35
(a)
 95 71 
G3 Cha Ac-f(Cha)LLREVLEBA-R 1434.86 701.96
(a)
 92 58 
H3 Dab Ac-f(Dab)LLREVLEBA-R 1381.81 1382.86 100 69 
Le
u
 3
 
A4 Ala Ac-fHALREVLEBA-R 1376.76 1377.15 100 79 
B4 Aib Ac-fH(Aib)LREVLEBA-R 1390.78 1391.05 97 75 
C4 D-Leu Ac-fH(D-Leu)LREVLEBA-R 1418.81 1418.92 96 81 
D4 Ile Ac-fHILREVLEBA-R 1418.81 1418.94 100 80 
E4 Val Ac-fHVLREVLEBA-R 1404.79 1404.96 100 46 
F4 Phe Ac-fHFLREVLEBA-R 1452.79 1452.98 100 57 
G4 Cha Ac-fH(Cha)LREVLEBA-R 1458.84 730.44
(a)
 93 84 
H4 tBuAla Ac-fH(tBuAla)LREVLEBA-R 1432.82 1433.00 86 72 
Le
u
 4
 
A5 Ala Ac-fHLAREVLEBA-R 1376.76 1377.01 100 77 
B5 Aib Ac-fHL(Aib)REVLEBA-R 1390.78 1390.99 89 75 
C5 D-Leu Ac-fHL(D-Leu)REVLEBA-R 1418.81 710.46
(a)
 90 45 
D5 Ile Ac-fHLIREVLEBA-R 1418.81 1418.98 72 86 
E5 Val Ac-fHLVREVLEBA-R 1404.79 1405.03 94 71 
F5 Phe Ac-fHLFREVLEBA-R 1452.79 727.35
(a)
 77 92 
G5 Cha Ac-fHL(Cha)REVLEBA-R 1458.84 730.38
(a)
 93 74 
H5 tBuAla Ac-fHL(D-Cha)REVLEBA-R 1432.82 1432.93 85 78 
A
rg
 5
 
A6 Ala Ac-fHLLAEVLEBA-R 1333.74 1333.78 90 81 
B6 Aib Ac-fHLL(Aib)EVLEBA-R 1347.76 1347.80 86 57 
C6 D-Arg Ac-fHLL(D-Arg)EVLEBA-R 1418.81 1418.99 87 69 
D6 Asn Ac-fHLLNEVLEBA-R 1376.75 1376.84 81 76 
E6 Gln Ac-fHLLQEVLEBA-R 1390.77 1390.79 86 71 
F6 Lys Ac-fHLLKEVLEBA-R 1390.80 1390.86 81 71 
G6 Cit Ac-fHLL(Cit)EVLEBA-R 1419.79 1419.95 85 56 
H6 Orn Ac-fHLL(Orn)EVLEBA-R 1376.79 1376.94 90 85 
G
lu
 6
 A7 Ala Ac-fHLLRAVLEBA-R 1360.80 1360.93 100 84 
B7 Aib Ac-fHLLR(Aib)VLEBA-R 1374.82 1374.96 89 75 
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C7 D-Glu Ac-fHLLR(D-Glu)VLEBA-R 1418.81 1418.98 91 74 
D7 Asp Ac-fHLLRDVLEBA-R 1404.79 1405.00 86 65 
E7 Gln Ac-fHLLRQVLEBA-R 1417.82 1417.96 77 81 
F7 His Ac-fHLLRHVLEBA-R 1426.82 1427.04 94 79 
G7 Dab Ac-fHLLR(Dab)VLEBA-R 1389.83 1390.08 92 71 
H7 Orn Ac-fHLLR(Orn)VLEBA-R 1403.84 1404.08 93 54 
V
al
 7
 
A8 Ala Ac-fHLLREALEBA-R 1390.78 1391.04 98 77 
B8 Aib Ac-fHLLRE(Aib)LEBA-R 1404.79 1405.07 91 64 
C8 D-Val Ac-fHLLRE(D-Val)LEBA-R 1418.81 1419.14 100 68 
D8 Ile Ac-fHLLREILEBA-R 1432.82 1432.94 91 71 
E8 Leu Ac-fHLLRELLEBA-R 1432.82 1432.94 77 78 
F8 Phe Ac-fHLLREFLEBA-R 1466.81 1466.92 85 62 
G8 Chg Ac-fHLLRE(Chg)LEBA-R 1458.84 1458.98 88 54 
H8 tBuGly Ac-fHLLRE(tBuGly)LEBA-R 1432.82 1433.06 100 80 
Le
u
 8
 
A9 Ala Ac-fHLLREVAEBA-R 1376.76 1376.91 90 87 
B9 Aib Ac-fHLLREV(Aib)EBA-R 1390.78 1390.93 88 52 
C9 D-Leu Ac-fHLLREV(D-Leu)EBA-R 1418.81 1418.98 88 67 
D9 Ile Ac-fHLLREVIEBA-R 1418.81 1418.94 100 72 
E9 Val Ac-fHLLREVVEBA-R 1404.79 1404.97 84 64 
F9 Phe Ac-fHLLREVFEBA-R 1452.79 1452.90 80 68 
G9 Cha Ac-fHLLREV(Cha)EBA-R 1458.84 1458.99 100 90 
H9 tBuAla Ac-fHLLREV(tBuAla)EBA-R 1432.82 1432.96 93 70 
G
lu
 9
 
A10 Ala Ac-fHLLREVLABA-R 1360.80 1360.95 100 58 
B10 Aib Ac-fHLLREVL(Aib)BA-R 1374.82 1375.02 97 79 
C10 D-Glu Ac-fHLLREVL(D-Glu)BA-R 1418.81 1419.03 87 74 
D10 Asp Ac-fHLLREVLDBA-R 1404.79 1404.93 94 71 
E10 Gln Ac-fHLLREVLQBA-R 1417.82 1417.97 90 83 
F10 Lys Ac-fHLLREVLKBA-R 1417.86 1418.08 83 56 
G10 Dab Ac-fHLLREVL(Dab)BA-R 1389.83 1458.99 97 69 
H10 Orn Ac-fHLLREVL(Orn)BA-R 1403.84 1404.04 86 68 
N
le
u
 
10
 
A11 Ala Ac-fHLLREVLEAA-R 1376.76 1376.96 94 79 
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B11 Aib Ac-fHLLREVLE(Aib)A-R 1390.78 1391.02 92 56 
C11 D-Nleu Ac-fHLLREVLE(D-Nleu)A-R 1418.81 1418.98 85 58 
D11 Leu Ac-fHLLREVLELA-R 1418.81 1418.93 89 67 
E11 Ile Ac-fHLLREVLEIA-R 1418.81 1418.95 89 87 
F11 Lys Ac-fHLLREVLEKA-R 1433.82 1434.03 100 73 
G11 Cha Ac-fHLLREVLE(Cha)A-R 1458.84 1459.10 93 71 
H11 tBuAla Ac-fHLLREVLE(tBuAla)A-R 1432.82 1432.94 83 69 
A
la
 1
1  
A12 Ala Ac-fHLLREVLEBA-R 1418.81 1418.94 100 78 
B12 Aib Ac-fHLLREVLEB(Aib)-R 1432.82 1432.94 80 56 
C12 D-Ala Ac-fHLLREVLEB(D-Ala)-R 1418.81 1418.99 93 43 
D12 Ser Ac-fHLLREVLEBS-R 1434.80 1435.00 50 58 
E12 Leu Ac-fHLLREVLEBL-R 1460.86 1461.01 82 69 
F12 Val Ac-fHLLREVLEBV-R 1446.84 1446.97 91 75 
G12 tBuGly Ac-fHLLREVLEB(tBuGly)-R 1460.86 1461.04 88 69 
H12 Nval Ac-fHLLREVLEB(Nval)-R 1446.84 1446.93 100 75 
Table 28. Characterization of crude single-substituted analogs of the C-terminally propargylated 
fragment of astressin1-11. (a) Mass found corresponds to [M + 2H]2+ or [M + H + Na]2+. 
 
5.2.3.6 Synthesis of C-terminally amidated peptides 
C-terminally amidated peptides were synthesized using a Rink Amide MBHA resin (Novabiochem) 
and the standard SPPS procedure described above. 
 
R = NH2 
Mass calc. 
[M+H]
+
 
Mass found 
[M+H]
+
 
Purity 
(%) 
Yield 
(%) Peptide sequence 
20b Ac-UCN4-15-R 1455.82 1455.78 95 23 
23 Ac-SLSIDLTFHLLR-spacer-K-R 1728.99 1729.12 100 14 
58b Ac-[Thr4Cha5]UCN4-15-R 1509.87 1509.87 94 35 
59b Ac-[Thr4Cha5D-Phe11]UCN4-15-R 1509.87 1509.83 95 32 
60b Ac-[Thr4Cha5,13D-Phe11]UCN4-15-R 1549.90 1549.80 97 28 
61b Ac-[Thr4Cha5,13Chg7D-Phe11]UCN4-15-R 1575.92 1575.91 96 31 
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62b Ac-[Thr4Cha5,13Chg7tBuAla9D-Phe11]UCN4-15-R 1589.93 1589.90 98 22 
63 Ac-[Cha5D-Phe11]UCN4-15-R 1495.86 1495.81 99 16 
64 Ac-[Thr4D-Phe11]UCN4-15-R 1469.84 1469.84 99 28 
65 Ac-[Thr4tBuAla5D-Phe11]Ucn14-15-R 1483.86 1483.85 98 10 
66 Ac-[Thr4tBuAla5D-Phe11Cha13]Ucn14-15-R 1523.89 1550.10 96 21 
67 Ac-[Thr4tBuAla5,13D-Phe11]Ucn14-15-R 1497.87 1498.01 96 32 
68 Ac-[Thr4Cha5D-Phe11α-MeLeu13]Ucn14-15-R 1523.89 1524.05 96 20 
69 Ac-[Thr4Cha5,13α-MeD-Phe11]Ucn14-15-R 1563.92 780.86 99 17 
70 Ac-[Thr4α-MeLeu5D-Phe11Cha13]Ucn14-15-R 1523.89 762.97 94 25 
71 Ac-[alloThr4Cha5,13D-Phe11]Ucn14-15-R 1549.90 1550.14 96 24 
72 Ac-[β-PheSer4Cha5,13D-Phe11]Ucn14-15-R 1611.92 1612.10 96 24 
73 Ac-[Thr4Cha5,13,14D-Phe11]Ucn14-15-R 1589.93 1589.84 97 24 
74 Ac-[Thr4Cha5,13tBuGly7D-Phe11]Ucn14-15-R 1549.90 1550.16 97 18 
75 Ac-[Thr4Cha5,13α-MeLeu9D-Phe11]Ucn14-15-R 1563.92 1564.04 97 11 
76 Ac-[Thr4Cha5,13D-Phe11tBuAla14]Ucn14-15-R 1563.92 1564.09 100 23 
77 Ac-[Thr4Cha5,13,14Chg7D-Phe11]Ucn14-15-R 1615.95 1615.91 93 35 
78 Ac-[Thr4Cha5,9,13Chg7D-Phe11]Ucn14-15-R 1615.95 1616.09 100 24 
79 Ac-[Thr4tBuAla5,9,13,14Chg7D-Phe11]Ucn14-15-R 1551.92 1551.88 95 18 
Table 29. Characterization of purified analogs of the C-terminally amidated fragment of human 
urocortin14-15. 
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5.2.4 The bioconjugation of peptide fragments 
5.2.4.1 Typical procedure for the CuCAAC of peptide fragments 
The azide functionalized peptide (1 mM solution in acetonitrile/water 50/50, v/v) (15 nmol) and the 
desired propargylated peptide (1 mM solution in acetonitrile/water 50/50, v/v) (4 eq., 60 nmol) 
were transferred to a reaction tube (1.5 mL). The mixture was evaporated under reduced pressure. 
The residue was dissolved in tert-butanol/water (43/1, v/v, 722 μL); sonication was used to help 
peptide dissolution when necessary. To this solution were added sequentially TBTA (1 mM solution 
in tert-butanol/water 43/1, v/v, 1.3 eq., 20 nmol, 20 μL), sodium ascorbate (71 mM solution in 
water, 28 eq., 412 nmol, 5.8 μL) and copper sulfate (140 mM solution in water, 21 eq., 308 nmol, 2.2 
μL). The mixture was shaken for 40 hrs at 37 °C. The tube was cooled down to room temperature, 
and then centrifugated (13000 rpm, 5 min). The supernatant was removed by decantation and the 
precipitate was washed with tert-butanol/water (43/1, v/v, 100 μL). The precipitate was dried under 
vacuum. Typically, the conjugates were dissolved in DMSO and analyzed by reverse phase HPLC. The 
NBD-tagged conjugates were systematically quantified by fluorescence spectroscopy using standard 
dilutions of peptide carrier 2 in DMSO as a reference. 
 
Peptide sequence 
R = 
carrier 
Mass calc. 
[M+3H]
3+
 
Mass found 
[M+3H]
3+
 
Purity 
(%) 
Yield 
(%) 
18 Ac-UCN1-15-R Ac-DNPSLSIDLTFHLLR-R 2 1263.33 1263.95 97 31 
19 Ac-UCN1-14-R Ac-DNPSLSIDLTFHLL-R 2 1211.29 1211.91 94 37 
20 Ac-UCN2-15-R Ac-NPSLSIDLTFHLLR-R 2 1224.98 1225.61 97 22 
21 Ac-UCN3-15-R Ac-PSLSIDLTFHLLR-R 2 1186.97 1187.31 98 14 
22 Ac-UCN4-15-R Ac-SLSIDLTFHLLR-R 2 1154.62 1154.91 93 26 
23 Ac-UCN5-15-R Ac-LSIDLTFHLLR-R 2 1125.61 1126.24 95 32 
24 Ac-UCN6-15-R Ac-SIDLTFHLLR-R 2 1087.91 1088.11 100 44 
32 Ac-UCN4-15-R Ac-SLSIDLTFHLLR-R 27 1110.59 1110.91 97 20 
33 Ac-UCN4-15-R Ac-SLSIDLTFHLLR-R 28 1125.27 1125.54 97 20 
34 Ac-UCN4-15-R Ac-SLSIDLTFHLLR-R 29 1139.94 1140.33 95 18 
35 Ac-UCN4-15-R Ac-SLSIDLTFHLLR-R 30 1169.29 1169.70 96 22 
36 Ac-UCN4-15-R Ac-SLSIDLTFHLLR-R 31 1183.97 1184.18 97 19 
Table 30. Characterization of purified truncated “clicked” analogs of the N-terminal fragment of 
human urocortin11-15. 
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  Peptide Subst. N-terminal Sequence 
Mass calc. 
[M+3H]
3+
 
Mass found 
[M+3H]
3+
 Purity (%) 
Yield 
(%) 
Activity 
(%)
(b)
 
Se
r 
4  
A1 Ala Ac-ALSIDLTFHLLR- 1149.29 1149.62 97 87 86.5 
B1 Aib Ac-(Aib)LSIDLTFHLLR- 1153.67 1154.27 100 58 35.7 
C1 D-Ser Ac-(D-Ser)LSIDLTFHLLR- 1154.64 1154.93 96 79 72.4 
D1 Thr Ac-TLSIDLTFHLLR- 1159.01 1159.60 95 99 90.3 
E1 Glu Ac-ELSIDLTFHLLR- 1168.62 1168.97 100 100 90.7 
F1 Lys Ac-KLSIDLTFHLLR- 1168.31 1168.83 100 69 80.0 
G1 Dap Ac-(Dap)LSIDLTFHLLR- 1154.01 1154.94 88 100 84.1 
H1 h-Ser Ac-(h-Ser)LSIDLTFHLLR- 1159.01 1159.93 88 97 85.1 
Le
u
 5
 
A2 Ala Ac-SASIDLTFHLLR- 1140.32 1140.94 100 84 5.2 
B2 Aib Ac-S(Aib)SIDLTFHLLR- 1144.99 1145.59 79 100 1.3 
C2 D-Leu Ac-S(D-Leu)SIDLTFHLLR- 1154.33 1155.27 86 87 4.2 
D2 Ile Ac-SISIDLTFHLLR- 1154.33 1155.14 73 100 56.8 
E2 Glu Ac-SESIDLTFHLLR- 1159.94 1160.44 91 99 9.7 
F2 Lys Ac-SKSIDLTFHLLR- 1159.29 1160.20 89 99 21.7 
G2 Cha Ac-S(Cha)SIDLTFHLLR- 1167.68 1168.20 92 78 94.5 
H2 Nleu Ac-S(Nleu)SIDLTFHLLR- 1154.62 1154.86 100 94 68.7 
Se
r 
6  
A3 Ala Ac-SLAIDLTFHLLR- 1149.30 1149.93 92 75 12.8 
B3 Aib Ac-SL(Aib)IDLTFHLLR- 1153.67 1154.27 100 87 22.3 
C3 D-Ser Ac-SL(D-Ser)IDLTFHLLR- 1154.64 1154.93 100 93 2.5 
D3 Thr Ac-SLTIDLTFHLLR- 1159.01 1159.94 95 98 0.6 
E3 Glu Ac-SLEIDLTFHLLR- 1168.62 1168.87 100 100 0.3 
F3 Lys Ac-SLKIDLTFHLLR- 1168.31 1168.78 100 87 0.4 
G3 Dap Ac-SL(Dap)IDLTFHLLR- 1154.01 1154.53 71 94 2.9 
H3 h-Ser Ac-SL(h-Ser)IDLTFHLLR- 1159.01 1159.52 92 95 4.7 
Il
e
 7
 
A4 Ala Ac-SLSADLTFHLLR- 1140.32 1141.18 63 100 0 
B4 Aib Ac-SLS(Aib)DLTFHLLR- 1144.99 1145.58 95 99 3.5 
C4 D-Ile Ac-SLS(D-Ile)DLTFHLLR- 1154.33 1154.96 83 79 0 
D4 Leu Ac-SLSLDLTFHLLR- 1154.33 1155.20 71 92 50.3 
E4 Val Ac-SLSVDLTFHLLR- 1149.66 1150.52 51 90 13.9 
MATERIAL & METHODS 
156 
F4 Thr Ac-SLSTDLTFHLLR- 1150.61 1151.28 50 87 2.7 
G4 Chg Ac-SLS(Chg)DLTFHLLR- 1163.29 1163.63 45 100 77.9 
H4 tBuGly Ac-SLS(tBuGly)DLTFHLLR- 1154.33 1154.94 66 94 42.7 
A
sp
 8
 
A5 Ala Ac-SLSIALTFHLLR- 1139.67 1140.60 83 86 2.9 
B5 Aib Ac-SLSI(Aib)LTFHLLR- 1144.34 1144.95 87 94 1.0 
C5 D-Asp Ac-SLSI(D-Asp)LTFHLLR- 1154.33 1155.19 66 71 3.0 
D5 Asn Ac-SLSINLTFHLLR- 1154.01 1154.53 73 90 12.5 
E5 Glu Ac-SLSIELTFHLLR- 1159.01 1159.33 69 98 25.8 
F5 Thr Ac-SLSITLTFHLLR- 1149.67 1150.60 68 93 4.9 
G5 Dab Ac-SLSI(Dab)LTFHLLR- 1149.35 1150.21 71 56 7.6 
H5 h-Ser Ac-SLSI(h-Ser)LTFHLLR- 1149.67 1150.63 76 78 3.0 
Le
u
 9
 
A6 Ala Ac-SLSIDATFHLLR- 1140.32 1140.91 100 84 0.3 
B6 Aib Ac-SLSID(Aib)TFHLLR- 1144.99 1145.95 82 97 2.9 
C6 D-Leu Ac-SLSID(D-Leu)TFHLLR- 1154.33 1154.93 100 100 16.6 
D6 Ile Ac-SLSIDITFHLLR- 1154.33 1155.30 73 86 33.4 
E6 Val Ac-SLSIDVTFHLLR- 1149.66 1150.60 79 67 24.3 
F6 Phe Ac-SLSIDFTFHLLR- 1165.66 1166.29 74 79 1.8 
G6 Cha Ac-SLSID(Cha)TFHLLR- 1167.68 1168.64 81 69 0.4 
H6 tBuAla Ac-SLSID(tBuAla)TFHLLR- 1159.01 1155.19 100 80 42.8 
Th
r 
10
 
A7 Ala Ac-SLSIDLAFHLLR- 1144.33 1145.26 97 98 28.7 
B7 Aib Ac-SLSIDL(Aib)FHLLR- 1149.00 1149.93 86 84 23.4 
C7 D-Thr Ac-SLSIDL(D-Thr)FHLLR- 1154.33 1155.19 80 100 2.9 
D7 Ser Ac-SLSIDLSFHLLR- 1149.66 1150.52 77 87 11.3 
E7 Glu Ac-SLSIDLEFHLLR- 1163.95 1163.63 86 67 0 
F7 Lys Ac-SLSIDLKFHLLR- 1163.64 1163.95 100 52 1.8 
G7 Dap Ac-SLSIDL(Dap)FHLLR- 1178.01 1178.21 43 91 0 
H7 h-Ser Ac-SLSIDL(h-Ser)FHLLR- 1154.33 1150.26 76 88 13.7 
P
h
e
 1
1
 
A8 Ala Ac-SLSIDLTAHLLR- 1128.99 1129.96 100 100 23.1 
B8 Aib Ac-SLSIDLT(Aib)HLLR- 1133.66 1134.26 85 85 60.4 
C8 D-Phe Ac-SLSIDLT(D-Phe)HLLR- 1154.33 1154.96 66 99 91.6 
D8 Tyr Ac-SLSIDLTYHLLR- 1159.95 1160.29 57 68 30.1 
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E8 Trp Ac-SLSIDLTWHLLR- 1167.62 1168.53 82 77 79.0 
F8 Lys Ac-SLSIDLTKHLLR- 1148.29 1148.54 100 97 6.2 
G8 pI-Phe Ac-SLSIDLT(pI-Phe)HLLR- 1196.30 1197.16 70 100 2.0 
H8 Phg Ac-SLSIDLT(Phg)HLLR- 1149.95 1150.19 51 64 0 
H
is
 1
2  
A9 Ala Ac-SLSIDLTFALLR- 1132.33 1132.93 100 95 63.9 
B9 Aib Ac-SLSIDLTF(Aib)LLR- 1137.28 1138.01 100 99 1.1 
C9 D-His Ac-SLSIDLTF(D-His)LLR- 1154.33 1155.26 100 86 0.2 
D9 Arg Ac-SLSIDLTFRLLR- 1160.68 1161.54 100 100 2.1 
E9 Glu Ac-SLSIDLTFRLLR- 1151.66 1152.62 68 81 0.3 
F9 Lys Ac-SLSIDLTFKLLR- 1151.63 1151.88 75 79 69.0 
G9 Cha Ac-SLSIDLTF(Cha)LLR- 1159.97 1160.29 78 98 47.7 
H9 h-Ser Ac-SLSIDLTF(h-Ser)LLR- 1142.33 1143.19 67 87 53.3 
Le
u
 1
3
 
A10 Ala Ac-SLSIDLTFHALR- 1140.32 1140.92 100 100 0 
B10 Aib Ac-SLSIDLTFH(Aib)LR- 1144.99 1145.92 100 100 3.3 
C10 D-Leu Ac-SLSIDLTFH(D-Leu)LR- 1154.33 1154.93 100 97 3.6 
D10 Ile Ac-SLSIDLTFHILR- 1154.33 1155.29 90 100 59.9 
E10 Val Ac-SLSIDLTFHVLR- 1149.66 1150.62 100 77 10.7 
F10 Phe Ac-SLSIDLTFHFLR- 1165.66 1166.19 85 84 6.6 
G10 Cha Ac-SLSIDLTFH(Cha)LR- 1167.68 1168.53 100 97 52.0 
H10 tBuAla Ac-SLSIDLTFH(tBuAla)LR- 1159.01 1159.94 77 100 70.6 
Le
u
 1
4
 
A11 Ala Ac-SLSIDLTFHLAR- 1140.32 1140.92 100 74 9.6 
B11 Aib Ac-SLSIDLTFHL(Aib)R- 1144.99 1145.92 100 89 13.1 
C11 D-Leu Ac-SLSIDLTFHL(D-Leu)R- 1154.33 1154.96 97 96 17.3 
D11 Ile Ac-SLSIDLTFHLIR- 1154.33 1155.27 80 100 46.6 
E11 Val Ac-SLSIDLTFHLVR- 1149.66 1150.60 83 78 18.1 
F11 Phe Ac-SLSIDLTFHLFR- 1165.66 1166.60 77 86 5.5 
G11 Cha Ac-SLSIDLTFHL(Cha)R- 1167.68 1168.53 100 100 19.3 
H11 tBuAla Ac-SLSIDLTFHL(tBuAla)R- 1159.01 1159.87 87 97 31.2 
A
rg
 1
5  
A12 Ala Ac-SLSIDLTFHLLA- 1125.98 1126.57 93 69 9.9 
B12 Aib Ac-SLSIDLTFHLL(Aib)- 1130.65 1130.21 100 100 60.3 
C12 D-Arg Ac-SLSIDLTFHLL(D-Arg)- 1154.33 1154.93 100 87 11.9 
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Table 31. Characterization of crude single-substituted “clicked” analogs of the human 
urocortin14-15. (a) cAMP stimulation activity at 2 nM. The cAMP stimulation activity of conjugate 
UCN4-15 (20a) was 56.7 % at 2 nM. 
 
 
Peptide 
 
Subst. 
[M+3H]
3+
 Purity (%) 
Calc. Found Crude Purified 
D1 Thr
4
 1159.01 1159.56 95 100 
G2 Cha
5
 1167.68 1168.24 82 100 
E4 Val
7
 1149.66 1150.19 42 98 
F4 Thr
7
 1150.61 1150.21 56 93 
G4 Chg
7
 1163.29 1163.56 50 90 
C5 D-Asp
8
 1154.33 1155.29 69 98 
H6 tBuAla
9
 1159.01 1159.96 100 100 
C8 D-Phe
11
 1154.33 1155.22 66 92 
D8 Tyr
11
 1159.95 1160.29 60 97 
H8 Phg
11
 1149.95 1150.53 51 96 
H9 h-Ser
12
 1142.33 1143.19 67 100 
E10 Val
13
 1149.66 1150.55 61 100 
G10 Cha
13
 1167.68 1168.30 100 97 
UCN
4-15
 - 1154.52 1154.91 78 100 
Table 32. Characterization of crude and purified single-substituted “clicked” analogs of the human 
urocortin14-15. 
 
 
D12 Gln Ac-SLSIDLTFHLLQ- 1144.99 1145.91 89 74 14.6 
E12 Glu Ac-SLSIDLTFHLLE- 1145.60 1145.85 69 64 9.0 
F12 Lys Ac-SLSIDLTFHLLK- 1145.00 1145.92 72 52 10.9 
G12 Cit Ac-SLSIDLTFHLL(Cit)- 1154.66 1155.52 100 97 33.5 
H12 Orn Ac-SLSIDLTFHLL(Orn)- 1140.33 1141.28 100 100 14.9 
MATERIAL & METHODS 
159 
 R = carrier 2 
Mass calc. 
[M+3H]
3+
 
Mass found 
[M+3H]
3+
 
Purity 
(%) 
Yield 
(%) Peptide sequence 
58a Ac-[Thr4Cha5]UCN4-15-R 1172.63 1172.72 98 47 
59a Ac-[Thr4Cha5D-Phe11]UCN4-15-R 1172.63 1172.65 100 59 
60a Ac-[Thr4Cha5,13D-Phe11]UCN4-15-R 1185.98 1186.13 94 55 
61a Ac-[Thr4Cha5,13Chg7D-Phe11]UCN4-15-R 1194.65 1194.81 97 51 
62a Ac-[Thr4Cha5,13Chg7tBuAla9D-Phe11]UCN4-15-R 1199.32 1199.39 98 43 
Table 33. Characterization of purified (multi-)substituted “clicked” analogs of the human 
urocortin14-15. 
 
Peptide sequence 
R = 
carrier 
Mass calc. 
[M+3H]
3+
 
Mass found 
[M+3H]
3+
 
Purity 
(%) 
Yield 
(%) 
90 Ac-AST1-14-R Ac-fHLLREVLEBARAE-R 2 1249.00 1249.14 94 12 
91 Ac-AST1-13-R Ac-fHLLREVLEBARA-R 2 1205.98 1206.13 97 31 
92 Ac-AST1-12-R Ac-fHLLREVLEBAR-R 2 1182.30 1182.38 100 47 
93 Ac-AST1-11-R Ac-fHLLREVLEBA-R 2 1130.27 1130.36 100 52 
94 Ac-AST1-10-R Ac-fHLLREVLEB-R 2 1106.59 1106.71 100 66 
95 Ac-AST1-9-R Ac-fHLLREVLE-R 2 1068.89 1069.00 98 50 
96 Ac-AST1-8-R Ac-fHLLREVL-R 2 1025.88 1025.93 95 63 
97 Ac-AST1-7-R Ac-fHLLREV-R 2 988.19 988.40 100 37 
98 Ac-AST1-6-R Ac-fHLLRE-R 2 954.50 955.67 100 45 
99 Ac-AST1-5-R Ac-fHLLR-R 2 911.49 912.38 100 79 
100 H2N-AST
1-11-R H2N-fHLLREVLEBA-R 2 1116.26 1116.31 100 56 
101 Ac-AST2-11-R Ac-HLLREVLEBA-R 2 1081.25 1081.32 99 62 
102 Ac-AST1-11-R Ac-fHLLREVLEBA-R 27 1085.91 1086.05 94 34 
103 Ac-AST1-11-R Ac-fHLLREVLEBA-R 28 1100.59 1100.65 97 22 
104 Ac-AST1-11-R Ac-fHLLREVLEBA-R 29 1115.26 1115.37 98 45 
105 Ac-AST1-11-R Ac-fHLLREVLEBA-R 30 1144.61 1144.75 98 38 
106 Ac-AST1-11-R Ac-fHLLREVLEBA-R 31 1159.29 1159.44 100 11 
Table 34. Characterization of purified truncated “clicked” analogs of the N-terminal fragment of 
astressin1-11. 
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 R = carrier 2 
Mass calc. 
[M+3H]
3+
 
Mass found 
[M+3H]
3+
 
Purity 
(%) 
Yield 
(%) Peptide sequence 
107b Ac-[Cha2tBuAla3]AST1-11-R 1140.29 1140.38 100 36 
108b Ac-[Cha2Aib4]AST1-11-R 1126.28 1126.46 97 27 
109b Ac-[tBuAla3Aib4]AST1-11-R 1125.60 1125.75 95 41 
110b Ac-[Cha2tBuAla3Aib4]AST1-11-R 1130.95 1131.16 98 38 
111b Ac-[Cha2Aib4tBuAla8]AST1-11-R 1130.95 1131.14 100 35 
112b Ac-[D-Pal1Cha2tBuAla3Aib4]AST1-11-R 1131.28 1131.39 99 46 
113b Ac-[Cha2tBuAla3,8Aib4]AST1-11-R 1135.62 1135.73 100 39 
114b Ac-[D-pBrPhe1Cha2,10Aib4tBuAla8]AST1-11-R 1170.26 1170.44 99 42 
115b Ac-[Cha2,10tBuAla3,8Aib4]AST1-11-R 1148.97 1148.99 99 33 
107a H2N-[Cha
2tBuAla3]AST1-11-R 1126.29 1126.46 98 69 
108a H2N -[Cha
2Aib4]AST1-11-R 1112.27 1112.35 100 74 
109a H2N -[tBuAla
3Aib4]AST1-11-R 1111.59 1111.77 95 68 
110a H2N -[Cha
2tBuAla3Aib4]AST1-11-R 1116.95 1117.08 100 54 
111a H2N -[Cha
2Aib4tBuAla8]AST1-11-R 1116.95 1117.12 97 82 
112a H2N -[D-Pal
1Cha2tBuAla3Aib4]AST1-11-R 1117.28 1117.46 100 78 
113a H2N -[Cha
2tBuAla3,8Aib4]AST1-11-R 1121.62 1121.81 97 73 
114a H2N -[D-pBrPhe
1Cha2,10Aib4tBuAla8]AST1-11-R 1156.26 1156.39 96 83 
115a H2N -[Cha
2,10tBuAla3,8Aib4]AST1-11-R 1134.96 1135.35 100 68 
Table 35. Characterization of purified (multi-)substituted “clicked” analogs of the N-terminal 
fragment of astressin1-11. 
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R = carrier 2 
Mass calc. 
[M+3H]
3+
 
Mass found 
[M+3H]
3+
 
Purity 
(%) 
   
Peptide Subst. N-terminal Sequence 
Yield 
(%) 
Activity 
(%)
(a)
 
Efficacy 
(%)
(b)
 
D
-P
h
e
 1
 
A1 Ala Ac-AHLLREVLEBA-R 1104.93 1105.20 76 39 9.2 72.0 
B1 Aib Ac-(Aib)HLLREVLEBA-R 1109.60 1110.47 87 27 14.3 73.8 
C1 Phe Ac-FHLLREVLEBA-R 1130.27 1130.64 76 46 9.0 64.0 
D1 D-Tyr Ac-(D-Tyr)HLLREVLEBA-R 1135.60 1135.80 88 46 9.7 68.2 
E1 D-Trp Ac-(D-Trp)HLLREVLEBA-R 1143.27 1143.38 49 51 98.8 100 
F1 D-His Ac-(D-His)HLLREVLEBA-R 1126.93 1127.00 82 34 17.2 71.7 
G1 D-3-Pal Ac-(D-Pal)HLLREVLEBA-R 1130.60 1130.88 86 42 17.8 60.9 
H1 D-pBrPhe Ac-(D-pBrPhe)HLLREVLEBA-R 1156.24 1156.93 84 42 12.9 60.1 
D
-P
h
e
 1
 
A2 D-pNO2Phe Ac-(D-pNO2Phe)HLLREVLEBA-R 1145.26 1145.47 82 45 10.1 67.3 
B2 D-Nal(1) Ac-(D-Nal1)HLLREVLEBA-R 1146.94 1146.97 83 45 9.4 70.2 
C2 D-Nal(2) Ac-(D-Nal2)HLLREVLEBA-R 1146.94 1147.18 82 44 15.4 72.5 
D2 D-αMePhe Ac-(D-αMePhe)HLLREVLEBA-R 1134.94 1135.13 90 21 29.2 71.9 
E2 thr-pheSer Ac-(thr-pheSer)HLLREVLEBA-R 1135.60 1135.94 49 47 14.1 68.1 
F2 Aic Ac-(Aic)HLLREVLEBA-R 1134.27 1134.63 88 28 13.7 68.3 
G2 Cha Ac-(Cha)HLLREVLEBA-R 1132.29 1132.46 79 41 15.4 67.7 
H2 D-Cha Ac-(D-Cha)HLLREVLEBA-R 1132.29 1132.42 90 37 14.3 63.5 
H
is
 2
 
A3 Ala Ac-fALLREVLEBA-R 1108.26 1108.86 100 23 11.8 66.1 
B3 Aib Ac-f(Aib)LLREVLEBA-R 1112.93 1113.30 75 18 16.5 73.8 
C3 D-His Ac-f(D-His)LLREVLEBA-R 1130.27 1131.00 78 22 18.2 74.6 
D3 Glu Ac-fELLREVLEBA-R 1127.60 1127.82 73 37 19.2 70.5 
E3 Trp Ac-fWLLREVLEBA-R 1146.60 1147.37 71 36 9.0 70.8 
F3 Phe Ac-fFLLREVLEBA-R 1133.61 1133.71 65 19 12.0 68.8 
G3 Cha Ac-f(Cha)LLREVLEBA-R 1135.62 1135.78 85 20 10.2 61.2 
H3 Dab Ac-f(Dab)LLREVLEBA-R 1117.94 1118.77 86 42 10.8 64.7 
Le
u
 3
 
A4 Ala Ac-fHALREVLEBA-R 1116.25 1116.51 88 37 12.3 73.2 
B4 Aib Ac-fH(Aib)LREVLEBA-R 1120.93 1121.12 90 17 11.7 67.2 
C4 D-Leu Ac-fH(D-Leu)LREVLEBA-R 1130.27 1130.44 82 28 15.8 69.0 
D4 Ile Ac-fHILREVLEBA-R 1130.27 1130.31 81 33 15.6 69.3 
E4 Val Ac-fHVLREVLEBA-R 1125.60 1125.79 80 42 16.8 69.8 
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F4 Phe Ac-fHFLREVLEBA-R 1141.60 1141.76 81 39 13.4 64.9 
G4 Cha Ac-fH(Cha)LREVLEBA-R 1143.61 1144.11 76 46 13.3 69.8 
H4 tBuAla Ac-fH(tBuAla)LREVLEBA-R 1134.94 1135.83 72 47 14.6 58.6 
Le
u
 4
 
A5 Ala Ac-fHLAREVLEBA-R 1116.25 1116.60 76 37 22.2 70.3 
B5 Aib Ac-fHL(Aib)REVLEBA-R 1120.93 1122.08 100 16 4.8 47.6 
C5 D-Leu Ac-fHL(D-Leu)REVLEBA-R 1130.27 1130.94 81 23 10.2 66.8 
D5 Ile Ac-fHLIREVLEBA-R 1130.27 1130.48 65 29 13.4 73.8 
E5 Val Ac-fHLVREVLEBA-R 1125.60 1125.96 70 48 16.3 72.5 
F5 Phe Ac-fHLFREVLEBA-R 1141.60 1142.47 76 37 23.1 70.4 
G5 Cha Ac-fHL(Cha)REVLEBA-R 1143.61 1143.81 74 44 13.7 76.5 
H5 tBuAla Ac-fHL(D-Cha)REVLEBA-R 1134.94 1135.52 79 41 14.2 67.0 
A
rg
 5
 
A6 Ala Ac-fHLLAEVLEBA-R 1101.91 1102.76 89 34 8.3 66.6 
B6 Aib Ac-fHLL(Aib)EVLEBA-R 1106.59 1106.71 100 12 37.9 71.2 
C6 D-Arg Ac-fHLL(D-Arg)EVLEBA-R 1130.27 1130.98 100 17 9.8 70.5 
D6 Asn Ac-fHLLNEVLEBA-R 1116.25 1137.85 78 51 8.4 71.7 
E6 Gln Ac-fHLLQEVLEBA-R 1120.92 1121.47 76 46 6.5 76.3 
F6 Lys Ac-fHLLKEVLEBA-R 1120.93 1121.09 86 36 20.7 75.8 
G6 Cit Ac-fHLL(Cit)EVLEBA-R 1130.60 1131.09 85 37 8.1 66.1 
H6 Orn Ac-fHLL(Orn)EVLEBA-R 1116.26 1116.78 100 20 38.2 69.8 
G
lu
 6
 
A7 Ala Ac-fHLLRAVLEBA-R 1110.93 1111.16 85 20 8.6 71.6 
B7 Aib Ac-fHLLR(Aib)VLEBA-R 1115.61 1116.49 100 17 15.6 72.3 
C7 D-Glu Ac-fHLLR(D-Glu)VLEBA-R 1130.27 1130.67 88 20 13.0 73.1 
D7 Asp Ac-fHLLRDVLEBA-R 1125.60 1126.49 88 23 12.8 71.1 
E7 Gln Ac-fHLLRQVLEBA-R 1129.94 1130.97 84 23 9.7 71.7 
F7 His Ac-fHLLRHVLEBA-R 1132.94 1133.28 79 7 8.0 73.9 
G7 Dab Ac-fHLLR(Dab)VLEBA-R 1120.61 1120.87 100 17 11.5 66.6 
H7 Orn Ac-fHLLR(Orn)VLEBA-R 1125.28 1125.32 100 17 10.9 70.8 
V
al
 7
 
A8 Ala Ac-fHLLREALEBA-R 1120.93 1121.38 100 16 15.0 62.0 
B8 Aib Ac-fHLLRE(Aib)LEBA-R 1125.60 1126.96 100 8 18.3 67.4 
C8 D-Val Ac-fHLLRE(D-Val)LEBA-R 1130.27 1130.80 76 27 11.4 73.6 
D8 Ile Ac-fHLLREILEBA-R 1134.94 1135.74 100 22 20.7 65.8 
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E8 Leu Ac-fHLLRELLEBA-R 1134.94 1135.82 100 13 10.1 65.0 
F8 Phe Ac-fHLLREFLEBA-R 1146.27 1146.41 100 16 10.3 65.2 
G8 Chg Ac-fHLLRE(Chg)LEBA-R 1143.61 1144.45 100 23 18.4 62.8 
H8 tBuGly Ac-fHLLRE(tBuGly)LEBA-R 1134.94 1135.64 89 23 89.9 92.6 
Le
u
 8
 
A9 Ala Ac-fHLLREVAEBA-R 1116.25 1116.39 100 15 8.4 71.6 
B9 Aib Ac-fHLLREV(Aib)EBA-R 1120.93 1120.98 100 9 8.6 70.4 
C9 D-Leu Ac-fHLLREV(D-Leu)EBA-R 1130.27 1130.99 100 13 8.2 69.5 
D9 Ile Ac-fHLLREVIEBA-R 1130.27 1130.51 90 27 15.8 70.8 
E9 Val Ac-fHLLREVVEBA-R 1125.60 1126.45 90 38 13.1 77.6 
F9 Phe Ac-fHLLREVFEBA-R 1141.60 1141.64 75 36 9.8 67.6 
G9 Cha Ac-fHLLREV(Cha)EBA-R 1143.61 1144.60 88 30 8.2 70.7 
H9 tBuAla Ac-fHLLREV(tBuAla)EBA-R 1134.94 1135.18 88 35 25.4 61.7 
G
lu
 9
 
A10 Ala Ac-fHLLREVLABA-R 1110.67 1111.28 100 14 16.8 65.1 
B10 Aib Ac-fHLLREVL(Aib)BA-R 1115.61 1115.79 100 9 8.7 66.4 
C10 D-Glu Ac-fHLLREVL(D-Glu)BA-R 1130.27 1131.06 100 9 7.0 67.3 
D10 Asp Ac-fHLLREVLDBA-R 1125.60 1125.85 91 22 13.3 69.7 
E10 Gln Ac-fHLLREVLQBA-R 1129.94 1130.60 100 15 17.0 72.1 
F10 Lys Ac-fHLLREVLKBA-R 1129.95 1130.05 79 41 6.2 64.8 
G10 Dab Ac-fHLLREVL(Dab)BA-R 1120.61 1120.79 100 19 7.0 70.6 
H10 Orn Ac-fHLLREVL(Orn)BA-R 1125.84 1125.56 100 19 14.8 63.2 
N
le
u
 1
0  
A11 Ala Ac-fHLLREVLEAA-R 1116.25 1116.51 90 24 17.3 63.6 
B11 Aib Ac-fHLLREVLE(Aib)A-R 1120.93 1121.14 100 10 18.0 64.0 
C11 D-Nleu Ac-fHLLREVLE(D-Nleu)A-R 1130.27 1130.39 92 23 11.7 72.6 
D11 Leu Ac-fHLLREVLELA-R 1130.27 1130.54 90 26 12.8 64.0 
E11 Ile Ac-fHLLREVLEIA-R 1130.27 1130.36 94 27 10.7 65.6 
F11 Lys Ac-fHLLREVLEKA-R 1135.27 1135.42 81 20 10.3 66.2 
G11 Cha Ac-fHLLREVLE(Cha)A-R 1143.61 1143.84 100 15 11.3 61.1 
H11 tBuAla Ac-fHLLREVLE(tBuAla)A-R 1134.94 1135.12 83 31 13.4 61.1 
A
la
 1
1  
A12 Ala Ac-fHLLREVLEBA-R 1130.27 1130.45 90 19 14.6 68.3 
B12 Aib Ac-fHLLREVLEB(Aib)-R 1134.94 1135.26 84 7 13.9 67.4 
C12 D-Ala Ac-fHLLREVLEB(D-Ala)-R 1130.27 1130.57 95 21 18.0 64.0 
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D12 Ser Ac-fHLLREVLEBS-R 1135.60 1135.78 72 33 8.5 70.3 
E12 Leu Ac-fHLLREVLEBL-R 1144.29 1144.48 98 11 7.3 70.3 
F12 Val Ac-fHLLREVLEBV-R 1139.61 1136.77  41 8.1 72.3 
G12 tBuGly Ac-fHLLREVLEB(tBuGly)-R 1144.29 1144.39  29 5.9 71.3 
H12 Nval Ac-fHLLREVLEB(Nval)-R 1139.61 1139.78  31 4.6 67.5 
Table 35. Characterization of crude single-substituted analogs of the N-terminal fragment of 
astressin1-11. (a) cAMP stimulatory activity at 250 nM. The cAMP stimulatory activity of conjugate 
AST1-11 (93) was 8.0 % at 250 nM. (b) cAMP inhibitory efficacy at 250 nM. The cAMP inhibitory efficacy 
of conjugate AST1-11 (93) and astressin were 68.3 % and 19.8 % at 250 nM respectively. 
 
5.2.4.2 Typical procedure for the hydrazone ligation of peptides 
Procedure for the SFB modification of peptides: 
 
Peptide 23 (1 µmol) was dissolved in DMF (100 µL) and DIEA (10 eq., 10 µmol) was added. The 
mixture was stirred for 15 min, and p-formylbenzoic acid N-hydroxysuccinimide ester 24 (10 eq., 10 
µmol) in DMF (50 µL) was added. The mixture was stirred for 16 hrs and then concentrated under 
reduced pressure. The crude was redissolved in acetonitrile/water (50/50, v/v) (100 µL) and the 
modified peptide was purified by preparative reverse phase HPLC to afford pure peptide 27 as a 
white fluffy solid (1.74 mg, 98 %). 
HPLC: B (30 %, 5 min), B (30-40 %, 2 min), B (40-55 %, 16 min), B (55-100 %, 3min), B (100 %, 5 min), 
B (100-30 %, 3 min), B (30 %, 2 min). Retention time: 19.34 min. 
HPLC purity: 100% 
MS (ESI) calc. for [C87H137N21O24 + H]
+: 1861.01; found: 1861.64. 
Typical procedure for the hydrazone ligation of peptides: 
The HNA functionalized peptide 3 (1 mM solution in acetonitrile/water 50/50, v/v) (100 nmol) and 
the SFB-modified peptide 27 (2 mM solution in acetonitrile/water 50/50, v/v) (4 eq., 400 nmol) were 
transferred to a reaction tube (1.5 mL). The mixture was evaporated under reduced pressure. The 
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residue was dissolved in “conjugation buffer” (100 mM acetate, pH = 5.0). The mixture was shaken 
at 40 °C for 24 hrs. The tube was cooled down to room temperature and the solvent was removed 
under reduced pressure. The crude residue was dissolved in acetonitrile/water (50/50, v/v) (100 µL) 
and purified by semi-preparative reverse phase HPLC to obtain conjugate 26. 
Typically, the conjugates were dissolved in DMSO and quantified by UV-absorption spectroscopy 
using standard dilutions of compound 133 as a standard. 
HPLC: B (30 %, 5 min), B (30-40 %, 2 min), B (40-55 %, 16 min), B (55-100 %, 3min), B (100 %, 5 min), 
B (100-30 %, 3 min), B (30 %, 2 min). Retention time: 14.21 min. 
HPLC purity: 100% 
Yield: 94 % 
MS (ESI) calc. for [C164H263N45O44 + 3H]
3+: 1189.99; found: 1190.05. 
MATERIAL & METHODS 
166 
5.2.5 Synthesis of nonpeptide CRHR1 antagonists 
5.2.5.1 Synthesis of building block 128 
Synthesis of 5-acetamidino-3-methylpyrazole 126:  
 
Ethyl acetamidate hydrochloride (6.46 g, 52.2 mmol) was added quickly to a rapidly stirred mixture 
of potassium carbonate (6.95 g, 50.0 mmol), methylene chloride (60 mL), and water (150 mL). The 
layers were separated and the aqueous layer was extracted with methylene chloride (2 x 60 mL). The 
combined organic layers were dried over magnesium sulfate and filtered. The solvent was removed 
under vacuum, and a clear pale-yellow liquid was obtained and used without further purification. 
Glacial acetic acid (1.0 mL, 17.4 mmol) was added to a stirred mixture of 5-amino-3-methylpyrazole 
(17.4 mmol), ethyl acetamidate free base, and dichloromethane (100 mL). The resulting reaction 
mixture was stirred at room temperature for 16hrs. Afterwards, the mixture was concentrated 
under reduced pressure. The residue was triturated with diethylether, and the product was filtered 
and washed with copious amounts of cold diethylether. A white solid was obtained and dried in 
vacuum. It was used without further purification (3.42 g, 100 %).  
Synthesis of 2,7-dimethyl-[1,5-a]pyrazolo[1,3,5]triazin-4(3H)-one 127:  
 
Sodium pellets (3.9 g, 169 mmol) were added portion wise to pure ethanol (200 mL) with vigorous 
stirring. After all the sodium reacted, 5-acetamidino-3-methylpyrazole 126, acetic acid salt (5.4 g, 
16.9 mmol) and diethylcarbonate (16.4 mL, 135.3 mmol) were added. The resulting reaction mixture 
was heated under reflux and stirred for 18 hrs. The mixture was cooled to room temperature, and 
the solvent was removed in vacuum. The residue was dissolved in water (50 mL), and the pH was 
adjusted to 6 with an aqueous hydrochloric acid solution (1M). The aqueous layer was extracted 
with ethyl acetate (3 x 100 mL). The combined organic layers were dried over magnesium sulfate 
and filtered. Solvent was removed in vacuum to give a yellowish solid which was purified by flash 
chromatography. A white solid was obtained (0.81 g, 30 %).  
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1H-NMR (300MHz, CDCl3): δ = 11.05 (br s, 1H), 6.23 (s, 1H), 2.52 (s, 3H), 2.45 (s, 3H) ppm. 
13C-NMR 
(75MHz, CDCl3):  = 157.67, 152.67, 149.45, 99.82, 21.59, 14.81 ppm. 
MS (ESI) calc. for [C7H8N4O + Na]
+: 187.06; found: 187.13. 
TLC (AcOEt): Rf = 0.51. 
Synthesis of 4-chloro-2,7-dimethyl-[1,5-a]pyrazolo-1,3,5-triazine 128:  
 
A mixture of 2,7-dimethyl-[1,5-a]pyrazolo[1,3,5]triazin-4(3H)-one 127 (2.25 g, 13.7 mmol), 
diisopropylethylamine (9.5 mL, 54.7 mmol), phosphorous oxylchloride (5.1 mL, 54.7 mmol), and 
toluene (75 mL) were stirred at reflux temperature for 4 hrs. The volatiles were removed in vacuum. 
The residue was purified by flash chromatography to give a light yellowish solid (1.43 g, 57 %).  
1H-NMR (300MHz, CDCl3): δ = 6.78 (s, 1H), 6.47 (S, 1H), 2.60 (s, 3H), 2.56 (s, 3H) ppm. 
13C-NMR 
(75MHz, CDCl3):  = 158.11, 155.99, 150.07, 107.85, 96.75, 30.91, 24.44, 14.70 ppm. 
MS (ESI) calc. for [C7H7ClN4 + Na]
+: 205.03; found: 205.05. 
TLC (AcOEt/Hexane, 1/2, v/v) Rf = 0.54. 
5.2.5.2 General procedure for the amine condensation with compound 128 
A mixture of 4-chloro-2,7-dimethyl-[1,5-a]pyrazolo-1,3,5-triazine 128 (0.30 g, 1.64 mmol), 2-amino-
1,3-dimethoxypropane or 3-pentylamine (1.5 eq.), diisopropylethylamine (4 eq.), and dry THF (2 
mL/mmol) was stirred at ambient temperature for 18 hrs. The solvent was removed under vacuum 
and the residue was purified by flash chromatography. 
 4-(3-aminopentyl)-2,7-dimethyl-[1,5-a]pyrazolo-1,3,5-triazine 129a:  
 
Light yellow oil was obtained (0.29 g, 76 %). 
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1H-NMR (300MHz, CDCl3): δ = 6.12 (br. d, J=10 Hz, 1H), 6.07 (s, 1H), 4.11 – 4.23 (m, 1H), 2.48 (s, 
3H), 2.42 (s, 3H), 1.52 – 1.80 (m, 4H), 0.97 (t, J=7 Hz, 6H) ppm. 13C-NMR (75MHz, CDCl3):  = 
163.81, 155.33, 149.92, 148.44, 94.92, 53.58, 27.52, 26.13, 14.66, 10.29 ppm. 
MS (ESI) calc. for [C12H19N5 + H]
+: 234.2; found: 234.4. 
TLC (AcOEt/Hexane, 1/4, v/v): Rf = 0.50. 
 4-(2-amino-1,3-dimethoxypropyl)-2,7-dimethyl-[1,5-a]pyrazolo-1,3,5-triazine 129b:  
 
A crystalline solid was obtained (0.28 g, 63 %). 
1H-NMR (300MHz, CDCl3): δ = 6.68 (br. d, J=8 Hz, 1H), 6.08 (s, 1H), 4.58 – 4.63 (m, 1H), 3.57 – 3.66 
(m, 4H), 3.41 (s, 6H), 2.49 (s, 3H), 2.43 (s, 3H) ppm. 13C-NMR (75MHz, CDCl3):  = 164.79, 156.12, 
149.71, 147.13, 93.58, 74.91, 59.34, 55.82, 14.61, 10.27 ppm. 
MS (ESI) calc. for [C12H19N5O2 + H]
+: 266.2; found: 266.5. 
TLC (AcOEt/Hexane, 1/1, v/v): Rf = 0.78. 
5.2.5.3 General procedure for the iodination of compounds 129a-b 
A solution of 129 (1.25 mmol) and N-iodosuccinimide (1.4 eq.) in anhydrous chloroform (10 mL) was 
stirred at reflux for 30 min. The solvent was evaporated under reduced pressure. The residue was 
dissolved in dichloromethane (12 mL) and washed with a saturated solution of sodium thiosulfate (3 
x 3 mL). The organic layer was dried over magnesium sulfate and evaporated to dryness under 
vacuum. The crude product was purified by flash chromatography to afford derivatives 130a-b. 
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 4-(3-aminopentyl)-2,7-dimethyl-8-iodo-[1,5-a]pyrazolo-1,3,5-triazine 130a:  
 
A light yellow solid was obtained (0.37 g, 83 %). 
1H-NMR (300MHz, CDCl3): δ = 6.12 (br. d, J=10 Hz, 1H), 4.11 – 4.23 (m, 1H), 2.54 (s, 3H), 2.43 (s, 
3H), 1.52 – 1.78 (m, 4H), 0.96 (t, J=8 Hz, 6H) ppm. 13C-NMR (75MHz, CDCl3):  = 165.43, 156.42, 
53.89, 50.58, 27.51, 26.35, 15.00, 10.27 ppm. 
MS (ESI) calc. for [C12H18IN5 + H]
+: 360.1; found: 360.3. 
TLC (AcOEt/Hexane 1/4): Rf = 0.67. 
 4-(2-amino-1,3-dimethoxypropyl)-2,7-dimethyl-8-iodo-[1,5-a]pyrazolo-1,3,5-triazine 
130b:  
 
A white solid was obtained (0.35 g, 74 %). 
1H-NMR (300MHz, CDCl3): δ = 6.67 (d, J = 4 Hz, 1H)), 4.58 - 4.63 (m, 1H), 3.62 (m, 4H), 3.41 (s, 6H), 
2.49 (s, 3H), 2.43 (s, 3H) ppm. 13C-NMR (75MHz, CDCl3):  = 162.97, 154.30, 147.89, 145.31, 91.76, 
73.09, 57.52, 54.00, 14.79, 10.46 ppm. 
MS (ESI) calc. for [C12H18IN5O2 + H]
+: 392.1; found: 392.4. 
TLC (AcOEt/Hexane, 1/4, v/v): Rf = 0.28. 
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5.2.5.4 General procedure for the Suzuki cross-coupling with compounds 130a-b 
To a stirred solution of 129a or 129b (0.19 mmol) in anhydrous toluene (1.5 mL) was added 
tetrakis(triphenylphosphine)palladium (33 mg, 0.028 mmol, 0.15 eq.). The mixture was stirred for 30 
min. at room temperature. Phenylboronic acid (0.28 mmol, 1.5 eq.) diluted in ethanol (1 mL) was 
then added, followed immediately by a saturated aqueous solution of sodium bicarbonate (1 mL). 
The heterogeneous solution was stirred at reflux for 12hrs. The palladium catalyst was removed by 
filtration. A saturated aqueous solution of sodium chloride was then added (2 mL), the layers were 
separated and the aqueous phase was extracted with ethyl acetate (3 x 5 mL). The combined organic 
extracts were dried over magnesium sulfate and evaporated under reduced pressure. The crude 
residue was purified by flash chromatography to afford the 8-phenyl derivatives 131. 
 4-(2-amino-1,3-dimethoxypropyl)-2,7-dimethyl-8-(2,4-dichlorophenyl)[1,5-a]pyrazolo-
1,3,5-triazine 131a: 
 
A light brown solid was obtained (0.045 g, 35 %). 
1H-NMR (300MHz, CDCl3): δ = 7.51 (m, 1H), 7.30 (m, 2H), 6.73 (br. d, J=9 Hz, 1H), 4.59 – 4.69 (m, 
1H), 3.58 – 3.70 (m, 4H), 3.43 (s, 6H), 2.48 (s, 3H), 2.34 (s, 3H) ppm. 13C-NMR (75MHz, CDCl3):  = 
164.42, 154.30, 147.98, 135.76, 134.22, 133.95, 129.84, 129.43, 127.34, 71.14, 59.39, 49.78, 
29.86, 26.24, 13.74 ppm. 
MS (ESI) calc. for [C18H21Cl2N5O2 + H]
+: 410.1; found: 410.3. 
TLC (AcOEt/Hexane, 1/4, v/v): Rf = 0.50. 
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 4-(3-aminopentyl)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)[1,5-a]pyrazolo-1,3,5-
triazine 131b: 
 
An orange oil was obtained (0.047 g, 70 %). 
1H-NMR (300MHz, CDCl3): δ = 7.12 (d, J=10 Hz, 1H), 6.86 (d, J=2 Hz, 1H), 6.79 (dd, J1=3 Hz, J2=8 Hz, 
1H), 6.16 (br. d, J=10 Hz, 1H), 4.14 – 4.26 (m, 1H), 3.82 (s, 3H), 2.47 (s, 3H), 2.30 (s, 3H), 2.19 (s, 
3H), 1.57 – 1.83 (m, 4H), 1.00 (t, J=8 Hz, 6H) ppm. 13C-NMR (75MHz, CDCl3):  = 163.66, 159.24, 
154.02, 139.68, 132.43, 123.34, 115.89, 111.40, 108.43, 55.39, 53.55, 27.54, 26.31, 20.80, 13.34, 
10.34 ppm. 
MS (ESI) calc. for [C20H27N5O + H]
+: 354.2; found: 354.5. 
TLC (AcOEt/Hexane, 1/4, v/v): Rf = 0.50. 
 4-(3-aminopentyl)-2,7-dimethyl-8-(2,4-dichlorophenyl)[1,5-a]pyrazolo-1,3,5-triazine 131c: 
 
A white solid was obtained (0.041g, 57 %). 
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1H-NMR (300MHz, CDCl3): δ = 7.52 (t, J=1 Hz, 1H), 7.31 (d, J=1 Hz, 2H), 6.18 (br. d, J=10 Hz, 1H), 
4.14 – 4.27 (m, 1H), 2.48 (s, 3H), 2.34 (s, 3H), 1.57 – 1.83 (m, 4H), 1.00 (t, J=8 Hz, 6H) ppm. 13C-
NMR (75MHz, CDCl3):  = 164.61, 153.94, 148.35, 147.21, 135.73, 134.17, 133.98, 129.84, 129.51, 
127.35, 105.83, 53.68, 27.51, 26.35, 13.73, 10.33 ppm. 
MS (ESI) calc. for [C18H21Cl2N5 + H]
+: 378.1; found: 378.3. 
TLC (AcOEt/Hexane, 1/4, v/v): Rf = 0.50. 
 
5.3 cAMP cell-based assays 
For the screening of CRHR1 ligands, a cell-based assay using the HTRF technology was used. This 
assay was developed by Cisbio International and allows the screening of GPCR ligands in high-
thoughput format (Figure 53, http://www.htrf-assays.com). 
 
Figure 53. Description of the HTRF cell-based cAMP stimulation assay and its components. Assay 
description: upon agonist binding, native cAMP produced by cells competes with the d2-labeled 
cAMP for binding a cryptate-labeled cAMP-antibody. The decrease of the FRET specific signal is 
inversely proportional to the concentration of cAMP in the sample. 
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5.3.1 Stimulation assay typical protocol 
For the stimulation assay, HEK293 cells overexpressing CRHR1 were prepared by Bas Hoogeland 
(AG Hausch). The cells grown to 50-60 % confluency in DMEM (+ FCS 10%, penicillin/streptomycin) 
were detached from the culture dish with cell dissociation solution (Sigma, Germany), resuspended 
in stimulation buffer (SB, 5 mM HEPES, 0,1% BSA, 0,1 mM IBMX in HBSS) and seeded in 5 µl into a 
Corning 384 well plate (#3572) at a density of 3000 cells/well by Bas Hoogeland. After equilibration 
for 10 min at room temperature 5 µl of SB containing peptides and/or DMSO, forskolin or DMP696 
(generous gift by Bristol-Myers-Squibb) were added. After incubation for 30 min at room 
temperature, cells were lysed and the cAMP content was measured using the cAMP dynamic HTRF 
detection kit (CisBio, France) according to the manufactures instructions and using a Tecan Genios 
Pro equipped with 320/35 nM  excitation and 620/10 nM  and 665/8 nM  emission filters. The 
ratiometric fluorescence signals obtained were normalized to the positive (forskolin, 100%) and 
negative controls (DMSO, 0%).  
 
Figure 54. Two-steps protocol for the cAMP stimulation assay. 
5.3.2 Inhibition assay standard protocol 
For the inhibition assay, the same conditions were used. After equilibration for 10 min at room 
temperature, 2.5 µL of SB containing the antagonist were added. The cells were incubated with the 
antagonist for 15 min and 2.5 µL of the peptide agonist were then added. After incubation for 30 
min, the cAMP content was determined as described previously (Figure 55).  
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Figure 55. Three-steps protocol for the cAMP inhibition assay. 
 
Figure 56. Agonist dose response set-up for the cAMP inhibition assay. Briefly, HEK293 cells 
overexpressing CRHR1 are incubated 15 min with a fixed concentration of antagonist. Increasing 
conscentrations of agonist are added and the cells are futher incubated for 30 min. The cAMP 
production level is then determined as described.  
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Figure 57. Antagonist dose response set-up for the cAMP inhibition assay. Briefly, HEK293 cells 
overexpressing CRHR1 are incubated 15 min with increasing antagonist concentrations. An EC50-
corresponding concentration of the agonist is then added and the cells are further incubated for 30 
min. After incubation, the cAMP production level is determined as described.  
Two setups were commonly used for the determination of the efficacy of antagonists. In a setup 
which measures the dose-response of the agonist, the cells were first incubated with a fixed 
concentration of the antagonist, and then increasing concentrations of the agonist were added 
(Figure 56). Increased EC50 value and minimal efficacy (Emin) compared to control indicate the 
inhibitory efficacy of the antagonist (Figure 57). Another assay setup that measures the dose 
response of the antagonist was used. Typically, the CRHR1-overexpressing cells were first incubated 
with increasing concentrations of the antagonist, and then a fixed EC50-corresponding concentration 
of the agonist was added. A sigmoidal response and a decreased minimal efficacy (Emin) compared to 
control indicate the inhibitory efficacy of the antagonist (Figure 57).  
CRHR1 radioactive ligand binding assays were performed by Bas Hoogeland as described 
previously (Devigny et al. 2011). 
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5.4 Data analysis 
SigmaPlot software version 11.0 was used for sigmoidal curve fitting of ligand concentration-
response curves and for calculating the EC50 values as an index of ligand potency. The statistical 
parameters were generated from a composite nonlinear regression (four parameter logistic curve, 
SigmaPlot 11.0) of pooled data from two independent samples. In general, the mean and the 
standard error of the mean (s.e.m.) were expressed for values obtained from duplicate samples. The 
cAMP production response was normalized to a positive control (Forskolin, 100 %) and a negative 
control (DMSO, 0 %). 
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